name,smiles,label100,phase,moa,drug_category
EBPC,CCOC(=O)C1CN(Cc2ccccc2)C(=O)C1=O,0,Preclinical,aldose reductase inhibitor,noncancer
levomepromazine,COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1,0,Launched,dopamine receptor antagonist,noncancer
8-hydroxy-DPAT,CCCN(CCC)C1CCc2cccc(O)c2C1,0,Preclinical,serotonin receptor agonist,noncancer
viloxazine,CCOc1ccccc1OCC1CNCCO1,0,Launched,norepinephrine reuptake inhibitor,noncancer
MR-16728,O=C(NCCCN1CCCCCC1)C(C1CCCCC1)c1ccccc1,0,Preclinical,acetylcholine release enhancer,noncancer
iocetamic-acid,CC(CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O,0,Launched,radiopaque medium,noncancer
C-1,O=S(=O)(N1CCNCC1)c1cccc2cnccc12,0,Preclinical,protein kinase inhibitor,noncancer
levobunolol-(+),CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12,0,Preclinical,adrenergic receptor antagonist,noncancer
MMPX,COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1,0,Preclinical,phosphodiesterase inhibitor,noncancer
2-aminobenzenesulfonamide,Nc1ccccc1S(N)(=O)=O,0,Preclinical,carbonic anhydrase inhibitor,Unknown
NAN-190,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,1,Preclinical,serotonin receptor agonist,noncancer
tyloxapol,C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1,1,Launched,NFkB pathway inhibitor,Unknown
FG-7142,CNC(=O)c1cc2c(cn1)[nH]c1ccccc21,0,Preclinical,GABA benzodiazepine site receptor inverse agonist,noncancer
desoxycortone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,1,Preclinical,mineralocorticoid receptor agonist,noncancer
BP-554,C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1,0,Preclinical,serotonin receptor agonist,noncancer
cyclopenthiazide,NS(=O)(=O)c1cc2c(NC(CC3CCCC3)NS2(=O)=O)cc1Cl,0,Launched,thiazide diuretic,Unknown
2-methyl-5-hydroxytryptamine,Cc1[nH]c2ccc(O)cc2c1CCN,0,Preclinical,serotonin receptor agonist,noncancer
zuclopenthixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1,0,Launched,dopamine receptor antagonist,noncancer
bortezomib,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,Launched,"NFkB pathway inhibitor, proteasome inhibitor",Unknown
tremorine,C(C#CCN1CCCC1)N1CCCC1,1,Preclinical,acetylcholine receptor agonist,noncancer
EMD-53998,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,1,Phase 1,phosphodiesterase inhibitor,noncancer
practolol,CC(C)NCC(O)COc1ccc(NC(C)=O)cc1,1,Withdrawn,adrenergic receptor antagonist,noncancer
cytisine,O=c1cccc2[C@H]3CNC[C@H](C3)Cn12,0,Launched,acetylcholine receptor agonist,noncancer
clebopride,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,1,Launched,dopamine receptor antagonist,noncancer
SCH-28080,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,0,Phase 1,ATPase inhibitor,noncancer
haloprogin,Clc1cc(Cl)c(OCC#CI)cc1Cl,0,Launched,other antifungal,noncancer
BMS-927711,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F,0,Phase 2,calcitonin antagonist,Unknown
androsterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O,0,Preclinical,androgen receptor agonist,Unknown
lobenzarit,OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O,0,Launched,immunosuppressant,noncancer
zotepine,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
primaquine,COc1cc(NC(C)CCCN)c2ncccc2c1,1,Launched,"antimalarial agent, DNA inhibitor",noncancer
chicago-sky-blue-6b,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,1,Preclinical,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",noncancer
phenytoin,O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1,0,Launched,hydantoin antiepileptic,noncancer
TMC-353121,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,1,Phase 2,RSV fusion inhibitor,noncancer
siguazodan,CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C,0,Phase 1,phosphodiesterase inhibitor,noncancer
R-1479,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1,0,Phase 1,HCV inhibitor,noncancer
guanethidine,NC(=N)NCCN1CCCCCCC1,0,Launched,adrenergic inhibitor,noncancer
Ro-9187,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,1,Preclinical,HCV inhibitor,noncancer
oxiconazole,Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
N-methylquipazine,CN1CCN(CC1)c1ccc2ccccc2n1,0,Preclinical,serotonin receptor agonist,noncancer
alfadolone-acetate,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,0,Phase 2,benzodiazepine receptor agonist,noncancer
alpha-methylhistamine-dihydrobromide-(R)-(-),C[C@@H](N)Cc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer
alfaxalone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,0,Launched,"chloride channel agonist, benzodiazepine receptor agonist",noncancer
alpha-methylhistamine-dihydrobromide-(S)-(+),C[C@H](N)Cc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer
fursultiamine,C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCC1CCCO1,0,Launched,vitamin B,noncancer
N-alpha-Methylhistamine-dihydrochloride,CNCCc1cnc[nH]1,0,Phase 3,histamine receptor agonist,noncancer
flucloxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
3-MPPI,COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1,0,Preclinical,adrenergic receptor ligand,noncancer
deptropine,CN1[C@H]2CC[C@@H]1CC(C2)OC1c2ccccc2CCc2ccccc12,0,Preclinical,histamine receptor antagonist,noncancer
metitepine,CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1,0,Preclinical,anti-HCVE2,noncancer
etilefrine,CCNCC(O)c1cccc(O)c1,0,Launched,adrenergic receptor agonist,noncancer
5-methylfurmethiodide,Cc1ccc(C[N+](C)(C)C)o1,0,Preclinical,acetylcholine receptor agonist,noncancer
nifekalant,Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O,0,Launched,potassium channel blocker,noncancer
PRE-084,O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1,0,Preclinical,sigma receptor agonist,noncancer
NPPB,OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O,0,Preclinical,chloride channel blocker,targeted cancer
nifurtimox,CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O,0,Launched,DNA inhibitor,noncancer
nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC,0,Launched,calcium channel blocker,noncancer
nomegestrol-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,1,Launched,progesterone receptor agonist,noncancer
cebranopadol,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,1,Phase 3,opioid receptor agonist,noncancer
losmapimod,Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1,0,Phase 3,p38 MAPK inhibitor,noncancer
voxtalisib,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,1,Phase 2,"mTOR inhibitor, PI3K inhibitor",targeted cancer
nemorubicin,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,1,Phase 2,topoisomerase inhibitor,Unknown
ABT-737,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1,1,Phase 1/Phase 2,BCL inhibitor,targeted cancer
buparvaquone,CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1,0,Launched,antiprotozoal agent,noncancer
amonafide,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,1,Phase 3,topoisomerase inhibitor,chemo
navarixin,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,1,Phase 2,CC chemokine receptor antagonist,targeted cancer
vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F,1,Launched,RAF inhibitor,targeted cancer
PGL5001,N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1,0,Phase 2,JNK inhibitor,noncancer
sulforaphane,CS(=O)CCCCN=C=S,0,Phase 2,"anticancer agent, aryl hydrocarbon receptor antagonist",targeted cancer
CNX-2006,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,1,Preclinical,EGFR inhibitor,targeted cancer
MK-2461,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,1,Phase 1/Phase 2,"FGFR inhibitor, VEGFR inhibitor",targeted cancer
raloxifene,Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1,1,Launched,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",targeted cancer
sulfametopyrazine,COc1nccnc1NS(=O)(=O)c1ccc(N)cc1,0,Launched,PABA antagonist,noncancer
PHA-793887,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,1,Phase 1,CDK inhibitor,targeted cancer
guanaben-acetate,NC(=N)N\N=C\c1c(Cl)cccc1Cl,0,Launched,adrenergic receptor agonist,noncancer
7-nitroindazole,[O-][N+](=O)c1cccc2cn[nH]c12,1,Preclinical,nitric oxide synthase inhibitor,noncancer
alcuronium,OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)c1ccccc41)c1ccccc21,0,Launched,muscle relaxant,noncancer
nicergoline,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,0,Launched,adrenergic receptor antagonist,noncancer
tridihexethyl,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
GW-583340,CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1,Preclinical,EGFR inhibitor,targeted cancer
pivmecillinam,CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
palmitoylcarnitine,CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C,0,Preclinical,protein kinase inhibitor,noncancer
BGT226,COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1,1,Phase 1/Phase 2,PI3K inhibitor,Unknown
parthenolide,C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,1,Phase 1,NFkB pathway inhibitor,targeted cancer
NVP-BVU972,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,1,Preclinical,MET inhibitor,targeted cancer
4-PPBP,C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1,0,Preclinical,sigma receptor ligand,noncancer
istradefylline,CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O,1,Launched,adenosine receptor antagonist,noncancer
2-PMDQ,O=C1Nc2ccccc2C2=NC(CN3CCN(CC3)c3ccccc3)CN12,0,Preclinical,adrenergic receptor antagonist,noncancer
ciproxifan,O=C(C1CC1)c1ccc(OCCCc2c[nH]cn2)cc1,0,Preclinical,histamine receptor antagonist,Unknown
rosmarinic-acid,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1,0,Launched,GABA transaminase inhibitor,targeted cancer
PHA-767491,O=C1NCCc2[nH]c(cc12)-c1ccncc1,1,Preclinical,CDC inhibitor,targeted cancer
spiroxatrine,O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1,0,Preclinical,serotonin receptor antagonist,noncancer
GW-788388,O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1,1,Preclinical,ALK tyrosine kinase receptor inhibitor,noncancer
TPCA-1,NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1,1,Preclinical,IKK inhibitor,targeted cancer
GW-4064,CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl,0,Preclinical,FXR agonist,noncancer
ambazone,NC(=N)N=Nc1ccc(NNC(S)=N)cc1,1,Phase 1,DNA damage inducer,chemo
fomepizole,Cc1cn[nH]c1,0,Launched,alcohol dehydrogenase inhibitor,noncancer
piricapiron,CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O,0,Phase 2,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
epirubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,1,Launched,topoisomerase inhibitor,Unknown
scopolamine,CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
2-hydroxyflutamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,0,Phase 1/Phase 2,androgen receptor antagonist,targeted cancer
dacinostat,OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1,1,Phase 1,HDAC inhibitor,Unknown
ioxaglic-acid,CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I,0,Launched,radiopaque medium,noncancer
dabigatran-etexilate,CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1,0,Launched,thrombin inhibitor,noncancer
thiethylperazine,CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,0,Launched,dopamine receptor antagonist,noncancer
selumetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,1,Phase 3,MEK inhibitor,targeted cancer
methiazole,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,1,Preclinical,anthelmintic agent,noncancer
dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,1,Phase 3,EGFR inhibitor,targeted cancer
spaglumic-acid,CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O,0,Launched,glutamate receptor antagonist,noncancer
pazufloxacin,C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1,0,Launched,topoisomerase inhibitor,noncancer
parbendazole,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,1,Preclinical,tubulin polymerization inhibitor,noncancer
nalbuphine,O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45,0,Launched,"opioid receptor agonist, opioid receptor antagonist",noncancer
clocortolone-pivalate,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,1,Launched,steroid,noncancer
tiapride,CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O,0,Launched,dopamine receptor antagonist,noncancer
bemesetron,CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1,0,Phase 3,serotonin receptor antagonist,noncancer
alpelisib,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,1,Phase 3,PI3K inhibitor,targeted cancer
"tropanyl-3,5-dimethylbenzoate",CN1C2CCC1CC(C2)OC(=O)c1cc(C)cc(C)c1,0,Preclinical,serotonin receptor antagonist,noncancer
SAR131675,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,1,Preclinical,VEGFR inhibitor,targeted cancer
thioperamide,S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1,0,Preclinical,histamine receptor antagonist,noncancer
CEP-33779,CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1,1,Preclinical,JAK inhibitor,targeted cancer
HTMT,CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer
tyrphostin-AG-879,CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S,0,Preclinical,tyrosine kinase inhibitor,targeted cancer
vesamicol,O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1,0,Preclinical,acetylcholinesterase inhibitor,noncancer
BI-D1870,CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12,1,Preclinical,ribosomal protein inhibitor,noncancer
FGIN-1-27,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1,0,Preclinical,inositol monophosphatase inhibitor,noncancer
CCT137690,CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
FGIN-1-43,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1,0,Preclinical,benzodiazepine receptor agonist,noncancer
3-methyladenine,Cn1cnc(=N)c2nc[nH]c12,0,Preclinical,PI3K inhibitor,targeted cancer
NU-7026,O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1,0,Preclinical,"DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor",targeted cancer
VU0357121,CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F,0,Preclinical,glutamate receptor positive allosteric modulator,noncancer
amthamine,Cc1nc(N)sc1CCN,0,Preclinical,histamine receptor agonist,noncancer
torin-2,Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1,1,Preclinical,mTOR inhibitor,Unknown
AH6809,CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O,0,Preclinical,prostanoid receptor antagonist,noncancer
ML133,COc1ccc(CNCc2cccc3ccccc23)cc1,1,Preclinical,potassium channel blocker,targeted cancer
enalapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
phenprobamate,NC(=O)OCCCc1ccccc1,0,Launched,muscle relaxant,noncancer
pentoxifylline,CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,0,Launched,phosphodiesterase inhibitor,noncancer
centpropazine,CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1,0,Phase 3,inositol monophosphatase inhibitor,noncancer
5-aminolevulinic-acid,NCC(=O)CCC(O)=O,0,Launched,oxidizing agent,targeted cancer
idasanutlin,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,1,Phase 3,MDM inhibitor,targeted cancer
fenigam,NCC(CC(O)=O)c1ccccc1,0,Launched,benzodiazepine receptor agonist,noncancer
vilazodone,NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1,0,Launched,serotonin reuptake inhibitor,noncancer
mebicar,CN1C2C(N(C)C1=O)N(C)C(=O)N2C,0,Launched,anxiolytic,noncancer
nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C,0,Launched,calcium channel blocker,noncancer
rasagiline,C#CCN[C@@H]1CCc2ccccc12,0,Launched,monoamine oxidase inhibitor,noncancer
telotristat,Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,0,Launched,tryptophan hydroxylase inhibitor,noncancer
latrepirdine,CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1,1,Phase 3,glutamate receptor antagonist,noncancer
JTE-907,CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12,0,Phase 1,cannabinoid receptor inverse agonist,noncancer
dalargin,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O,0,Phase 2,opioid receptor agonist,noncancer
mebendazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,1,Launched,tubulin polymerization inhibitor,noncancer
NPC-15199,CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O,0,Phase 2,ICAM1 antagonist,noncancer
CZC24832,CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1,0,Preclinical,PI3K inhibitor,noncancer
AJ76-(+),CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C,0,Preclinical,dopamine receptor antagonist,noncancer
"MNS-(3,4-Methylenedioxy-nitrostyrene)",[O-][N+](=O)\C=C\c1ccc2OCOc2c1,1,Preclinical,"src inhibitor, syk inhibitor",noncancer
2-phenylmelatonin,COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1,0,Preclinical,melatonin receptor agonist,noncancer
S-Sulfo-L-cysteine-sodium-salt,N[C@@H](CSS(O)(=O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
wnt-c59,Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1,0,Preclinical,porcupine inhibitor,targeted cancer
cis-ACPD,N[C@]1(CC[C@@H](C1)C(O)=O)C(O)=O.N[C@@]1(CC[C@H](C1)C(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,Unknown
SGC-0946,CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12,0,Preclinical,histone lysine methyltransferase inhibitor,noncancer
L-Quisqualic-acid,N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
blebbistatin-(-),Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,1,Preclinical,ATPase inhibitor,noncancer
DNQX,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O,0,Preclinical,glutamate receptor antagonist,noncancer
NU6027,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,1,Preclinical,CDK inhibitor,targeted cancer
homoquinolinic-acid,OC(=O)Cc1cccnc1C(O)=O,1,Preclinical,glutamate receptor agonist,noncancer
CFTRinh-172,OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F,0,Preclinical,chloride channel blocker,noncancer
kainic-acid,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O,0,Preclinical,kainate receptor agonist,noncancer
PD-168393,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,1,Preclinical,EGFR inhibitor,targeted cancer
kynurenic-acid,OC(=O)c1cc(O)c2ccccc2n1,1,Preclinical,glutamate receptor antagonist,noncancer
EPZ-5676,CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1,1,Phase 1,histone lysine methyltransferase inhibitor,targeted cancer
metocurine,COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3,0,Launched,acetylcholine receptor antagonist,noncancer
selamectin,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,1,Launched,nematocide,noncancer
metoxibutropate,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,1,Launched,cyclooxygenase inhibitor,noncancer
dexfenfluramine,CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F,0,Withdrawn,serotonin receptor agonist,noncancer
cianidanol,O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1,0,Withdrawn,fatty acid synthase inhibitor,noncancer
nibentan,CCN(CC)CCCCC(NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1,0,Phase 2,potassium channel blocker,noncancer
rocuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
SR-2640,OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1,0,Phase 2,leukotriene receptor antagonist,noncancer
SCP-1,Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1,0,Phase 1,analgesic agent,Unknown
AM-24,Oc1c(I)cc(I)cc1I,0,Phase 2,lipoxygenase inhibitor,noncancer
D-64131,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,1,Preclinical,microtubule inhibitor,chemo
oxybenzone,COc1ccc(C(=O)c2ccccc2)c(O)c1,0,Launched,lipase inhibitor,noncancer
GR125487,COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,0,Preclinical,serotonin receptor antagonist,noncancer
MF-101,Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1,0,Phase 3,estrogen receptor agonist,targeted cancer
SB-206553,Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1,0,Preclinical,serotonin receptor antagonist,noncancer
etazolate,CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C,0,Phase 2,phosphodiesterase inhibitor,targeted cancer
SKF-77434,Oc1cc2CCN(CC=C)CC(c3ccccc3)c2cc1O,0,Preclinical,dopamine receptor agonist,noncancer
propentofylline,CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12,0,Launched,"adenosine reuptake inhibitor, phosphodiesterase inhibitor",noncancer
quinolinic-acid,OC(=O)c1cccnc1C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
guvacine,OC(=O)C1=CCCNC1,0,Preclinical,GABA uptake inhibitor,noncancer
EPZ005687,Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
isoguvacine,OC(=O)C1=CCNCC1,0,Preclinical,benzodiazepine receptor agonist,noncancer
IPI-145,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,Phase 3,PI3K inhibitor,targeted cancer
7-chlorokynurenic-acid,OC(=O)c1cc(O)c2ccc(Cl)cc2n1,0,Preclinical,glutamate receptor antagonist,noncancer
MK-8745,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
2-hydroxysaclofen,NCC(O)(CS(O)(=O)=O)c1ccc(Cl)cc1,0,Preclinical,GABA receptor antagonist,noncancer
endo-IWR-1,O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O,1,Preclinical,PARP inhibitor,targeted cancer
saclofen,NCC(CS(O)(=O)=O)c1ccc(Cl)cc1,0,Preclinical,GABA receptor antagonist,noncancer
BAM7,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,1,Preclinical,BAX activator,targeted cancer
AMPA-(S),Cc1onc(O)c1C[C@H](N)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
3-deazaneplanocin-A,Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
HA-966-(R)-(+),N[C@@H]1CCN(O)C1=O,0,Preclinical,glutamate receptor agonist,noncancer
P5091,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,1,Preclinical,ubiquitin specific protease inhibitor,targeted cancer
HA-966-(S)-(-),N[C@H]1CCN(O)C1=O,0,Preclinical,glutamate receptor antagonist,noncancer
NSC-697923,Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O,1,Preclinical,ubiquitin-conjugating enzyme inhibitor,Unknown
"5,7-dichlorokynurenic-acid",OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1,0,Preclinical,glutamate receptor antagonist,noncancer
tenovin-6,CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1,1,Preclinical,SIRT inhibitor,targeted cancer
BW-373U86,CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1,0,Preclinical,opioid receptor agonist,noncancer
MLN0128,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,1,Phase 2,mTOR inhibitor,targeted cancer
GW-1929,CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,0,Preclinical,PPAR receptor agonist,noncancer
AZD8330,Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,1,Phase 1,MEK inhibitor,targeted cancer
OSI-420,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,1,Preclinical,EGFR inhibitor,targeted cancer
voglibose,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,0,Launched,glucosidase inhibitor,noncancer
linopirdine,O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1,0,Phase 3,potassium channel blocker,noncancer
sonidegib,C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1,1,Launched,smoothened receptor antagonist,targeted cancer
tozasertib,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1,1,Phase 2,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor",targeted cancer
PIK-293,Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O,0,Preclinical,PI3K inhibitor,targeted cancer
ICI-192605,OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl,0,Phase 2,thromboxane receptor antagonist,Unknown
SB-590885,CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1,1,Preclinical,RAF inhibitor,targeted cancer
tedizolid,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
AR-42,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,1,Phase 1,HDAC inhibitor,targeted cancer
fidarestat,NC(=O)C1CC2(NC(=O)NC2=O)c2cc(F)ccc2O1,0,Phase 3,aldose reductase inhibitor,noncancer
fudosteine,N[C@@H](CSCCCO)C(O)=O,1,Launched,mucolytic agent,noncancer
TG100-115,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,1,Phase 1/Phase 2,PI3K inhibitor,targeted cancer
sitafloxacin,N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F,0,Launched,bacterial DNA gyrase inhibitor,noncancer
quinidine,COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,1,Launched,sodium channel blocker,noncancer
3-carboxy-4-hydroxyphenylglycine-(R),N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer
AZD2461,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,1,Phase 1,PARP inhibitor,targeted cancer
3-carboxy-4-hydroxyphenylglycine-(S),N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer
GSK-J4,CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1,1,Preclinical,histone lysine demethylase inhibitor,targeted cancer
nor-Binaltorphimine-dihydrochloride,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O,0,Preclinical,opioid receptor antagonist,noncancer
UNC1215,O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1,0,Preclinical,L3MBTL antagonist,Unknown
2-BFI,C1CN=C(N1)c1cc2ccccc2o1,0,Preclinical,imidazoline receptor ligand,noncancer
1-acetyl-4-methylpiperazine,CN1CCN(CC1)C(C)=O,0,Preclinical,acetylcholine receptor agonist,noncancer
LGK-974,Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C,0,Phase 2,porcupine inhibitor,targeted cancer
"4-acetyl-1,1-dimethylpiperazinium",CC(=O)N1CC[N+](C)(C)CC1,0,Preclinical,acetylcholine receptor agonist,noncancer
EVP4593,Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1,1,Preclinical,NFkB pathway inhibitor,noncancer
N-acetyltryptamine,CC(=O)NCCc1c[nH]c2ccccc12,0,Preclinical,melatonin receptor agonist,noncancer
EPZ004777,CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
"1-(1,2-Diphenylethyl)piperidine-(+/-)",C(C(N1CCCCC1)c1ccccc1)c1ccccc1,0,Preclinical,glutamate receptor antagonist,noncancer
SANT-1,Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1,0,Preclinical,smoothened receptor antagonist,Unknown
NBQX,NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O,0,Preclinical,glutamate receptor antagonist,noncancer
SC-144,Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21,1,Preclinical,P glycoprotein inhibitor,targeted cancer
A-7,NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,0,Preclinical,calmodulin antagonist,noncancer
JZL-184,OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1,1,Preclinical,monoacylglucerol lipase inhibitor,targeted cancer
PF-4708671,CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F,0,Preclinical,ribosomal protein inhibitor,targeted cancer
pasireotide,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1,0,Launched,somatostatin receptor agonist,noncancer
FPL-62064,COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1,0,Phase 2,"cyclooxygenase inhibitor, lipoxygenase inhibitor",noncancer
LY2608204,O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1,1,Phase 2,glucokinase activator,noncancer
CB-10-277,CN(C)\N=N\c1ccc(cc1)C(O)=O,1,Phase 1,DNA synthesis inhibitor,chemo
givinostat,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,1,Phase 2,HDAC inhibitor,targeted cancer
diclofensine,COc1ccc2C(CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1,0,Phase 3,dopamine reuptake inhibitor,noncancer
AST-1306,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,1,Phase 1,EGFR inhibitor,targeted cancer
tiagabine,Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C,1,Launched,GABA uptake inhibitor,noncancer
diclofenamide,NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
niacin,OC(=O)c1cccnc1,1,Launched,"NAD precursor, vitamin B",noncancer
SB-505124,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,1,Preclinical,ALK tyrosine kinase receptor inhibitor,noncancer
carglumic-acid,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,0,Launched,carbamoyl phosphate synthase activator,noncancer
PIK-294,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O,0,Preclinical,PI3K inhibitor,targeted cancer
LY2228820,CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C,0,Phase 2,p38 MAPK inhibitor,noncancer
roxithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
TXA127,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O,0,Phase 2,angiotensin receptor agonist,targeted cancer
PX-12,CCC(C)SSc1ncc[nH]1,0,Phase 2,thioredoxin inhibitor,targeted cancer
arecaidine-but-2-ynyl-ester,CC#CCOC(=O)C1=CCCN(C)C1,0,Preclinical,acetylcholine receptor agonist,noncancer
GSK2656157,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,1,Preclinical,PERK inhibitor,targeted cancer
arecaidine-propargyl-ester,CN1CCC=C(C1)C(=O)OCC#C,0,Preclinical,acetylcholine receptor agonist,Unknown
NMDA,CN[C@H](CC(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
JQ1-(+),Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1,1,Preclinical,bromodomain inhibitor,targeted cancer
atenolol-(-),CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1,1,Phase 2,adrenergic receptor antagonist,noncancer
KPT-185,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,1,Preclinical,exportin antagonist,Unknown
N-acetylglycyl-D-glutamic-acid,CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
DMH1,CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12,1,Preclinical,ALK tyrosine kinase receptor inhibitor,targeted cancer
beta-CCB,CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21,0,Launched,benzodiazepine receptor ligand,noncancer
IKK-2-inhibitor,NC(=O)c1sc(cc1N)-c1ccsc1,0,Preclinical,"IKK inhibitor, SYK inhibitor",targeted cancer
MDL-72832,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,0,Preclinical,serotonin receptor agonist,noncancer
XL388,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,1,Preclinical,mTOR inhibitor,targeted cancer
Ro-20-1724,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC,0,Preclinical,phosphodiesterase inhibitor,noncancer
AZ20,C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O,1,Preclinical,ATR kinase inhibitor,targeted cancer
YS-035,COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,0,Preclinical,calcium channel blocker,noncancer
KY02111,COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC,1,Preclinical,Wnt pathway inhibitor,noncancer
GBR-13069,Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,0,Preclinical,dopamine uptake inhibitor,noncancer
LDN-212854,C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,1,Preclinical,bone morphogenic protein inhibitor,noncancer
ipragliflozin-l-proline,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1,0,Launched,sodium/glucose cotransporter inhibitor,noncancer
gliclazide,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1,0,Launched,"ATP channel blocker, insulin secretagogue",noncancer
BIBN4096,NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1,0,Phase 2,calcitonin antagonist,noncancer
combretastatin-A-4,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,1,Phase 2,tubulin polymerization inhibitor,chemo
ertugliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1,0,Launched,sodium/glucose cotransporter inhibitor,noncancer
medroxyprogesterone-acetate,C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12,0,Launched,progesterone receptor agonist,noncancer
adrenosterone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O,0,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,noncancer
loperamide,CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1,0,Launched,opioid receptor agonist,noncancer
PU-H71,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,1,Phase 1,HSP inhibitor,Unknown
romidepsin,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,1,Launched,HDAC inhibitor,Unknown
pafuramidine,CONC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(=N)NOC,0,Phase 3,DNA synthesis inhibitor,targeted cancer
emtricitabine,Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1,0,Launched,nucleoside reverse transcriptase inhibitor,noncancer
IDO5L,Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1,0,Preclinical,"indoleamine 2,3-dioxygenase inhibitor",targeted cancer
resatorvid,CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,1,Phase 3,toll-like receptor antagonist,noncancer
tarafenacin,Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2,0,Phase 2,acetylcholine receptor antagonist,noncancer
idelalisib,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,1,Launched,PI3K inhibitor,targeted cancer
Ro-106-9920,O=S(c1ccccc1)c1ccc2nnnn2n1,1,Preclinical,NFkB pathway inhibitor,noncancer
ambroxol,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,0,Launched,sodium channel blocker,noncancer
piroxicam,CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O,1,Launched,cyclooxygenase inhibitor,noncancer
TBOA-(DL),N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O,0,Preclinical,excitatory amino acid transporter inhibitor,Unknown
oprozomib,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,1,Phase 1/Phase 2,proteasome inhibitor,Unknown
apigenin,Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1,0,Preclinical,"casein kinase inhibitor, cell proliferation inhibitor",targeted cancer
pibenzimol,c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1,1,Phase 2,DNA inhibitor,targeted cancer
brefeldin-a,C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1,1,Preclinical,protein synthesis inhibitor,Unknown
etofenamate,OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
SB-216641,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,1,Preclinical,serotonin receptor antagonist,noncancer
tagatose,OCC(O)C(O)C(O)C(=O)CO,1,Phase 3,phosphorylase inhibitor,noncancer
PD-128907,CCCN1CCO[C@H]2[C@@H]1COc1ccc(O)cc21,0,Preclinical,dopamine receptor agonist,noncancer
atenolol-(+/-),CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,Launched,adrenergic receptor antagonist,noncancer
KB-R7943,NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1,0,Preclinical,sodium/calcium exchange inhibitor,noncancer
exemestane,C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O,1,Launched,aromatase inhibitor,targeted cancer
CGP-55845,C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,0,Preclinical,GABA receptor antagonist,noncancer
azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
SDZ-220-581,N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer
danegaptide,NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1,0,Phase 2,gap junction modulator,noncancer
1-deoxymannojirimycin,OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O,0,Preclinical,alpha mannosidase inhibitor,noncancer
fluoxetine,CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
gabazine,COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1,0,Preclinical,GABA receptor antagonist,noncancer
vanoxerine,Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1,1,Phase 3,dopamine uptake inhibitor,noncancer
tempol,CC1(C)CC(O)CC(C)(C)N1O,0,Phase 2,free radical scavenger,targeted cancer
taselisib,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,1,Phase 3,PI3K inhibitor,targeted cancer
proglumide,CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1,0,Withdrawn,CCK receptor antagonist,noncancer
tosufloxacin,NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F,0,Launched,bacterial DNA gyrase inhibitor,noncancer
zolpidem,CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1,0,Launched,benzodiazepine receptor agonist,noncancer
fomocaine,C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1,0,Launched,voltage-gated sodium channel modulator,noncancer
carebastine,CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,0,Phase 1,histamine receptor antagonist,Unknown
ticagrelor,CCCSc1nc(N[C@@H]2C[C@@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)c2n1,0,Launched,purinergic receptor antagonist,noncancer
famciclovir,CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O,1,Launched,DNA polymerase inhibitor,noncancer
fluticasone-propionate,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF,1,Launched,glucocorticoid receptor agonist,noncancer
octenidine,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,1,Launched,membrane integrity inhibitor,noncancer
methoxsalen,COc1c2occc2cc2ccc(=O)oc12,0,Launched,DNA synthesis inhibitor,noncancer
arglabin,CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13,0,Launched,farnesyltransferase inhibitor,targeted cancer
glutathione-monoisopropyl-ester,CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O,0,Phase 2,lipid peroxidase inhibitor,noncancer
GR-144053,NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1,0,Preclinical,integrin antagonist,noncancer
dacarbazine,CN(C)\N=N\c1[nH]cnc1C(N)=O,1,Launched,DNA alkylating agent,chemo
GR-159897,COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1,0,Preclinical,tachykinin antagonist,noncancer
resorcinol,Oc1cccc(O)c1,0,Launched,phosphodiesterase inhibitor,noncancer
olomoucine,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12,0,Preclinical,CDK inhibitor,targeted cancer
irsogladine,Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl,0,Launched,phosphodiesterase inhibitor,noncancer
loreclezole,Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl,0,Phase 2,benzodiazepine receptor agonist,noncancer
IKK-2-inhibitor-V,Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F,1,Phase 1,"IKK inhibitor, NFkB pathway inhibitor",targeted cancer
monastrol,CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1,0,Preclinical,kinesin inhibitor,targeted cancer
tamsulosin,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O,0,Launched,adrenergic receptor antagonist,noncancer
pirinixic-acid,Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,0,Preclinical,PPAR receptor agonist,noncancer
arofylline,CCCn1c(=O)n(-c2ccc(Cl)cc2)c2[nH]cnc2c1=O,0,Phase 3,phosphodiesterase inhibitor,noncancer
ZM-336372,CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1,0,Preclinical,RAF inhibitor,targeted cancer
NSI-189,CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1,0,Phase 2,neurotrophic agent,noncancer
GR-113808,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12,0,Preclinical,serotonin receptor antagonist,noncancer
dolutegravir,C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,1,Launched,HIV integrase inhibitor,noncancer
RX-821002,COC1(COc2ccccc2O1)C1=NCCN1,0,Preclinical,adrenergic receptor antagonist,noncancer
suprofen,CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1,0,Withdrawn,cyclooxygenase inhibitor,noncancer
RS-100329,Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O,0,Preclinical,adrenergic receptor antagonist,noncancer
tivantinib,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,1,Phase 3,tyrosine kinase inhibitor,targeted cancer
SB-756050,COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1,0,Phase 1,G protein-coupled receptor agonist,noncancer
ursodeoxycholyltaurine,C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Phase 2,cholesterol inhibitor,noncancer
eperisone,CCc1ccc(cc1)C(=O)C(C)CN1CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
clofibrate,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,1,Launched,PPAR receptor agonist,noncancer
diethylstilbestrol,CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1,0,Withdrawn,estrogen receptor agonist,targeted cancer
N-salicoylaminophenol,Oc1ccc(NC(=O)c2ccccc2O)cc1,0,Preclinical,ribonucleotide reductase inhibitor,noncancer
delivert,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O,0,Launched,angiotensin receptor agonist,targeted cancer
delapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1,0,Launched,angiotensin converting enzyme inhibitor,noncancer
amuvatinib,S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12,0,Phase 2,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor",targeted cancer
letosteine,CCOC(=O)CSCCC1NC(CS1)C(O)=O,0,Launched,mucolytic agent,noncancer
CC-401,C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1ncn[nH]1,0,Phase 1,JNK inhibitor,targeted cancer
cefoselis,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
RU-58841,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,1,Phase 2,androgen receptor antagonist,noncancer
milacemide,CCCCCNCC(N)=O,0,Phase 3,monoamine oxidase inhibitor,noncancer
allopurinol-riboside,OC[C@H]1O[C@H](C(O)[C@H]1O)n1[nH]cc2c1ncnc2=O,0,Phase 2,anti-leishmanial agent,noncancer
orlistat,CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O,0,Launched,lipase inhibitor,noncancer
xipamide,Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
"L-655,708",CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21,0,Preclinical,GABA receptor inverse agonist,noncancer
tofacitinib,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,0,Launched,JAK inhibitor,noncancer
CH223191,Cc1cc(ccc1NC(=O)c1ccnn1C)\N=N\c1ccccc1C,0,Preclinical,aryl hydrocarbon receptor antagonist,noncancer
pralatrexate,Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,1,Launched,dihydrofolate reductase inhibitor,targeted cancer
UB-165,Clc1ccc(cn1)C1=CCCC2CCC1N2,0,Preclinical,acetylcholine receptor agonist,noncancer
bropirimine,Nc1nc(-c2ccccc2)c(Br)c(=O)[nH]1,0,Phase 3,interferon inducer,targeted cancer
rolipram-R(-),COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1,0,Preclinical,phosphodiesterase inhibitor,noncancer
carbachol,C[N+](C)(C)CCOC(N)=O,1,Launched,cholinergic receptor agonist,noncancer
rolipram-S(+),COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1,0,Preclinical,phosphodiesterase inhibitor,noncancer
procainamide,CCN(CC)CCNC(=O)c1ccc(N)cc1,0,Launched,sodium channel blocker,noncancer
U-99194,CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,0,Preclinical,dopamine receptor antagonist,noncancer
hydrocortisone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
SB-200646,Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12,1,Preclinical,serotonin receptor antagonist,noncancer
alisertib,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,1,Phase 3,Aurora kinase inhibitor,targeted cancer
SB-228357,COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F,1,Preclinical,serotonin receptor antagonist,noncancer
IB-MECA,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12,0,Phase 3,adenosine receptor agonist,targeted cancer
SB-218795,COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1,1,Preclinical,tachykinin antagonist,noncancer
lacitol,OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,1,Launched,osmosis stimulant,noncancer
SB-221284,CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F,0,Preclinical,serotonin receptor antagonist,noncancer
lucitanib,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,1,Phase 2,"FGFR inhibitor, VEGFR inhibitor",targeted cancer
doxapram,CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1,0,Launched,potassium channel blocker,noncancer
preladenant,COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1,0,Phase 3,adenosine receptor antagonist,targeted cancer
acetylcysteine,CC(=O)N[C@@H](CS)C(O)=O,1,Launched,mucolytic agent,noncancer
hymecromone,Cc1cc(=O)oc2cc(O)ccc12,0,Phase 2,monoamine oxidase inhibitor,targeted cancer
maltobionic-acid,OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O,0,Launched,matrix metalloprotease inhibitor,noncancer
dapagliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,0,Launched,sodium/glucose cotransporter inhibitor,noncancer
deserpidine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,0,Launched,angiotensin converting enzyme inhibitor,noncancer
zofenopril-calcium,C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1,0,Launched,angiotensin converting enzyme inhibitor,noncancer
iobenguane,NC(=N)NCc1cccc(I)c1,1,Launched,antineoplastic agent,targeted cancer
umeclidinium,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,0,Launched,acetylcholine receptor antagonist,noncancer
semaxanib,Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1,1,Phase 3,VEGFR inhibitor,targeted cancer
tiquizium,C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1,0,Launched,acetylcholine receptor antagonist,noncancer
BI-2536,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,1,Phase 2,PLK inhibitor,targeted cancer
stepronin,CC(SC(=O)c1cccs1)C(=O)NCC(O)=O,0,Launched,mucolytic agent,noncancer
gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,1,Launched,EGFR inhibitor,targeted cancer
L-152804,CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1,0,Preclinical,neuropeptide receptor antagonist,noncancer
sotalol,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,0,Launched,adrenergic receptor antagonist,noncancer
BML-190,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1,0,Preclinical,cannabinoid receptor inverse agonist,noncancer
mCPP,Clc1cccc(c1)N1CCNCC1,0,Phase 2,serotonin receptor agonist,noncancer
SB-222200,CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1,0,Preclinical,tachykinin antagonist,Unknown
SU014813,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,1,Phase 2,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
PP-1,Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C,1,Preclinical,src inhibitor,targeted cancer
tranilast,COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC,1,Launched,angiogenesis inhibitor,noncancer
kenpaullone,Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1,1,Preclinical,"CDK inhibitor, glycogen synthase kinase inhibitor",targeted cancer
r(-)-apomorphine,CN1CCc2cccc-3c2C1Cc1ccc(O)c(O)c-31,0,Launched,dopamine receptor agonist,noncancer
CP-339818,CCCCCN=c1ccn(Cc2ccccc2)c2ccccc12,0,Preclinical,potassium channel blocker,noncancer
ulipristal,CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,1,Launched,progesterone receptor antagonist,noncancer
NU-1025,Cc1nc2c(O)cccc2c(=O)[nH]1,0,Preclinical,PARP inhibitor,targeted cancer
losartan,CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Launched,angiotensin receptor antagonist,noncancer
FPL-64176,COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1,0,Preclinical,calcium channel activator,noncancer
miltefosine,CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C,0,Launched,membrane integrity inhibitor,noncancer
PP-2,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12,1,Preclinical,src inhibitor,targeted cancer
SR-27897,OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl,1,Phase 2,CCK receptor antagonist,targeted cancer
SDM25N,CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O,0,Preclinical,opioid receptor antagonist,noncancer
alvespimycin,CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O,1,Phase 2,HSP inhibitor,targeted cancer
SK&F-10047-(+),C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C,0,Phase 1,sigma receptor agonist,noncancer
bevantolol,COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC,0,Launched,adrenergic receptor antagonist,noncancer
oltipraz,Cc1c(ssc1=S)-c1cnccn1,1,Phase 3,"nuclear factor erythroid derived, like (NRF2) activator",targeted cancer
arotinolol,CC(C)(C)NCC(O)CSc1nc(cs1)-c1ccc(s1)C(N)=O,0,Launched,adrenergic receptor antagonist,noncancer
eperezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1,0,Phase 1,bacterial 30S ribosomal subunit inhibitor,Unknown
landiolol,CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1,0,Launched,adrenergic receptor antagonist,noncancer
apixaban,COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O,0,Launched,coagulation factor inhibitor,noncancer
flavoxate,Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
cefetamet-pivoxil,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
piclamilast,COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl,0,Phase 2,phosphodiesterase inhibitor,noncancer
pranidipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,1,Phase 2,calcium channel blocker,noncancer
penciclovir,Nc1nc(O)c2ncn(CCC(CO)CO)c2n1,0,Launched,DNA directed DNA polymerase inhibitor,noncancer
timofibrate,CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSCC1C(O)=O,0,Phase 2,"cholesterol inhibitor, lipase clearing factor inhibitor",noncancer
pilsicainide,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,0,Launched,sodium channel blocker,noncancer
avanafil,COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl,1,Launched,phosphodiesterase inhibitor,noncancer
AVN-944,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,1,Phase 2,inosine monophosphate dehydrogenase inhibitor,targeted cancer
lanoconazole,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,1,Launched,sterol demethylase inhibitor,noncancer
1400W,CC(=N)NCc1cccc(CN)c1,0,Preclinical,nitric oxide synthase inhibitor,noncancer
methylnaltrexone,C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@]3(O)CCC4=O)ccc5O,0,Launched,opioid receptor antagonist,noncancer
daidzein,Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,0,Phase 2,estrogen receptor agonist,targeted cancer
naloxone-benzoylhydrazone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1,0,Preclinical,opioid receptor antagonist,noncancer
metamizole,CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O,0,Withdrawn,"cyclooxygenase inhibitor, opioid receptor agonist",noncancer
tazarotene,CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1,0,Launched,retinoid receptor agonist,noncancer
dimethindene-(S)-(+),C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1,0,Preclinical,acetylcholine receptor antagonist,noncancer
yohimbine,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,0,Launched,adrenergic receptor antagonist,noncancer
PPT,CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1,1,Preclinical,estrogen receptor agonist,noncancer
indoramin,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,0,Launched,adrenergic receptor antagonist,noncancer
ezetimibe,OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1,0,Launched,"cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist",noncancer
NVP-DPP728,O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N,0,Phase 2,dipeptidyl peptidase inhibitor,noncancer
amprenavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,0,Launched,HIV protease inhibitor,noncancer
dimethyl-fumarate,COC(=O)\C=C\C(=O)OC,0,Launched,"nuclear factor erythroid derived, like (NRF2) activator",noncancer
adefovir-dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C,1,Launched,DNA polymerase inhibitor,noncancer
bindarit,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,1,Phase 2,NFkB pathway inhibitor,noncancer
aminophylline,Cn1c2nc[nH]c2c(=O)n(C)c1=O,0,Launched,adenosine receptor antagonist,noncancer
ivabradine,COc1cc2C[C@@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC,0,Launched,"HCN channel antagonist, potassium channel blocker, sodium channel blocker",noncancer
CC-930,O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1,0,Phase 2,JNK inhibitor,noncancer
barnidipine,COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1,0,Launched,calcium channel blocker,noncancer
mitomycin-c,CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,1,Launched,"DNA alkylating agent, DNA synthesis inhibitor",chemo
omeprazole-sulfide,COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1,0,Phase 1,ATPase inhibitor,noncancer
zonisamide,NS(=O)(=O)Cc1noc2ccccc12,0,Launched,"sodium channel blocker, T-type calcium channel blocker",noncancer
morniflumate,FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1,0,Launched,anti-inflammatory agent,noncancer
febuxostat,CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O,0,Launched,xanthine oxidase inhibitor,noncancer
perospirone,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
bruceantin,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,1,Phase 2,protein synthesis inhibitor,Unknown
propacetamol,CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,0,Launched,cyclooxygenase inhibitor,noncancer
fosfomycin,C[C@@H]1O[C@@H]1P(O)(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
azosemide,NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl,0,Launched,electrolyte reabsorption inhibitor,noncancer
ivermectin,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,1,Launched,benzodiazepine receptor agonist,noncancer
PYM50028,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1,0,Phase 2,neurotrophic agent,noncancer
moxifloxacin,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
triptorelin,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,0,Launched,gonadotropin releasing factor hormone receptor agonist,targeted cancer
chlorothiazide,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,0,Launched,diuretic,noncancer
glasdegib,CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N,0,Phase 2,hedgehog pathway inhibitor,targeted cancer
lubiprostone,CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,0,Launched,chloride channel activator,noncancer
ropinirole,CCCN(CCC)CCc1cccc2NC(=O)Cc12,0,Launched,dopamine receptor agonist,noncancer
desonide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
fluspirilene,Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1,0,Launched,dopamine receptor antagonist,noncancer
monobenzone,Oc1ccc(OCc2ccccc2)cc1,1,Launched,melanin inhibitor,noncancer
furosemide,NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl,0,Launched,diuretic,noncancer
flucytosine,Nc1nc(=O)[nH]cc1F,0,Launched,other antifungal,noncancer
LY2090314,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,1,Phase 2,glycogen synthase kinase inhibitor,targeted cancer
GP2a,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1,0,Preclinical,cannabinoid receptor agonist,noncancer
oxiperomide,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,1,Phase 2,dopamine receptor antagonist,noncancer
PD-407824,Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1,1,Preclinical,PKC inhibitor,targeted cancer
enoxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1,0,Launched,topoisomerase inhibitor,noncancer
LY364947,c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1,1,Preclinical,"TGF beta receptor inhibitor, p38 MAPK inhibitor",targeted cancer
pemirolast,Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O,0,Launched,mediator release inhibitor,noncancer
RWJ-21757,Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1,0,Phase 1,toll-like receptor agonist,noncancer
indinavir,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12,0,Launched,HIV protease inhibitor,noncancer
SB-225002,Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O,1,Preclinical,CC chemokine receptor antagonist,noncancer
levobunolol,CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12,1,Launched,adrenergic receptor antagonist,noncancer
nintedanib,COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1,1,Launched,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
ifosfamide,ClCCNP1(=O)OCCCN1CCCl,1,Launched,DNA alkylating agent,chemo
pentolinium,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,0,Launched,cholinergic receptor antagonist,noncancer
donepezil,COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC,0,Launched,acetylcholinesterase inhibitor,noncancer
piperaquine-phosphate,Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1,0,Launched,antimalarial agent,noncancer
GSK2636771,Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O,0,Phase 2,PI3K inhibitor,targeted cancer
2-[1-(4-piperonyl)piperazinyl]benzothiazole,C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1,0,Preclinical,serotonin receptor agonist,noncancer
dasatinib,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,1,Launched,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor",targeted cancer
2-iodomelatonin,COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1,0,Preclinical,melatonin receptor agonist,noncancer
thioguanine,Nc1nc2nc[nH]c2c(=S)[nH]1,1,Launched,purine antagonist,targeted cancer
naltrindole,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O,0,Preclinical,opioid receptor antagonist,noncancer
desmopressin-acetate,NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCNC(N)=N)C(=O)NCC(N)=O,0,Launched,vasopressin receptor agonist,noncancer
DPPE,CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,0,Phase 3,histamine receptor antagonist,Unknown
SDZ-NKT-343,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O,0,Phase 1,tachykinin antagonist,noncancer
ceramide,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O,0,Launched,"phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator",noncancer
picotamide,COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1,0,Launched,"thromboxane receptor antagonist, thromboxane synthase inhibitor",noncancer
4-IBP,Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1,0,Preclinical,sigma receptor agonist,targeted cancer
miglitol,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,0,Launched,glucosidase inhibitor,noncancer
PG-9,CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1,0,Preclinical,acetylcholine receptor agonist,noncancer
TC2559,CCOc1cncc(\C=C\CCNC)c1,0,Preclinical,acetylcholine receptor agonist,noncancer
methocarbamol,COc1ccccc1OCC(O)COC(N)=O,1,Launched,muscle relaxant,noncancer
caffeic-acid-phenethyl-ester,Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O,1,Preclinical,HIV integrase inhibitor,targeted cancer
indobufen,CCC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,0,Launched,"cyclooxygenase inhibitor, platelet aggregation inhibitor",noncancer
NNC-05-2090,COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1,0,Preclinical,"GABA uptake inhibitor, GAT inhibitor",Unknown
lonidamine,OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12,0,Launched,glucokinase inhibitor,targeted cancer
KF-38789,COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1,1,Preclinical,P selectin inhibitor,noncancer
dolastatin-10,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,1,Phase 2,tubulin polymerization inhibitor,targeted cancer
GP1a,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1,0,Preclinical,cannabinoid receptor agonist,noncancer
ixazomib,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,1,Launched,proteasome inhibitor,Unknown
PQ-401,COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,1,Preclinical,IGF-1 inhibitor,targeted cancer
leflunomide,Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F,0,Launched,"dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor",noncancer
PI-828,Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1,1,Preclinical,PI3K inhibitor,noncancer
cefotetan,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
EO-1428,Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl,0,Preclinical,p38 MAPK inhibitor,noncancer
AMG-208,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,1,Phase 1,tyrosine kinase inhibitor,targeted cancer
GW-843682X,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC,1,Preclinical,PLK inhibitor,targeted cancer
ZK-93423,CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC,1,Phase 3,benzodiazepine receptor agonist,noncancer
1-naphthyl-PP1,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12,1,Preclinical,src inhibitor,targeted cancer
oxypurinol,O=c1[nH]c2n[nH]cc2c(=O)[nH]1,0,Phase 2/Phase 3,xanthine oxidase inhibitor,noncancer
ketanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,0,Launched,serotonin receptor antagonist,noncancer
SM-21,CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C,0,Preclinical,sigma receptor antagonist,noncancer
TTNPB,C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C,0,Phase 1,retinoid receptor agonist,noncancer
clobenpropit,Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1,0,Preclinical,histamine receptor antagonist,noncancer
fludroxycortide,CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
N-benzylnaltrindole,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1,0,Preclinical,opioid receptor antagonist,noncancer
benazepril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
AM-580,CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O,1,Preclinical,retinoid receptor agonist,targeted cancer
etofylline-clofibrate,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,1,Launched,platelet aggregation inhibitor,noncancer
N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide,Ic1ccc(cc1)C(=O)NCCN1CCCCC1,0,Preclinical,sigma receptor ligand,noncancer
PD-0325901,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,1,Phase 2,MEK inhibitor,targeted cancer
PF-04447943,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2n(ncc2c(=O)[nH]1)C1CCOCC1,0,Phase 2,phosphodiesterase inhibitor,noncancer
UH-232-(+),CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,1,Preclinical,dopamine receptor antagonist,noncancer
linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
ICI-199441,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1,0,Preclinical,opioid receptor agonist,noncancer
dipraglurant,Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1,0,Phase 2,glutamate receptor negative allosteric modulator,noncancer
iodophenpropit,Ic1ccc(CCNC(=N)SCCCc2c[nH]cn2)cc1,0,Preclinical,histamine receptor antagonist,noncancer
cordycepin,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O,0,Phase 1/Phase 2,DNA inhibitor,chemo
NCS-382,OC1c2ccccc2CCC\C1=C/C(O)=O,0,Preclinical,GABA receptor antagonist,noncancer
GSK-3-inhibitor-IX,O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12,1,Preclinical,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor",targeted cancer
primidone,CCC1(C(=O)NCNC1=O)c1ccccc1,0,Launched,GABA receptor antagonist,noncancer
SD-208,Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1,0,Preclinical,TGF beta receptor inhibitor,noncancer
MK-0893,COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1,0,Phase 2,glucagon receptor antagonist,noncancer
compound-401,O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1,0,Preclinical,DNA dependent protein kinase inhibitor,noncancer
cyclizine,CN1CCN(CC1)C(c1ccccc1)c1ccccc1,0,Launched,histamine receptor modulator,noncancer
BI-78D3,Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1,1,Preclinical,JNK inhibitor,noncancer
bavisant,O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1,0,Phase 2,histamine receptor antagonist,noncancer
JK-184,CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1,1,Preclinical,hedgehog pathway inhibitor,targeted cancer
metformin,CN(C)C(=N)NC(N)=N,0,Launched,insulin sensitizer,noncancer
"L-798,106",COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1,1,Preclinical,prostanoid receptor antagonist,noncancer
sildenafil,CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1,0,Launched,phosphodiesterase inhibitor,noncancer
sirolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O,1,Launched,mTOR inhibitor,noncancer
CGP-52411,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12,1,Preclinical,EGFR inhibitor,targeted cancer
dextromethorphan,COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1,0,Launched,"glutamate receptor antagonist, sigma receptor agonist",noncancer
JNJ-17203212,FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1,0,Preclinical,TRPV antagonist,noncancer
levalbuterol,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,0,Launched,adrenergic receptor agonist,noncancer
WAY-200070,Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1,0,Preclinical,estrogen receptor agonist,noncancer
etomoxir,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,1,Phase 2,carnitine palmitoyltransferase inhibitor,noncancer
meclofenamic-acid,Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl,0,Launched,"cyclooxygenase inhibitor, prostanoid receptor antagonist",noncancer
2-CMDO,CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12,0,Preclinical,dopamine receptor antagonist,noncancer
clomethiazole,Cc1ncsc1CCCl,0,Launched,"GABA receptor antagonist, GABA receptor modulator",noncancer
N-MPPP,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1,0,Preclinical,opioid receptor agonist,noncancer
taladegib,CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F,0,Phase 2,smoothened receptor antagonist,targeted cancer
SB-203186,O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,0,Preclinical,serotonin receptor antagonist,noncancer
E-2012,COc1cc(ccc1-n1cnc(C)c1)\C=C1/CCCN([C@@H](C)c2ccc(F)cc2)C1=O,0,Phase 1,gamma secretase modulator,noncancer
antazoline,C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1,0,Launched,antihistamine,Unknown
capsaicin,COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O,1,Launched,TRPV agonist,noncancer
fipronil,Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)S(=O)C(F)(F)F,0,Launched,"chloride channel blocker, GABA gated chloride channel blocker",noncancer
"ICI-118,551",CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12,0,Phase 2,adrenergic receptor antagonist,noncancer
CTS-1027,ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,0,Phase 2,metalloproteinase inhibitor,noncancer
tiotidine,CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N,1,Phase 2,histamine receptor antagonist,noncancer
progesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,progesterone receptor agonist,noncancer
talarozole,CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1,0,Phase 2,cytochrome P450 inhibitor,noncancer
nefiracetam,Cc1cccc(C)c1NC(=O)CN1CCCC1=O,1,Phase 3,"acetylcholine receptor agonist, benzodiazepine receptor agonist",noncancer
ASP3026,COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,0,Phase 1,ALK tyrosine kinase receptor inhibitor,targeted cancer
ixazomib-citrate,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,1,Launched,proteasome inhibitor,Unknown
bilastine,CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1,0,Launched,histamine receptor antagonist,noncancer
ABT-702,Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1,1,Preclinical,adenosine kinase inhibitor,noncancer
hexylcaine,CC(CNC1CCCCC1)OC(=O)c1ccccc1,0,Launched,sodium channel blocker,noncancer
T-0901317,OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F,0,Preclinical,LXR agonist,noncancer
ezatiostat,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,0,Phase 2,glutathione transferase inhibitor,targeted cancer
GW-405833,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,1,Preclinical,cannabinoid receptor agonist,noncancer
EMD-386088,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1,0,Preclinical,serotonin receptor agonist,noncancer
AMN-082,C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1,0,Preclinical,glutamate receptor modulator,noncancer
acitazanolast,OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1,0,Launched,mediator release inhibitor,Unknown
LY456236,COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1,1,Preclinical,glutamate receptor antagonist,noncancer
obidoxime,O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,1,Launched,cholinesterase reactivator,noncancer
hydroxyfasudil,Oc1nccc2c(cccc12)S(=O)(=O)N1CCCNCC1,0,Preclinical,rho associated kinase inhibitor,noncancer
BIBU-1361,CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,1,Preclinical,EGFR inhibitor,targeted cancer
icariin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,0,Phase 3,phosphodiesterase inhibitor,targeted cancer
LY303511,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1,1,Preclinical,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor",targeted cancer
matrine,O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34,0,Phase 2,opioid receptor agonist,targeted cancer
S26948,COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC,1,Preclinical,PPAR receptor agonist,noncancer
AC-264613,C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1,1,Preclinical,PAR agonist,noncancer
"4,4-pentamethylenepiperidine",C1CCC2(CC1)CCNCC2,0,Preclinical,M2 channel blocker,noncancer
gedunin,CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1,0,Preclinical,HSP inhibitor,targeted cancer
A740003,COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC,0,Preclinical,purinergic receptor antagonist,noncancer
LY2365109,CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O,0,Preclinical,Glycine transporter 1 inhibitor,Unknown
AG-490,Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1,0,Preclinical,"EGFR inhibitor, JAK inhibitor",targeted cancer
BMS-649,CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O,0,Preclinical,retinoid receptor agonist,noncancer
cimaterol,CC(C)NCC(O)c1ccc(N)c(c1)C#N,0,Preclinical,adrenergic receptor agonist,noncancer
oncrasin-1,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,1,Preclinical,apoptosis stimulant,targeted cancer
tyrphostin-AG-18,Oc1ccc(C=C(C#N)C#N)cc1O,0,Preclinical,"EGFR inhibitor, tyrosine kinase inhibitor",targeted cancer
4-iodo-6-phenylpyrimidine,Ic1cc(ncn1)-c1ccccc1,1,Preclinical,macrophage migration inhibiting factor inhibitor,targeted cancer
tyrphostin-AG-99,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,1,Preclinical,tyrosine kinase inhibitor,targeted cancer
GSK-0660,COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC,0,Preclinical,PPAR receptor antagonist,noncancer
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1,1,Preclinical,serotonin receptor antagonist,noncancer
SID-7969543,CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O,1,Preclinical,steroidogenic factor antagonist,noncancer
tyrphostin-AG-835,C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1,0,Preclinical,protein tyrosine kinase inhibitor,targeted cancer
fludarabine,Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,Launched,ribonucleotide reductase inhibitor,chemo
tyrphostin-AG-494,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,1,Preclinical,EGFR inhibitor,targeted cancer
FERb-033,O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O,1,Preclinical,EGFR inhibitor,targeted cancer
CCT018159,CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O,0,Preclinical,HSP inhibitor,targeted cancer
paeonol,COc1ccc(C(C)=O)c(O)c1,0,Preclinical,anti-inflammatory agent,noncancer
JNJ-10191584,CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1,0,Preclinical,histamine receptor antagonist,noncancer
sinomenine,COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,0,Preclinical,angiogenesis inhibitor,Unknown
CGP-53353,Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1,0,Preclinical,"EGFR inhibitor, PKC inhibitor",targeted cancer
cinchonidine,O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12,0,Phase 1,P glycoprotein inhibitor,targeted cancer
LY344864,CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1,0,Preclinical,serotonin receptor agonist,noncancer
LY2183240,CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1,1,Preclinical,"FAAH inhibitor, FAAH reuptake inhibitor",noncancer
parthenolide-(-),C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,1,Preclinical,NFkB pathway inhibitor,targeted cancer
CO-101244,Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,0,Preclinical,glutamate receptor antagonist,noncancer
4-methylgenistein,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,1,Preclinical,protein tyrosine kinase inhibitor,targeted cancer
arcyriaflavin-a,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,1,Preclinical,CDK inhibitor,targeted cancer
emodin,Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,0,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,targeted cancer
ZM-447439,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
gramine,CN(C)Cc1c[nH]c2ccccc12,0,Preclinical,norepinephrine reputake inhibitor,noncancer
lazabemide,NCCNC(=O)c1ccc(Cl)cn1,0,Phase 3,monoamine oxidase inhibitor,noncancer
nobiletin,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,1,Preclinical,MEK inhibitor,targeted cancer
2-TEDC,Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O,0,Preclinical,lipoxygenase inhibitor,noncancer
3-AQC,C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N,0,Preclinical,serotonin receptor agonist,noncancer
PNU-74654,Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1,0,Preclinical,beta-catenin inhibitor,targeted cancer
8-hydroxy-PIPAT,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,1,Preclinical,dopamine receptor ligand,noncancer
KU-55933,O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1,0,Preclinical,ATM kinase inhibitor,noncancer
ICI-89406,OC(CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N,0,Phase 1,adrenergic receptor antagonist,noncancer
INH1,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,1,Preclinical,Hec1 inhibitor,targeted cancer
cyanopindolol,CC(C)(C)NCC(O)COc1cccc2[nH]c(cc12)C#N,0,Phase 2,adrenergic receptor antagonist,noncancer
SB-657510,COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1,1,Preclinical,urotensin receptor antagonist,noncancer
U-0126,N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N,1,Preclinical,MEK inhibitor,targeted cancer
GSK650394,OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1,1,Preclinical,serum/glucocorticoid regulated kinase inhibitor,targeted cancer
LFM-A13,CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br,0,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1,1,Launched,HDAC inhibitor,Unknown
nafadotride,CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC,0,Preclinical,dopamine receptor antagonist,noncancer
STF-62247,Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1,0,Preclinical,autophagy inducer,targeted cancer
chromanol-(+/-),CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Preclinical,potassium channel blocker,Unknown
ZSTK-474,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,1,Phase 1/Phase 2,PI3K inhibitor,targeted cancer
"chromanol-293B-(-)-[3R,4S]",CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Preclinical,potassium channel blocker,noncancer
GDC-0879,OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1,1,Preclinical,RAF inhibitor,targeted cancer
SDZ-WAG-994,CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12,1,Phase 2,adenosine receptor agonist,noncancer
phloretin,Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1,0,Launched,sodium/glucose cotransporter inhibitor,noncancer
brimonidine,Brc1c(NC2=NCCN2)ccc2nccnc12,0,Launched,adrenergic receptor agonist,noncancer
IBC-293,CC(C)n1nnc2cc(ccc12)C(O)=O,0,Preclinical,hydroxycarboxylic acid receptor agonist,noncancer
butylscopolamine-bromide,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,1,Launched,cholinergic receptor antagonist,noncancer
hesperetin,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,0,Launched,ACAT inhibitor,targeted cancer
kinetin,C(Nc1ncnc2[nH]cnc12)c1ccco1,0,Launched,cell division inducer,noncancer
inimur,CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1,0,Launched,other antifungal,noncancer
oleanolic-acid,CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O,1,Preclinical,G protein-coupled receptor agonist,noncancer
nepicastat,NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1,0,Phase 2,dopamine beta hydroxylase inhibitor,noncancer
phlorizin,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,1,Preclinical,sodium/glucose cotransporter inhibitor,noncancer
exatecan-mesylate,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45,1,Phase 3,topoisomerase inhibitor,Unknown
TG-100572,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,1,Preclinical,"src inhibitor, VEGFR inhibitor",targeted cancer
tangeritin,COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,0,Preclinical,cell cycle inhibitor,noncancer
CS-917,CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O,0,Phase 2,fructose biphosphate inhibitor,noncancer
dioscin,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,1,Preclinical,apoptosis stimulant,targeted cancer
plinabulin,CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O,1,Phase 3,tubulin polymerization inhibitor,Unknown
deflazacort,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,1,Launched,glucocorticoid receptor agonist,noncancer
diarylpropionitrile,Oc1ccc(CC(C#N)c2ccc(O)cc2)cc1,0,Preclinical,estrogen receptor agonist,targeted cancer
sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,1,Launched,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor",targeted cancer
BAY-11-7085,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,1,Preclinical,NFkB pathway inhibitor,targeted cancer
SB-216763,Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12,0,Preclinical,glycogen synthase kinase inhibitor,noncancer
BAY-11-7082,Cc1ccc(cc1)S(=O)(=O)\C=C\C#N,1,Preclinical,NFkB pathway inhibitor,noncancer
LY294002,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1,0,Preclinical,"mTOR inhibitor, PI3K inhibitor, DNA dependent protein kinase inhibitor, phosphodiesterase inhibitor, PLK inhibitor",targeted cancer
U-0124,CS\C(N)=C(C#N)\C(C#N)=C(/N)SC,0,Preclinical,MEK inhibitor,noncancer
NVP-AEW541,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,1,Preclinical,IGF-1 inhibitor,targeted cancer
MEK1-2-inhibitor,N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F,1,Preclinical,MEK inhibitor,noncancer
NVP-ADW742,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1,0,Preclinical,insulin growth factor receptor inhibitor,targeted cancer
LY320135,COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N,0,Preclinical,cannabinoid receptor antagonist,noncancer
BTZ043-racemate,CC1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1,0,Preclinical,DPRE1 inhibitor,noncancer
MRS3777,C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12,0,Preclinical,adenosine receptor antagonist,noncancer
AR-12,NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F,1,Phase 1,phosphoinositide dependent kinase inhibitor,targeted cancer
proxyfan,C(COCc1ccccc1)Cc1cnc[nH]1,0,Preclinical,histamine receptor modulator,noncancer
axitinib,CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1,1,Launched,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
Y-27632,C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1,1,Preclinical,rho associated kinase inhibitor,targeted cancer
SB-202190,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,0,Preclinical,p38 MAPK inhibitor,targeted cancer
K-858,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,1,Preclinical,kinesin-like spindle protein inhibitor,targeted cancer
rucaparib,CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23,0,Phase 3,PARP inhibitor,targeted cancer
valaciclovir,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O,0,Launched,DNA polymerase inhibitor,noncancer
myricetin,Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O,0,Preclinical,"androgen receptor agonist, cytochrome P450 inhibitor",targeted cancer
alibendol,COc1cc(CC=C)cc(C(=O)NCCO)c1O,0,Launched,antispasmodic,noncancer
oridonin,O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C,1,Preclinical,BCL inhibitor,targeted cancer
YM-155,COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C,1,Phase 2,survivin inhibitor,Unknown
sclareolide,C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2,0,Launched,other antifungal,noncancer
AS-77,O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1,0,Preclinical,potassium channel blocker,noncancer
xanthone,O=c1c2ccccc2oc2ccccc12,0,Preclinical,antimalarial agent,noncancer
BMS-986020,C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1,1,Phase 2,lysophosphatidic acid receptor antagonist,noncancer
bilobalide,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)C123,0,Preclinical,GABA receptor modulator,noncancer
SB-2343,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,1,Phase 1,"mTOR inhibitor, PI3K inhibitor",targeted cancer
dihydroartemisinin,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,Launched,antimalarial agent,noncancer
CGM097,COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1,1,Phase 1,MDM inhibitor,targeted cancer
limonin,CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1,0,Preclinical,HIV protease inhibitor,targeted cancer
faropenem-medoxomil,C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C,0,Launched,lactamase inhibitor,noncancer
myricitrin,C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](O)[C@H]1O,0,Preclinical,PKC inhibitor,noncancer
FK-3311,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,1,Phase 2,cyclooxygenase inhibitor,noncancer
sarafloxacin,OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,Launched,bacterial DNA gyrase inhibitor,noncancer
FR-180204,Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1,0,Preclinical,MAP kinase inhibitor,targeted cancer
NVP-TAE684,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,1,Preclinical,ALK tyrosine kinase receptor inhibitor,targeted cancer
VU0361737,COc1cc(NC(=O)c2ccccn2)ccc1Cl,1,Preclinical,glutamate receptor positive allosteric modulator,noncancer
dovitinib,CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O,1,Phase 3,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
AS-1949490,C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1,1,Preclinical,SHIP2 phosphatase inhibitor,noncancer
obatoclax,COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1,1,Phase 3,BCL inhibitor,targeted cancer
efonidipine-monoethanolate,CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1,1,Launched,"L-type calcium channel blocker, T-type calcium channel blocker",Unknown
NVP-AUY922,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,1,Phase 2,HSP inhibitor,targeted cancer
BYK-204165,Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12,0,Preclinical,PARP inhibitor,noncancer
SU-11274,CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1,0,Preclinical,"hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor",targeted cancer
UPF-1069,O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1,0,Preclinical,PARP inhibitor,noncancer
PHA-665752,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,1,Preclinical,c-Met inhibitor,targeted cancer
BF2.649,Clc1ccc(CCCOCCCN2CCCCC2)cc1,1,Phase 3,histamine receptor antagonist,noncancer
GSK1904529A,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,1,Preclinical,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand",targeted cancer
RN-1747,[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,0,Preclinical,TRPV agonist,noncancer
candesartan-cilextil,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Launched,angiotensin receptor antagonist,noncancer
RN-1734,CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl,1,Preclinical,TRPV antagonist,noncancer
diclazuril,Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O,1,Launched,antiprotozoal agent,noncancer
CCMI,Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1,1,Preclinical,acetylcholine receptor allosteric modulator,noncancer
temocapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,1,Launched,angiotensin converting enzyme inhibitor,noncancer
puerarin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O,0,Phase 2,serotonin receptor antagonist,noncancer
taurine,NCCS(O)(=O)=O,1,Launched,antioxidant,noncancer
avobenzone,COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C,0,Launched,UV blocker,Unknown
diosgenin,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1,0,Preclinical,steroid,targeted cancer
PCI-34051,COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1,0,Preclinical,HDAC inhibitor,targeted cancer
formononetin,COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,0,Preclinical,alcohol dehydrogenase inhibitor,targeted cancer
PF-573228,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1,1,Preclinical,focal adhesion kinase inhibitor,targeted cancer
nalidixic-acid,CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12,0,Launched,bacterial DNA gyrase inhibitor,noncancer
tropisetron,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12,1,Launched,serotonin receptor antagonist,noncancer
osthol,COc1ccc2ccc(=O)oc2c1CC=C(C)C,0,Preclinical,calcium channel blocker,noncancer
adenine,Nc1ncnc2[nH]cnc12,0,Preclinical,protein synthesis stimulant,noncancer
taxifolin,O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1,0,Phase 2,opioid receptor antagonist,noncancer
BMS-265246,CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F,1,Preclinical,CDK inhibitor,targeted cancer
hyodeoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,1,Phase 1,atherosclerosis formation inhibitor,noncancer
diosmetin,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1,0,Launched,aryl hydrocarbon receptor agonist,noncancer
magnolol,Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O,0,Preclinical,PPAR receptor agonist,targeted cancer
salidroside,OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,1,Preclinical,beta amyloid protein neurotoxicity inhibitor,noncancer
naringin,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O,0,Preclinical,cytochrome P450 inhibitor,noncancer
isoliquiritigenin,Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O,0,Preclinical,guanylate cyclase activator,targeted cancer
cardiogenol-c,COc1ccc(Nc2nccc(NCCO)n2)cc1,0,Preclinical,cardiomyogenesis inducer,Unknown
imidapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,1,Launched,angiotensin converting enzyme inhibitor,noncancer
tranylcypromine,N[C@H]1C[C@@H]1c1ccccc1,0,Launched,monoamine oxidase inhibitor,noncancer
benidipine,COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1,0,Launched,calcium channel blocker,noncancer
bicuculline-methochloride-(-),C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21,0,Preclinical,GABA receptor antagonist,noncancer
uridine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O,1,Phase 2,dopamine receptor agonist,noncancer
bicuculline-(+),CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21,0,Preclinical,GABA receptor antagonist,noncancer
clindamycin-phosphate,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,1,Launched,protein synthesis inhibitor,noncancer
muscimol,NCc1cc(O)no1,0,Phase 1,benzodiazepine receptor agonist,noncancer
cleviprex,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC,0,Launched,calcium channel blocker,noncancer
ambenonium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,0,Launched,cholinesterase inhibitor,noncancer
bromhexine,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1,0,Launched,mucolytic agent,noncancer
rivastigmine,CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,0,Launched,acetylcholinesterase inhibitor,noncancer
cilazapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
galantamine,COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24,0,Launched,acetylcholinesterase inhibitor,noncancer
detomidine,Cc1cccc(Cc2c[nH]cn2)c1C,0,Launched,adrenergic receptor agonist,noncancer
EIT-hydrobromide,CCSC(N)=N,0,Preclinical,nitric oxide synthase inhibitor,noncancer
guanfacine,NC(=N)NC(=O)Cc1c(Cl)cccc1Cl,0,Launched,adrenergic receptor agonist,noncancer
memantine,CC12CC3CC(C)(C1)CC(N)(C3)C2,0,Launched,glutamate receptor antagonist,noncancer
genipin,COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO,1,Preclinical,choleretic agent,targeted cancer
rutaecarpine,O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12,0,Preclinical,cyclooxygenase inhibitor,noncancer
fleroxacin,CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O,1,Launched,topoisomerase inhibitor,noncancer
mannitol-D,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,Launched,diuretic,noncancer
naringin-dihydrochalcone,C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,0,Preclinical,cytochrome P450 inhibitor,noncancer
corticosterone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,0,Preclinical,mineralocorticoid receptor agonist,noncancer
palmatine-chloride,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,1,Preclinical,dopamine synthesis inhibitor,noncancer
digitoxigenin,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,1,Preclinical,ATPase inhibitor,Unknown
geniposidic-acid,OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O,0,Preclinical,cyclooxygenase inhibitor,noncancer
clobutinol,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,1,Withdrawn,antitussive,noncancer
evodiamine,CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12,1,Preclinical,"ATPase inhibitor, TRPV agonist",targeted cancer
"hydroxytacrine-maleate-(r,s)",Nc1c2C(O)CCCc2nc2ccccc12,1,Preclinical,cholinesterase inhibitor,noncancer
chrysophanic-acid,Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,0,Preclinical,EGFR inhibitor,targeted cancer
stanozolol,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4Cc5[nH]ncc5C[C@]4(C)[C@H]3CC[C@]12C,0,Launched,androgen receptor agonist,noncancer
astragaloside-a,CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C,0,Preclinical,antiinflammatory agent,noncancer
oxotremorine-m,C[N+](C)(C)CC#CCN1CCCC1=O,0,Preclinical,acetylcholine receptor agonist,noncancer
cyclopiazonic-acid,CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O,0,Preclinical,ATPase inhibitor,noncancer
almotriptan,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,0,Launched,serotonin receptor agonist,noncancer
vincristine,CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC,1,Launched,tubulin polymerization inhibitor,chemo
azasetron,CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC1CN2CCC1CC2,0,Launched,serotonin receptor antagonist,noncancer
anisomycin,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,1,Preclinical,DNA synthesis inhibitor,noncancer
ginkgolide-a,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,1,Preclinical,GABA receptor antagonist,noncancer
BADGE,CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1,0,Preclinical,PPAR receptor antagonist,targeted cancer
dimaprit,CN(C)CCCSC(N)=N,0,Preclinical,histamine receptor agonist,noncancer
sulindac,CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O,0,Launched,cyclooxygenase inhibitor,noncancer
thonzonium,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1,1,Launched,ATPase inhibitor,noncancer
flurbiprofen-(+/-),CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
metrizamide,CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I,0,Launched,radiopaque medium,noncancer
ipsapirone,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,1,Phase 3,serotonin receptor agonist,noncancer
NSC-3852,Oc1ccc([N+][O-])c2cccnc12,1,Preclinical,HDAC inhibitor,targeted cancer
digoxigenin,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,1,Preclinical,steroid,noncancer
butalbital,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,0,Launched,GABA receptor antagonist,noncancer
niridazole,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,1,Launched,phosphofructokinase inhibitor,noncancer
20-hydroxyecdysone,CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C,0,Preclinical,ecdysone receptor modulator,noncancer
benperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,0,Launched,dopamine receptor antagonist,noncancer
norcyclobenzaprine,CNCCC=C1c2ccccc2C=Cc2ccccc12,0,Preclinical,"adrenergic receptor agonist, serotonin receptor antagonist",noncancer
finafloxacin,OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,1,Launched,bacterial DNA gyrase inhibitor,noncancer
pirenperone,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,1,Preclinical,serotonin receptor antagonist,noncancer
benserazide,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,0,Launched,DOPA decarboxylase inhibitor,noncancer
parthenolide-(alternate-stereo),C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,0,Preclinical,NFkB pathway inhibitor,targeted cancer
hexestrol,CCC(C(CC)c1ccc(O)cc1)c1ccc(O)cc1,0,Launched,synthetic estrogen,noncancer
BP-897,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,0,Phase 2,dopamine receptor agonist,noncancer
olopatadine,CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12,0,Launched,histamine receptor antagonist,noncancer
prenylamine,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,0,Withdrawn,calcium channel blocker,noncancer
celiprolol,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(C)=O,0,Launched,adrenergic receptor antagonist,noncancer
demecarium,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,1,Launched,acetylcholinesterase inhibitor,noncancer
cephalomannine,C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1,1,Preclinical,DNA polymerase inhibitor,Unknown
picrotoxinin,CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C,0,Preclinical,GABA receptor antagonist,noncancer
XE-991,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12,0,Preclinical,potassium channel blocker,noncancer
GS-39783,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,1,Preclinical,GABA receptor modulator,noncancer
nalmefene,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O,0,Launched,opioid receptor antagonist,noncancer
SKF-86002,Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1,0,Preclinical,p38 MAPK inhibitor,noncancer
dicycloverine,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,1,Launched,acetylcholine receptor antagonist,noncancer
PSB-1115,CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O,1,Preclinical,adenosine receptor antagonist,noncancer
isoxicam,CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O,0,Withdrawn,cyclooxygenase inhibitor,noncancer
PSB-11,CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1,0,Preclinical,adenosine receptor antagonist,noncancer
ethoxzolamide,CCOc1ccc2nc(sc2c1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
PSB-36,CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3,0,Preclinical,adenosine receptor antagonist,noncancer
oxethazaine,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1,0,Launched,local anesthetic,noncancer
LE-135,CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C,1,Preclinical,retinoid receptor agonist,noncancer
ractopamine,CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1,0,Launched,adrenergic receptor agonist,noncancer
cinalukast,CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O,1,Phase 2,leukotriene receptor antagonist,noncancer
cloprostenol-(+/-),O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,0,Launched,prostaglandin receptor agonist,noncancer
dimethisoquin,CCCCc1cc2ccccc2c(OCCN(C)C)n1,1,Launched,local anesthetic,noncancer
dipivefrine,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,0,Launched,adrenergic receptor agonist,noncancer
moroxydine,NC(=N)NC(=N)N1CCOCC1,0,Launched,antiviral,noncancer
acefylline,Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O,0,Launched,adenosine receptor agonist,Unknown
opipramol,OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1,0,Launched,sigma receptor agonist,noncancer
10-deacetylbaccatin,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C,1,Preclinical,antitumor agent,targeted cancer
lappaconite,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,1,Phase 2,sodium channel blocker,noncancer
GW-501516,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F,1,Phase 2,PPAR receptor agonist,noncancer
rheochrysidin,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,1,Preclinical,protein tyrosine kinase inhibitor,targeted cancer
chlorotrianisene,COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1,0,Launched,estrogenic hormone,targeted cancer
geniposide,COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO,0,Preclinical,GLP receptor agonist,targeted cancer
alclometasone-dipropionate,CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,0,Launched,glucocorticoid receptor agonist,noncancer
hypoxanthine,O=c1[nH]cnc2nc[nH]c12,0,Preclinical,PARP inhibitor,noncancer
sulfamethazine,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,1,Launched,PABA antagonist,noncancer
pantothenic-acid,CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O,0,Launched,coenzyme A precursor,noncancer
fosbretabulin,COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O,1,Phase 3,"tubulin polymerization inhibitor, VE-cadherin antagonist",Unknown
ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1,1,Launched,CDK inhibitor,targeted cancer
SDZ-205-557,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,0,Preclinical,serotonin receptor antagonist,noncancer
T-0070907,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1,0,Preclinical,PPAR receptor antagonist,noncancer
aminopurvalanol-a,CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,1,Preclinical,"CDK inhibitor, tyrosine kinase inhibitor",targeted cancer
PNU-282987,Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2,0,Preclinical,cholinergic receptor agonist,noncancer
UBP-302,N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer
L-168049,CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1,0,Preclinical,glucagon receptor antagonist,noncancer
GTP-14564,c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21,1,Preclinical,"FLT3 inhibitor, tyrosine kinase inhibitor",targeted cancer
AMG-9810,CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1,0,Preclinical,TRPV antagonist,noncancer
DMNB,COc1cc(C=O)c(cc1OC)[N+]([O-])=O,0,Preclinical,DNA dependent protein kinase inhibitor,noncancer
Ro-10-5824,Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1,1,Preclinical,dopamine receptor agonist,noncancer
RS-102895,FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1,0,Preclinical,CCR antagonist,noncancer
JNJ-16259685,CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1,1,Preclinical,glutamate receptor antagonist,noncancer
PNU-37883,C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2,0,Preclinical,ATP-sensitive potassium channel antagonist,Unknown
trequinsin,COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC,1,Phase 1,phosphodiesterase inhibitor,noncancer
DAU-5884,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O,0,Preclinical,acetylcholine receptor antagonist,noncancer
4-methylhistamine,Cc1nc[nH]c1CCN,1,Preclinical,histamine receptor agonist,noncancer
apoptosis-activator-II,Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl,0,Preclinical,carboxylesterase inhibitor,noncancer
CGH2466,Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1,0,Preclinical,adenosine receptor antagonist,noncancer
amisulpride,CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC,1,Launched,dopamine receptor antagonist,noncancer
salubrinal,ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12,0,Preclinical,eukaryotic translation initiation factor inhibitor,noncancer
eslicarbazepine-acetate,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12,0,Launched,sodium channel blocker,noncancer
PFK-015,O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1,1,Phase 1,phosphofructokinase inhibitor,targeted cancer
BMS-690514,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,1,Phase 2,"EGFR inhibitor, VEGFR inhibitor",targeted cancer
MK-3697,COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC,0,Phase 2,orexin receptor antagonist,noncancer
iododexetimide,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,1,Phase 2,acetylcholine receptor antagonist,noncancer
capadenoson,Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N,0,Phase 2,adenosine receptor agonist,noncancer
tozadenant,COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,0,Phase 3,adenosine receptor antagonist,noncancer
PRT062070,CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1,1,Phase 1,"JAK inhibitor, syk inhibitor",targeted cancer
sotagliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1,0,Phase 3,sodium/glucose cotransporter inhibitor,noncancer
L-701324,Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12,0,Preclinical,glutamate receptor antagonist,noncancer
PSI-7976,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,Preclinical,HCV inhibitor,noncancer
cilostamide,CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1,1,Preclinical,phosphodiesterase inhibitor,targeted cancer
BMS-626529,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,1,Phase 3,HIV attachment inhibitor,noncancer
remoxipride,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,1,Withdrawn,dopamine receptor antagonist,noncancer
VS-4718,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,1,Phase 1,focal adhesion kinase inhibitor,targeted cancer
3-CPMT,CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1,0,Preclinical,dopamine reuptake inhibitor,noncancer
AZD5069,C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,0,Phase 2,CC chemokine receptor antagonist,targeted cancer
3-alpha-bis-(4-fluorophenyl)-methoxytropane,CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1,0,Preclinical,dopamine uptake inhibitor,noncancer
SPP301,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1,0,Phase 3,endothelin receptor antagonist,noncancer
SKF-38393,Oc1cc2CCNCC(c3ccccc3)c2cc1O,0,Preclinical,dopamine receptor agonist,noncancer
amikacin,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
lomefloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12,1,Launched,bacterial DNA gyrase inhibitor,noncancer
ursodiol,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,"nuclear factor erythroid derived, like (NRF2) activator",noncancer
difloxacin,CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
AZD7545,CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1,0,Phase 1,pyruvate dehydrogenase kinase inhibitor,noncancer
ibuprofen-(s),CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O,0,Preclinical,cyclooxygenase inhibitor,noncancer
tenidap,NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12,0,Phase 3,cyclooxygenase inhibitor,noncancer
pizotifen,CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12,0,Launched,serotonin receptor antagonist,noncancer
amorolfine,CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1,0,Launched,membrane integrity inhibitor,noncancer
AVL-292,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,1,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
amprolium,CCCc1ncc(C[n+]2ccccc2C)c(N)n1,1,Launched,thiamine uptake blocker,noncancer
alvocidib,CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,1,Phase 2,CDK inhibitor,Unknown
marbofloxacin,CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
aminoguanidine,NNC(N)=N,0,Phase 3,nitric oxide synthase inhibitor,noncancer
eprinomectin,CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,1,Launched,benzodiazepine receptor agonist,noncancer
CX-516,O=C(N1CCCCC1)c1ccc2OCOc2c1,0,Phase 2/Phase 3,glutamate receptor modulator,noncancer
fenclonine-(+/-),NC(Cc1ccc(Cl)cc1)C(O)=O,0,Preclinical,tryptophan hydroxylase inhibitor,noncancer
batimastat,CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO,1,Phase 3,matrix metalloprotease inhibitor,targeted cancer
lumiracoxib,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1,0,Withdrawn,cyclooxygenase inhibitor,noncancer
JDTic,CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1,0,Phase 1,opioid receptor antagonist,noncancer
dizocilpine-(+),C[C@]12N[C@H](Cc3ccccc13)c1ccccc21,0,Preclinical,glutamate receptor antagonist,noncancer
Ro-28-1675,CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1,0,Preclinical,glucokinase activator,noncancer
SCH-23390,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1,0,Preclinical,dopamine receptor antagonist,noncancer
Y-320,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,1,Preclinical,interleukin inhibitor,noncancer
beta-funaltrexamine,COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45,0,Preclinical,opioid receptor antagonist,noncancer
vonoprazan,CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1,0,Launched,potassium-competitive acid antagonist,noncancer
ARC-239,COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,0,Preclinical,adrenergic receptor antagonist,noncancer
necrostatin-1,CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O,0,Preclinical,RIPK inhibitor,noncancer
"ICI-215,001",O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1,0,Preclinical,adrenergic receptor agonist,noncancer
immepip,C(C1CCNCC1)c1c[nH]cn1,0,Preclinical,histamine receptor agonist,Unknown
LB42708,Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1,1,Preclinical,farnesyltransferase inhibitor,targeted cancer
MM77,COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1,0,Preclinical,serotonin receptor antagonist,Unknown
SMI-4a,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,1,Preclinical,Pim kinase inhibitor,targeted cancer
olvanil,CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1,0,Preclinical,TRPV agonist,noncancer
ETP-46464,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,1,Preclinical,ATR kinase inhibitor,targeted cancer
WB-4101,COc1cccc(OC)c1OCCNCC1COc2ccccc2O1,0,Preclinical,adrenergic receptor antagonist,noncancer
trelagliptin,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O,0,Launched,dipeptidyl peptidase inhibitor,noncancer
BRL-37344,C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,0,Phase 2,adrenergic receptor agonist,noncancer
xaliproden,FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1,0,Phase 3,serotonin receptor agonist,targeted cancer
diperodon,O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1,0,Preclinical,local anesthetic,noncancer
trimetazidine,COc1ccc(CN2CCNCC2)c(OC)c1OC,0,Launched,3-ketoacyl CoA thiolase inhibitor,noncancer
dihydrostreptomycin,CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO,0,Withdrawn,bacterial 30S ribosomal subunit inhibitor,noncancer
pyrimethamine,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,Launched,dihydrofolate reductase inhibitor,noncancer
KD025,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,1,Phase 2,rho associated kinase inhibitor,targeted cancer
cefmenoxime,CO\N=C(\C(=O)NC1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
10058-F4,CCc1ccc(cc1)\C=C1\SC(=S)NC1=O,0,Preclinical,c-Myc inhibitor,targeted cancer
imiquimod,CC(C)Cn1cnc2c(N)nc3ccccc3c12,1,Launched,"interferon inducer, toll-like receptor agonist",Unknown
DBeQ,C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1,0,Preclinical,ATPase inhibitor,targeted cancer
aniracetam,COc1ccc(cc1)C(=O)N1CCCC1=O,0,Launched,glutamate receptor agonist,noncancer
CNX-774,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,1,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
blonanserin,CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
SGI-1027,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,1,Preclinical,DNA methyltransferase inhibitor,targeted cancer
pritelivir,CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O,0,Phase 2,helicase primase inhibitor,noncancer
TG-003,CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O,0,Preclinical,CLK inhibitor,targeted cancer
potassium-canrenoate,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O,0,Launched,mineralocorticoid receptor antagonist,noncancer
PTC-209,COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1,1,Preclinical,BMI-1 inhibitor,targeted cancer
BIX-01294,COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
xamoterol,OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1,0,Phase 3,adrenergic receptor agonist,noncancer
GSK3787,FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1,0,Preclinical,PPAR receptor antagonist,noncancer
dizocilpine-(-),C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21,0,Phase 1,glutamate receptor antagonist,noncancer
VER-49009,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,1,Preclinical,HSP inhibitor,targeted cancer
BD-1047,CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,0,Preclinical,adrenergic receptor antagonist,noncancer
ML167,Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1,0,Preclinical,"CLK inhibitor, DYRK inhibitor",targeted cancer
spermidine,NCCCCNCCCN,1,Preclinical,glutamate receptor modulator,noncancer
VE-821,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,1,Preclinical,ATR kinase inhibitor,targeted cancer
SYM-2206,CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1C,0,Preclinical,glutamate receptor antagonist,noncancer
tyrphostin-AG-1296,COc1cc2ncc(nc2cc1OC)-c1ccccc1,1,Preclinical,FLT3 inhibitor,targeted cancer
1-phenylbiguanide,NC(=N)NC(=N)Nc1ccccc1,1,Preclinical,serotonin receptor agonist,noncancer
FPH1-(BRD-6125),Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,1,Preclinical,hepatocyte function enhancer,noncancer
RS-17053,CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1,1,Preclinical,adrenergic receptor antagonist,noncancer
crizotinib-(S),C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,1,Preclinical,MTH1 inhibitor,targeted cancer
RS-79948,CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12,0,Preclinical,adrenergic receptor antagonist,noncancer
PRT062607,N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1,1,Phase 2,syk inhibitor,targeted cancer
CD-437,OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,1,Preclinical,retinoid receptor agonist,targeted cancer
BMS-345541,Cc1cnc2c(NCCN)nc3ccc(C)cc3n12,1,Preclinical,IKK inhibitor,targeted cancer
SC-560,COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F,0,Preclinical,cyclooxygenase inhibitor,targeted cancer
tandutinib,COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1,1,Phase 2,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor",targeted cancer
CGP-57380,Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12,0,Preclinical,MAP kinase inhibitor,targeted cancer
sorbinil,Fc1ccc2OCCC3(NC(=O)NC3=O)c2c1,0,Phase 3,aldose reductase inhibitor,noncancer
SKI-II,Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1,1,Preclinical,sphingosine kinase inhibitor,targeted cancer
topiramate,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,0,Launched,"carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist",noncancer
bisindolylmaleimide-ix,Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12,1,Preclinical,PKC inhibitor,noncancer
indacaterol,CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,0,Launched,adrenergic receptor agonist,Unknown
SKLB1002,COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,0,Preclinical,VEGFR inhibitor,targeted cancer
DMP-543,Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1,0,Phase 2,acetylcholine release enhancer,noncancer
ZCL-278,Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1,0,Preclinical,CDC inhibitor,Unknown
ramipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,Unknown
AR-A014418,COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1,0,Preclinical,glycogen synthase kinase inhibitor,targeted cancer
pirenzepine,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,0,Launched,acetylcholine receptor antagonist,noncancer
thiamet-g,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1,0,Preclinical,GLCNAC phosphotransferase inhibitor,noncancer
licochalcone-a,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,1,Phase 3,topoisomerase inhibitor,targeted cancer
erastin,CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1,1,Preclinical,ion channel antagonist,targeted cancer
zaldaride,CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12,1,Phase 3,calmodulin antagonist,noncancer
17-hydroxyprogesterone-caproate,CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,0,Launched,progesterone receptor agonist,targeted cancer
K02288,COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1,0,Preclinical,bone morphogenic protein inhibitor,targeted cancer
pacritinib,C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3,1,Phase 3,"FLT3 inhibitor, JAK inhibitor",targeted cancer
FH1,CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1,0,Preclinical,hepatocyte function enhancer,noncancer
purvalanol-a,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,0,Preclinical,CDK inhibitor,targeted cancer
CK-636,Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1,0,Preclinical,actin related protein inhibitor,noncancer
purvalanol-b,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1,0,Preclinical,tyrosine kinase inhibitor,targeted cancer
scriptaid,ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23,1,Preclinical,HDAC inhibitor,targeted cancer
SKF-83566,CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1,0,Preclinical,dopamine receptor antagonist,noncancer
P276-00,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,1,Phase 2,CDK inhibitor,Unknown
indatraline,CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1,0,Preclinical,norepinephrine transporter inhibitor,noncancer
NBI-27914,CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl,0,Preclinical,corticosteroid releasing factor receptor antagonist,noncancer
alrestatin,OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23,0,Preclinical,aldose reductase inhibitor,noncancer
"1,3-dipropyl-8-phenylxanthine",CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)-c1ccccc1,0,Preclinical,adenosine receptor antagonist,noncancer
SB-269970,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,0,Preclinical,serotonin receptor antagonist,noncancer
DY131,CCN(CC)c1ccc(cc1)\C=N\NC(=O)c1ccc(O)cc1,0,Preclinical,estrogen-related receptor agonist,noncancer
SB-431542,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1,1,Preclinical,TGF beta receptor inhibitor,targeted cancer
NNC-55-0396,CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1,0,Preclinical,T-type calcium channel blocker,Unknown
SB-366791,COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1,1,Preclinical,TRPV antagonist,noncancer
retigabine,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,0,Launched,potassium channel activator,noncancer
NH125,CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C,1,Preclinical,eukaryotic translation elongation factor 2 inhibitor,targeted cancer
chlorpromazine,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,0,Launched,dopamine receptor antagonist,noncancer
abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,1,Launched,CDK inhibitor,targeted cancer
bazedoxifene,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,0,Launched,selective estrogen receptor modulator (SERM),noncancer
skepinone-l,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,1,Preclinical,p38 MAPK inhibitor,noncancer
selegiline,CC(Cc1ccccc1)N(C)CC#C,0,Launched,monoamine oxidase inhibitor,noncancer
JIB04,Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1,1,Preclinical,histone lysine demethylase inhibitor,noncancer
eptifibatide,NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,1,Launched,platelet aggregation inhibitor,noncancer
IWP-L6,O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1,0,Preclinical,porcupine inhibitor,targeted cancer
clinofibrate,CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(OC(C)(CC)C(O)=O)cc1)C(O)=O,0,Launched,lipase clearing factor inhibitor,noncancer
OTX015,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1,1,Phase 1/Phase 2,bromodomain inhibitor,targeted cancer
cutamesine,COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC,0,Phase 2,sigma receptor agonist,noncancer
loxistatin-acid,CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O,1,Preclinical,cysteine peptidase inhibitor,noncancer
lomeguatrib,Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1,0,Phase 2,O6-alkylguanine-DNA alkyltransferase inhibitor,targeted cancer
sal003,Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1,0,Preclinical,eukaryotic translation initiation factor inhibitor,noncancer
saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,0,Launched,HIV protease inhibitor,noncancer
ellagic-acid,Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O,0,Phase 2,"glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor",targeted cancer
xanomeline,CCCCCCOc1nsnc1C1=CCCN(C)C1,1,Phase 3,acetylcholine receptor agonist,noncancer
SCH-58261,Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1,1,Preclinical,adenosine receptor antagonist,noncancer
remacemide,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,0,Phase 3,glutamate receptor antagonist,noncancer
DFB,Fc1cccc(c1)\C=N\N=C\c1cccc(F)c1,0,Preclinical,glutamate receptor agonist,noncancer
"4,5,6,7-tetrabromobenzotriazole",Brc1c(Br)c(Br)c2[nH]nnc2c1Br,0,Preclinical,casein kinase inhibitor,targeted cancer
IEM1460,C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,0,Preclinical,glutamate receptor antagonist,noncancer
2'-MeCCPA,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12,1,Preclinical,adenosine receptor agonist,noncancer
U-18666A,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,1,Preclinical,oxidosqualene cyclase inhibitor,noncancer
SEW-2871,FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F,0,Preclinical,lysophospholipid receptor agonist,Unknown
AY-9944,Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1,0,Preclinical,hedgehog pathway modulator,targeted cancer
O-1918,COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C,0,Preclinical,cannabinoid receptor antagonist,noncancer
OLDA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,1,Preclinical,TRPV agonist,noncancer
AQ-RA741,CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,0,Preclinical,acetylcholine receptor antagonist,noncancer
RS-56812,Cn1cc(C(=O)C(=O)N[C@H]2CN3CCC2CC3)c2ccccc12,0,Preclinical,serotonin receptor partial agonist,noncancer
GW-9508,OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,0,Preclinical,"free fatty acid receptor agonist, G protein-coupled receptor agonist",noncancer
RS-67333,CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1,0,Preclinical,serotonin receptor partial agonist,noncancer
VU0364439,Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl,0,Preclinical,glutamate receptor positive allosteric modulator,noncancer
RS-67506,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,1,Preclinical,serotonin receptor partial agonist,noncancer
GW-2580,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,0,Preclinical,cFMS kinase inhibitor,targeted cancer
RS-39604,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,0,Preclinical,serotonin receptor antagonist,noncancer
rotigotine,CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,0,Launched,dopamine receptor agonist,noncancer
VCH-916,CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1,0,Phase 1,HCV inhibitor,noncancer
telcagepant,Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F,0,Phase 3,calcitonin antagonist,noncancer
nortriptyline,CNCCC=C1c2ccccc2CCc2ccccc12,0,Launched,tricyclic antidepressant,noncancer
dofequidar,OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1,0,Phase 3,"MRP inhibitor, P glycoprotein inhibitor",targeted cancer
uprosertib,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,1,Phase 2,AKT inhibitor,targeted cancer
ASA-404,Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C,0,Phase 3,angiogenesis inhibitor,targeted cancer
apalutamide,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F,0,Launched,androgen receptor antagonist,targeted cancer
rostafuroxine,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1,0,Phase 2,ATPase inhibitor,noncancer
betahistine,CNCCc1ccccn1,0,Launched,"histamine receptor agonist, histamine receptor antagonist",noncancer
amifampridine,Nc1ccncc1N,0,Launched,potassium channel blocker,noncancer
pyrazinamide,NC(=O)c1cnccn1,0,Launched,fatty acid synthase inhibitor,noncancer
carteolol,CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,0,Launched,adrenergic receptor antagonist,noncancer
calcitriol,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer
iopamidol,C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,0,Launched,radiopaque medium,noncancer
cyproheptadine,CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12,1,Launched,histamine receptor antagonist,noncancer
tecovirimat,FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O,0,Phase 3,orthopoxvirus egress inhibitor,noncancer
NSC-405020,CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1,0,Preclinical,matrix metalloprotease inhibitor,noncancer
isamoltane,CC(C)NCC(O)COc1ccccc1-n1cccc1,0,Phase 1,adrenergic receptor antagonist,noncancer
AH11110,OC(COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1,0,Preclinical,adrenergic receptor ligand,noncancer
nexturastat-a,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,1,Preclinical,HDAC inhibitor,targeted cancer
L-745870,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,0,Preclinical,dopamine receptor antagonist,noncancer
GW-0742,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F,0,Preclinical,PPAR receptor agonist,noncancer
L-741742,Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1,0,Preclinical,dopamine receptor antagonist,noncancer
butein,Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1,0,Preclinical,"EGFR inhibitor, src inhibitor",noncancer
BMY-7378,COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,0,Preclinical,"adrenergic receptor antagonist, serotonin receptor antagonist",noncancer
plurisin-#1,O=C(NNc1ccccc1)c1ccncc1,0,Preclinical,stearoyl-CoA desaturase inhibitor,Unknown
QX-314,CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C,0,Preclinical,sodium channel blocker,noncancer
MDL-11939,OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1,0,Phase 2,serotonin receptor antagonist,noncancer
RS-16566,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,1,Preclinical,serotonin receptor antagonist,noncancer
aminomethyltransferase,CC1CCN=C(N)S1,0,Preclinical,nitric oxide synthase inhibitor,noncancer
LY225910,CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O,0,Preclinical,CCK receptor antagonist,noncancer
AM-92016,CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1,0,Preclinical,potassium channel blocker,noncancer
BRL-52537,Clc1ccc(CC(=O)N2CCCCC2CN2CCCC2)cc1Cl,0,Preclinical,opioid receptor agonist,noncancer
oleamide,CCCCCCCC\C=C/CCCCCCCC(N)=O,0,Preclinical,cannabinoid receptor agonist,noncancer
3'-fluorobenzylspiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1,1,Preclinical,dopamine receptor ligand,noncancer
chloroquine,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,0,Launched,antimalarial agent,noncancer
medroxyprogesterone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12,0,Launched,progesterone receptor agonist,Unknown
dimesna,OS(=O)(=O)CCSSCCS(O)(=O)=O,0,Phase 3,tubulin polymerization inhibitor,noncancer
S-111,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C,0,Phase 2,PARP inhibitor,targeted cancer
ZK811752,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,1,Phase 2,CC chemokine receptor antagonist,targeted cancer
mdivi-1,COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O,0,Preclinical,dynamin inhibitor,Unknown
capecitabine,CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,1,Launched,"DNA synthesis inhibitor, thymidylate synthase inhibitor",chemo
1-azakenpaullone,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer
O6-Benzylguanine,Nc1nc(OCc2ccccc2)c2[nH]cnc2n1,0,Phase 3,O6-alkylguanine-DNA alkyltransferase inhibitor,chemo
OAC1,O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1,0,Preclinical,Oct activator,noncancer
triamterene,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,1,Launched,sodium channel blocker,noncancer
KPT-276,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,1,Preclinical,exportin antagonist,targeted cancer
doxorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,1,Launched,topoisomerase inhibitor,Unknown
MM-102,CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1,0,Preclinical,WDR5/MLL interaction inhibitor,noncancer
acebutolol,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O,0,Launched,adrenergic receptor antagonist,noncancer
NMS-E973,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,1,Preclinical,HSP inhibitor,targeted cancer
PCA-4248,COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1,0,Phase 1,platelet activating factor receptor antagonist,noncancer
atglistatin,CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C,0,Preclinical,adipose triglyceride lipase inhibitor,noncancer
aminoglutethimide,CCC1(CCC(=O)NC1=O)c1ccc(N)cc1,1,Launched,glucocorticoid receptor antagonist,targeted cancer
aloxistatin,CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,0,Phase 3,protease inhibitor,noncancer
ZM-226600,CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F,0,Preclinical,Kir6 channel (KATP) activator,noncancer
CS-110266,C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1,1,Preclinical,dopamine receptor agonist,noncancer
BD-1063,CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,0,Preclinical,sigma receptor antagonist,noncancer
anpirtoline,Clc1cccc(SC2CCNCC2)n1,0,Phase 1,serotonin receptor agonist,noncancer
cirazoline,C(Oc1ccccc1C1CC1)C1=NCCN1,0,Preclinical,adrenergic receptor agonist,noncancer
L-701252,Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12,0,Preclinical,glutamate receptor antagonist,noncancer
RS-45041-190,Clc1cccc2CN(Cc12)C1=NCCN1,0,Preclinical,imidazoline receptor agonist,noncancer
7-hydroxy-DPAT,CCCN(CCC)C1CCc2ccc(O)cc2C1,0,Preclinical,dopamine receptor agonist,noncancer
naltriben,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O,0,Preclinical,opioid receptor antagonist,noncancer
pirlindole,Cc1ccc2n3CCNC4CCCc(c34)c2c1,0,Launched,monoamine oxidase inhibitor,noncancer
sulpiride,CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O,0,Launched,dopamine receptor antagonist,noncancer
BU-224,C1CN=C(N1)c1ccc2ccccc2n1,0,Preclinical,imidazoline receptor ligand,noncancer
levosulpiride,CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O,0,Launched,dopamine receptor antagonist,noncancer
BU-239,C1CN=C(N1)c1cnc2ccccc2n1,0,Preclinical,"imidazoline receptor ligand, imidazoline receptor agonist",Unknown
GR-135531,COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,Preclinical,melatonin receptor agonist,noncancer
RS-23597-190,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,0,Preclinical,serotonin receptor antagonist,noncancer
S-Isopropylisothiourea,CC(C)SC(N)=N,0,Preclinical,nitric oxide synthase inhibitor,noncancer
imetit,NC(=N)SCCc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer
BNTX,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1,1,Preclinical,opioid receptor antagonist,noncancer
3-bromo-7-nitroindazole,[O-][N+](=O)c1cccc2c(Br)n[nH]c12,0,Preclinical,nitric oxide synthase inhibitor,noncancer
desvenlafaxine,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,0,Launched,serotonin-norepinephrine reuptake inhibitor (SNRI),noncancer
ME0328,CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,0,Preclinical,PARP inhibitor,targeted cancer
epinastine,NC1=NCC2N1c1ccccc1Cc1ccccc21,1,Launched,histamine receptor antagonist,noncancer
VU0155069,C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1,0,Preclinical,phospholipase inhibitor,targeted cancer
AZD5363,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,1,Phase 2,AKT inhibitor,targeted cancer
5'-Chloro-5'-deoxy-ENBA-(+/-),O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12,0,Preclinical,adenosine receptor agonist,Unknown
PS178990,Cc1c(ccc(C#N)c1Cl)N1C(=O)[C@@H]2[C@H](O)CCN2C1=O,0,Phase 1,androgen receptor modulator,noncancer
G-1,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,1,Preclinical,G protein-coupled receptor agonist,targeted cancer
linifanib,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,1,Phase 3,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",Unknown
5-BDBD,Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21,0,Preclinical,purinergic receptor antagonist,noncancer
hexachlorophene,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,1,Launched,potassium channel activator,Unknown
kaempferol,Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O,0,Preclinical,"bone resorption inhibitor, estrogen-related receptor inverse agonist",targeted cancer
carisoprodol,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
CR8-(R),CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1,1,Preclinical,CDK inhibitor,Unknown
MK-8245,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,1,Phase 2,stearoyl-CoA desaturase inhibitor,noncancer
SU3327,Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1,1,Preclinical,JNK inhibitor,noncancer
hypericin,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,1,Phase 2,tyrosine kinase inhibitor,targeted cancer
DRF053-(R),CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1,0,Preclinical,CDK inhibitor,targeted cancer
clobetasol-propionate,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl,1,Launched,glucocorticoid receptor agonist,noncancer
SANT-2,CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1,0,Preclinical,smoothened receptor antagonist,targeted cancer
betaxolol,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,0,Launched,adrenergic receptor antagonist,noncancer
apraclonidine,Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1,0,Launched,adrenergic receptor agonist,noncancer
nedocromil,CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O,0,Launched,histamine receptor antagonist,noncancer
azimilide,CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1,0,Phase 3,potassium channel blocker,Unknown
pyroxamide,ONC(=O)CCCCCCC(=O)Nc1cccnc1,1,Phase 1,HDAC inhibitor,targeted cancer
afobazole,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,1,Launched,anxiolytic,noncancer
teprenone,CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C,1,Launched,mucus protecting agent,noncancer
adrafinil,ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
AZD1283,CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1,0,Preclinical,purinergic receptor antagonist,noncancer
nimorazole,[O-][N+](=O)c1cncn1CCN1CCOCC1,1,Launched,bacterial DNA inhibitor,targeted cancer
preclamol,CCCN1CCC[C@@H](C1)c1cccc(O)c1,0,Phase 2,dopamine receptor agonist,noncancer
UNBS-5162,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,1,Phase 1,CC chemokine receptor antagonist,targeted cancer
cefpirome,CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
TG-02,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,1,Phase 1,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor",targeted cancer
sapropterin,C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1,0,Launched,phenylalanine 4-hydroxylase stimulant,noncancer
quinine,COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1,0,Launched,hemozoin biocrystallization inhibitor,noncancer
VU0238429,COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1,1,Preclinical,acetylcholine receptor allosteric modulator,noncancer
ftorafur,Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O,1,Launched,thymidylate synthase inhibitor,Unknown
SX-011,CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,0,Preclinical,MAP kinase inhibitor,noncancer
lopinavir,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1,0,Launched,HIV protease inhibitor,Unknown
SRC-kinase-inhibitor-I,COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC,0,Preclinical,src inhibitor,noncancer
acenocoumarol,CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O,0,Launched,vitamin K antagonist,Unknown
SB-328437,COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12,0,Preclinical,CCR antagonist,noncancer
felbinac,OC(=O)Cc1ccc(cc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
BAN-ORL-24,O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1,1,Preclinical,nociceptin/orphanin FQ receptor antagonist,noncancer
chlormezanone,CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O,0,Withdrawn,GABA receptor modulator,noncancer
SKA-31,Nc1nc2c(ccc3ccccc23)s1,0,Preclinical,potassium channel activator,noncancer
bucladesine,CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC,1,Launched,"adenosine receptor agonist, cAMP stimulant",noncancer
NPY-5RA972,CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12,0,Preclinical,neuropeptide receptor antagonist,noncancer
ASC-J9,COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1,0,Phase 2,androgen receptor enhancer,targeted cancer
G-15,Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12.Brc1cc2OCOc2cc1[C@@H]1Nc2ccccc2[C@@H]2C=CC[C@H]12,0,Preclinical,estrogen receptor antagonist,Unknown
timolol,CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1,0,Launched,adrenergic receptor antagonist,noncancer
tegobuvir,Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1,0,Phase 3,"HCV inhibitor, protease inhibitor",noncancer
CITCO,Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1,0,Preclinical,constitutive androstane receptor (CAR) agonist,noncancer
parecoxib,CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
AZD8055,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,1,Phase 1,mTOR inhibitor,Unknown
filanesib,CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F,1,Phase 3,"kinesin inhibitor, kinesin-like spindle protein inhibitor",Unknown
H-89,Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1,0,Preclinical,PKA inhibitor,noncancer
sarpogrelate,COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1,0,Launched,serotonin receptor antagonist,noncancer
oligomycin-a,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,1,Preclinical,"ATP synthase inhibitor, ATPase inhibitor",noncancer
oxiracetam,NC(=O)CN1C[C@H](O)CC1=O,1,Launched,acetylcholine receptor agonist,noncancer
BIX-02189,CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1,0,Preclinical,MEK inhibitor,targeted cancer
limaprost-alfadex,CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O,0,Launched,prostanoid receptor agonist,noncancer
PHT-427,CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1,0,Preclinical,"AKT inhibitor, pyruvate dehydrogenase inhibitor",targeted cancer
telotristat-ethyl,CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1,1,Launched,tryptophan hydroxylase inhibitor,noncancer
KU-60019,C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1,0,Preclinical,ATM kinase inhibitor,noncancer
bardoxolone,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,1,Phase 1,"nuclear factor erythroid derived, like (NRF2) activator",targeted cancer
TWS-119,Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer
epothilone-d,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,1,Phase 2,"microtubule stabilizing agent, tubulin polymerization inhibitor",chemo
TGX-221,CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1,0,Preclinical,PI3K inhibitor,targeted cancer
ADD-233089,Clc1ccc(cc1)N1CC(=NC1=O)N1CCOCC1,0,Phase 1,benzodiazepine receptor agonist,noncancer
PLX-4720,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,1,Preclinical,RAF inhibitor,targeted cancer
bedaquiline,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,0,Launched,ATPase inhibitor,noncancer
WZ-3146,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,1,Preclinical,EGFR inhibitor,targeted cancer
bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F,1,Launched,androgen receptor antagonist,targeted cancer
UK-383367,NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO,1,Phase 1,Procollagen C-Endopeptidase Inhibitors,noncancer
GSK2110183,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,1,Phase 2,AKT inhibitor,targeted cancer
olanzapine,CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",Unknown
GW-842166,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,1,Phase 2,cannabinoid receptor agonist,noncancer
estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,1,Launched,estrogen receptor agonist,noncancer
ampalex,O=C(N1CCCCC1)c1ccc2nccnc2c1,0,Phase 2,glutamate receptor agonist,noncancer
neostigmine,CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C,0,Launched,acetylcholinesterase inhibitor,noncancer
troglitazone,Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O,0,Withdrawn,"insulin sensitizer, PPAR receptor agonist",targeted cancer
LY2801653,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,1,Phase 2,MET inhibitor,targeted cancer
flutamide,CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,1,Launched,androgen receptor antagonist,targeted cancer
mubritinib,FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,1,Phase 1,protein tyrosine kinase inhibitor,targeted cancer
AZD4547,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,1,Phase 2/Phase 3,FGFR inhibitor,targeted cancer
darapladib,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,1,Phase 3,phospholipase inhibitor,noncancer
mifobate,COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC,0,Phase 2,PPAR receptor antagonist,noncancer
colchicine,COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC,1,Launched,microtubule inhibitor,noncancer
floxuridine,OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O,1,Launched,DNA synthesis inhibitor,chemo
raltegravir,Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C,0,Launched,HIV integrase inhibitor,noncancer
diazoxide,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1,0,Launched,potassium channel activator,noncancer
BMY-14802,OC(CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1,0,Phase 2,sigma receptor antagonist,noncancer
GSK2816126,CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O,0,Phase 1,histone lysine methyltransferase inhibitor,targeted cancer
WZ8040,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,1,Preclinical,EGFR inhibitor,targeted cancer
asunaprevir,COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12,0,Phase 3,HCV inhibitor,noncancer
CYC116,Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1,1,Phase 1,Aurora kinase inhibitor,targeted cancer
pronethalol,CC(C)NCC(O)c1ccc2ccccc2c1,0,Withdrawn,adrenergic receptor antagonist,noncancer
XAV-939,Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F,0,Preclinical,tankyrase inhibitor,targeted cancer
propranolol-(S),CC(C)NC[C@H](O)COc1cccc2ccccc12,0,Preclinical,adrenergic receptor antagonist,targeted cancer
mocetinostat,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1,1,Phase 2,HDAC inhibitor,Unknown
propranolol-(R),CC(C)NC[C@@H](O)COc1cccc2ccccc12,0,Preclinical,adrenergic receptor antagonist,targeted cancer
SNS-314,Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1,1,Phase 1,Aurora kinase inhibitor,targeted cancer
ditolylguanidine,Cc1ccccc1NC(=N)Nc1ccccc1C,0,Preclinical,sigma receptor agonist,noncancer
serdemetan,C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1,1,Phase 1,MDM inhibitor,targeted cancer
MTPG,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,1,Preclinical,glutamate receptor antagonist,noncancer
raltitrexed,CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,1,Launched,thymidylate synthase inhibitor,targeted cancer
GR46611,COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1,0,Preclinical,serotonin receptor agonist,noncancer
abiraterone,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,1,Launched,androgen biosynthesis inhibitor,targeted cancer
"L-732,138",CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F,0,Preclinical,tachykinin antagonist,noncancer
WZ-4002,COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1,1,Preclinical,EGFR inhibitor,targeted cancer
PD-102807,CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12,0,Preclinical,acetylcholine receptor antagonist,noncancer
danoprevir,CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1,0,Phase 2,HCV inhibitor,noncancer
seocalcitol,CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,0,Phase 3,vitamin D receptor agonist,targeted cancer
deferiprone,Cc1c(O)c(=O)ccn1C,0,Launched,chelating agent,noncancer
resminostat,CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO,1,Phase 2,HDAC inhibitor,targeted cancer
CNQX,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N,0,Phase 1,glutamate receptor antagonist,noncancer
nicotinamide,NC(=O)c1cccnc1,0,Launched,protein synthesis stimulant,noncancer
piracetam,NC(=O)CN1CCCC1=O,0,Launched,acetylcholine receptor agonist,noncancer
ketotifen,CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12,0,Launched,"histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor",noncancer
buflomedil,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,0,Launched,"adrenergic receptor antagonist, calcium channel blocker",noncancer
BVD-523,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,1,Phase 1/Phase 2,MAP kinase inhibitor,targeted cancer
SGX523,Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1,0,Phase 1,hepatocyte growth factor receptor inhibitor,targeted cancer
temozolomide,Cn1nnc2c(ncn2c1=O)C(N)=O,1,Launched,DNA alkylating agent,chemo
celecoxib,Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
chlorambucil,OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,1,Launched,DNA inhibitor,chemo
ruxolitinib,N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,1,Launched,JAK inhibitor,targeted cancer
duloxetine,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,0,Launched,"norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)",noncancer
anamorelin,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N,0,Phase 3,growth hormone secretagogue receptor agonist,targeted cancer
levamisole,C1CN2C[C@@H](N=C2S1)c1ccccc1,0,Withdrawn,acetylcholine receptor agonist,targeted cancer
foretinib,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,1,Phase 2,VEGFR inhibitor,targeted cancer
dihydroergotamine,CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,0,Launched,serotonin receptor agonist,noncancer
rimonabant,Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,0,Withdrawn,cannabinoid receptor antagonist,noncancer
RU-28318,CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12,0,Phase 2,cytochrome P450 inhibitor,noncancer
BMS-754807,C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1,1,Phase 2,IGF-1 inhibitor,targeted cancer
T-0156,COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1,0,Preclinical,phosphodiesterase inhibitor,noncancer
barasertib-HQPA,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,1,Phase 2/Phase 3,Aurora kinase inhibitor,targeted cancer
GW-7647,CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O,0,Preclinical,PPAR receptor agonist,noncancer
CUDC-101,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,1,Phase 1,EGFR inhibitor,targeted cancer
NECA,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,0,Launched,adenosine receptor agonist,noncancer
triciribine,Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,1,Phase 1/Phase 2,AKT inhibitor,targeted cancer
CGS-15943,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,1,Preclinical,adenosine receptor antagonist,noncancer
SRT1720,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,1,Preclinical,SIRT activator,noncancer
N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12,0,Preclinical,adenosine receptor agonist,Unknown
ADL5859,CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12,1,Phase 2,opioid receptor agonist,noncancer
2-chloro-N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12,0,Preclinical,adenosine receptor agonist,noncancer
BIBR-1532,C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1,1,Preclinical,telomerase inhibitor,targeted cancer
CV-1808,Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,0,Preclinical,adenosine receptor agonist,noncancer
PIK-75,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,1,Preclinical,"DNA protein kinase inhibitor, PI3K inhibitor",Unknown
R-96544,COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1,0,Preclinical,serotonin receptor antagonist,noncancer
posaconazole,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O,1,Launched,sterol demethylase inhibitor,noncancer
PETCM,OC(Cc1ccncc1)C(Cl)(Cl)Cl,1,Preclinical,caspase activator,noncancer
artemisinin,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,Launched,DNA synthesis inhibitor,noncancer
acifran,CC1(OC(=CC1=O)C(O)=O)c1ccccc1,0,Phase 3,cholesterol inhibitor,noncancer
eplerenone,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13,1,Launched,cytochrome P450 inhibitor,noncancer
amlexanox,CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O,0,Launched,histamine receptor modulator,noncancer
atovaquone,Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O,0,Launched,mitochondrial electron transport inhibitor,noncancer
brivanib,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,0,Phase 3,"FGFR inhibitor, VEGFR inhibitor",targeted cancer
flutrimazole,Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1,0,Launched,sterol demethylase inhibitor,noncancer
ABT-202,NC1CCN(C1)c1cccnc1,0,Phase 1,acetylcholine receptor agonist,noncancer
closantel,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O,0,Launched,"chitinase inhibitor, NFkB pathway inhibitor",noncancer
lorglumide,CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1,0,Phase 1,CCK receptor antagonist,noncancer
apabetalone,COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1,0,Phase 3,apolipoprotein expression enhancer,noncancer
clomifene,CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1,1,Launched,estrogen receptor antagonist,noncancer
LCQ908,OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1,0,Phase 3,diacylglycerol O acyltransferase inhibitor,noncancer
KX2-391,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,1,Phase 2,"src inhibitor, tubulin polymerization inhibitor",targeted cancer
rufinamide,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,Launched,voltage-gated sodium channel blocker,noncancer
secnidazole,CC(O)Cn1c(C)ncc1[N+]([O-])=O,1,Launched,"acetylcholinesterase inhibitor, microtubule inhibitor",noncancer
naftopidil,COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,0,Launched,adrenergic receptor antagonist,Unknown
vidarabine,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,Launched,antiviral,noncancer
indole-3-carbinol,OCc1c[nH]c2ccccc12,0,Phase 2/Phase 3,"aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor",noncancer
KD-023,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,1,Phase 2,ACAT inhibitor,noncancer
norgestrel,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,1,Launched,progesterone receptor agonist,noncancer
blebbistatin-(+/-),Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1,0,Preclinical,ATPase inhibitor,noncancer
AG-1024,CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O,0,Preclinical,insulin growth factor receptor inhibitor,Unknown
baicalein,Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1,1,Preclinical,lipoxygenase inhibitor,targeted cancer
prasugrel,CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F,0,Launched,purinergic receptor antagonist,noncancer
zimelidine,CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1,0,Withdrawn,selective serotonin reuptake inhibitor (SSRI),noncancer
JNJ-7706621,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,1,Preclinical,CDK inhibitor,targeted cancer
S-14506,COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,0,Preclinical,serotonin receptor agonist,noncancer
ku-0063794,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1,1,Preclinical,mTOR inhibitor,targeted cancer
arctigenin,COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O,1,Preclinical,MEK inhibitor,targeted cancer
leucovorin,Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1,1,Launched,folate receptor ligand,targeted cancer
NNC-711,OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1,0,Preclinical,GABA uptake inhibitor,noncancer
cinacalcet,C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,1,Launched,calcium channel activator,Unknown
AC-55649,CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O,0,Preclinical,retinoid receptor agonist,targeted cancer
BX-912,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,1,Preclinical,pyruvate dehydrogenase kinase inhibitor,targeted cancer
trifluoperazine,CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,0,Launched,dopamine receptor antagonist,noncancer
epothilone-a,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,1,Preclinical,microtubule stabilizing agent,chemo
NNC-63-0532,COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O,0,Preclinical,opioid receptor agonist,noncancer
YM-201636,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,1,Preclinical,PI3K inhibitor,targeted cancer
zacopride,COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2,0,Phase 2,serotonin receptor antagonist,noncancer
KI-16425,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,1,Preclinical,lysophosphatidic acid receptor antagonist,targeted cancer
levothyroxine,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O,0,Launched,thyroid hormone stimulant,noncancer
dazmegrel,Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O,0,Phase 2,thromboxane synthase inhibitor,noncancer
felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC,0,Launched,calcium channel blocker,noncancer
olprinone,Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N,0,Launched,phosphodiesterase inhibitor,noncancer
GDC-0834,CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1,0,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
castanospermine,O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12,0,Phase 2,glucosidase inhibitor,targeted cancer
rifabutin,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(c(O)c3C)c(O)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1=NC3(CCN(CC(C)C)CC3)N=c21,0,Launched,protein synthesis inhibitor,noncancer
histamine,NCCc1c[nH]cn1,0,Launched,histamine receptor agonist,noncancer
API-001,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,0,Phase 2,sigma receptor antagonist,targeted cancer
TH-302,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,1,Phase 3,DNA alkylating agent,chemo
TAK-733,Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O,1,Phase 1,MEK inhibitor,targeted cancer
VP-20629,OC(=O)CCc1c[nH]c2ccccc12,0,Phase 1,beta amyloid antagonist,noncancer
paclitaxel,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1,1,Launched,tubulin polymerization inhibitor,chemo
riluzole,Nc1nc2ccc(OC(F)(F)F)cc2s1,1,Launched,glutamate inhibitor,noncancer
golvatinib,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,1,Phase 2,VEGFR inhibitor,targeted cancer
cefoperazone,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
fludarabine-phosphate,Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O,1,Launched,ribonucleotide reductase inhibitor,chemo
epitiostanol,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O,0,Launched,androgen receptor agonist,noncancer
VX-222,C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C,0,Phase 2,HCV inhibitor,noncancer
fluorometholone,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,1,Launched,glucocorticoid receptor agonist,noncancer
OMDM-2,CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1,0,Preclinical,FAAH inhibitor,noncancer
idarubicin,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O,1,Launched,topoisomerase inhibitor,Unknown
WAY-161503,Clc1cc2NC(=O)C3CNCCN3c2cc1Cl,0,Preclinical,serotonin receptor agonist,noncancer
costunolide,C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1,1,Preclinical,telomerase inhibitor,targeted cancer
E-4031,Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1,0,Phase 1,potassium channel blocker,noncancer
PD-173074,CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1,1,Preclinical,"FGFR inhibitor, VEGFR inhibitor",targeted cancer
indirubin-3-monoxime,O\N=C1c2ccccc2NC/1=C1\C(=O)Nc2ccccc12,0,Preclinical,"CDK inhibitor, glycogen synthase kinase inhibitor",targeted cancer
WYE-354,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,1,Preclinical,mTOR inhibitor,targeted cancer
ICI-63197,CCCn1c2nc(N)nn2cc(C)c1=O,0,Preclinical,phosphodiesterase inhibitor,noncancer
IRL-2500,CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1,0,Preclinical,endothelin receptor antagonist,Unknown
2-deoxyglucose,OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O,0,Phase 2,glycolysis inhibitor,targeted cancer
RHC-80267,O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,0,Preclinical,triacylglycerol lipase inhibitor,noncancer
exifone,Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O,0,Withdrawn,nootropic agent,noncancer
eticlopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC,0,Preclinical,dopamine receptor antagonist,noncancer
cerulenin,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O,0,Launched,fatty acid synthase inhibitor,noncancer
EMD-66684,CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Preclinical,angiotensin receptor antagonist,noncancer
EXO-1,COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1,0,Preclinical,ARF inhibitor,noncancer
vinorelbine,CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC,1,Launched,tubulin polymerization inhibitor,chemo
"ICI-185,282",OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F,0,Phase 1,thromboxane receptor antagonist,noncancer
moracizine,CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1,0,Launched,sodium channel blocker,noncancer
aliskiren-hemifumarate,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC,0,Launched,renin inhibitor,noncancer
medetomidine,CC(c1c[nH]cn1)c1cccc(C)c1C,0,Launched,adrenergic receptor agonist,noncancer
PF-04620110,Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12,0,Phase 1,diacylglycerol O acyltransferase inhibitor,noncancer
cariporide,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,1,Phase 3,sodium/hydrogen exchanger inhibitor,noncancer
donitriptan,NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12,0,Phase 2,serotonin receptor agonist,noncancer
mitoxantrone,OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,1,Launched,topoisomerase inhibitor,Unknown
eugenol,COc1cc(CC=C)ccc1O,0,Launched,androgen receptor antagonist,noncancer
sofalcone,CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1,0,Launched,mucus protecting agent,noncancer
mozavaptan,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,1,Launched,vasopressin receptor antagonist,noncancer
praziquantel,O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1,0,Launched,anthelmintic agent,noncancer
pravastatin,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12,0,Launched,HMGCR inhibitor,noncancer
mizolastine,CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nccc(=O)[nH]1,0,Launched,histamine receptor antagonist,noncancer
mazindol,OC1(N2CCN=C2c2ccccc12)c1ccc(Cl)cc1,0,Launched,"dopamine reuptake inhibitor, selective serotonin reuptake inhibitor (SSRI)",noncancer
minaprine,Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1,0,Withdrawn,serotonin reuptake inhibitor,Unknown
phenylacetylglutamine,NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O,0,Phase 2,"DNA methylase inhibitor, protein synthesis inhibitor",noncancer
clofoctol,CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1,1,Launched,protein synthesis inhibitor,noncancer
escitalopram,CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
midostaurin,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,1,Launched,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor",targeted cancer
testosterone-enanthate,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,androgen receptor agonist,noncancer
L-165041,CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O,0,Preclinical,PPAR receptor agonist,noncancer
triazolam,Cc1nnc2CN=C(c3ccccc3Cl)c3cc(Cl)ccc3-n12,0,Withdrawn,GABA benzodiazepine site receptor agonist,noncancer
PRIMA1,OCC1(CO)N2CCC(CC2)C1=O,0,Preclinical,TP53 inhibitor,targeted cancer
nelfinavir,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,Launched,HIV protease inhibitor,noncancer
MRS1845,CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC,0,Preclinical,calcium channel blocker,noncancer
alosetron,Cc1[nH]cnc1CN1CCc2c(C1=O)c1ccccc1n2C,0,Withdrawn,serotonin receptor antagonist,noncancer
NSC-663284,ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O,1,Preclinical,CDC inhibitor,targeted cancer
cefixime,Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
clobazam,CN1c2ccc(Cl)cc2N(c2ccccc2)C(=O)CC1=O,0,Launched,GABA benzodiazepine site receptor agonist,noncancer
CDK1-5-inhibitor,Nc1n[nH]c2nc3ccccc3nc12,0,Preclinical,"CDK inhibitor, glycogen synthase kinase inhibitor",targeted cancer
desogestrel,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,0,Launched,progesterone receptor agonist,noncancer
etonogestrel,CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C,0,Launched,progesterone receptor agonist,noncancer
o-3M3FBS,Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F,0,Preclinical,phospholipase activator,noncancer
L-670596,CS(=O)(=O)c1ccc(Cn2c3C(CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1,0,Preclinical,prostanoid receptor antagonist,noncancer
nitisinone,[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F,1,Launched,hydroxyphenylpyruvate dioxygenase inhibitor,noncancer
tolazamide,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1,0,Launched,ATP channel blocker,noncancer
OCO-1112,CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O,0,Phase 2,cholesterol inhibitor,noncancer
apafant,Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl,0,Phase 3,platelet activating factor receptor antagonist,noncancer
CL-218872,Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F,1,Phase 1,benzodiazepine receptor agonist,noncancer
MBX-2982,CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1,0,Phase 2,glucose dependent insulinotropic receptor agonist,noncancer
benfluorex,CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1,0,Withdrawn,gluconeogenesis inhibitor,noncancer
methiopril,CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O,0,Phase 2,angiotensin converting enzyme inhibitor,noncancer
pantoprazole,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,0,Launched,ATPase inhibitor,Unknown
AZD7687,Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1,0,Phase 1,diacylglycerol O acyltransferase inhibitor,noncancer
dalfampridine,Nc1ccncc1,0,Launched,potassium channel blocker,noncancer
PF-02545920,Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1,0,Phase 2,phosphodiesterase inhibitor,noncancer
licarbazepine,NC(=O)N1c2ccccc2CC(O)c2ccccc12,0,Phase 3,voltage-gated sodium channel blocker,noncancer
AZD9668,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,1,Phase 2,elastase inhibitor,noncancer
ganciclovir,Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1,0,Launched,DNA polymerase inhibitor,noncancer
phenylbutyrate,OC(=O)CCCc1ccccc1,0,Launched,HDAC inhibitor,noncancer
roflumilast,FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl,0,Launched,phosphodiesterase inhibitor,noncancer
ibrutinib,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C,1,Launched,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
KBG,OC1O[C@@H]2COC(O[C@H]2[C@H](O)[C@H]1O)c1ccccc1,0,Phase 2,neprilysin inhibitor,targeted cancer
diacerein,CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O,0,Launched,interleukin inhibitor,noncancer
meisoindigo,CN1C(=O)\C(c2ccccc12)=C1\C(=O)Nc2ccccc12,0,Phase 3,STAT inhibitor,targeted cancer
"3,3'-dichlorobenzaldazine",Clc1cccc(c1)\C=N\N=C\c1cccc(Cl)c1,0,Preclinical,glutamate receptor allosteric ligand,noncancer
oxazepam,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,Launched,GABA benzodiazepine site receptor agonist,noncancer
amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,1,Launched,topoisomerase inhibitor,chemo
fluoxymesterone,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,0,Launched,androgen receptor modulator,noncancer
chlorcyclizine,CN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,0,Launched,histamine receptor antagonist,noncancer
volinanserin,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,0,Phase 3,serotonin receptor antagonist,noncancer
tryptanthrin,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,1,Preclinical,cyclooxygenase inhibitor,targeted cancer
AZD6765,NC(Cc1ccccn1)c1ccccc1,0,Phase 2,glutamate receptor antagonist,noncancer
pinocembrin,Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1,0,Phase 2,cytochrome P450 inhibitor,targeted cancer
k-strophanthidin,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,1,Phase 2,ATPase inhibitor,targeted cancer
peruvoside,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,1,Phase 1,cardiac glycoside,Unknown
nebracetam,NCC1CN(Cc2ccccc2)C(=O)C1,0,Phase 3,acetylcholine receptor agonist,noncancer
tioconazole,Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl,0,Launched,sterol demethylase inhibitor,Unknown
diphenylpyraline,CN1CCC(CC1)OC(c1ccccc1)c1ccccc1,0,Launched,dopamine uptake inhibitor,noncancer
cytarabine,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,1,Launched,ribonucleotide reductase inhibitor,chemo
chloramphenicol,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
adapalene,COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O,1,Launched,retinoid receptor agonist,noncancer
itraconazole,CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O,1,Launched,cytochrome P450 inhibitor,noncancer
actarit,CC(=O)Nc1ccc(CC(O)=O)cc1,0,Launched,interleukin receptor agonist,noncancer
butaclamol,CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34,0,Phase 2,dopamine receptor antagonist,noncancer
rociletinib,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,1,Phase 3,EGFR inhibitor,targeted cancer
AV-412,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,1,Phase 1,protein tyrosine kinase inhibitor,targeted cancer
zidovudine,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,0,Launched,nucleoside reverse transcriptase inhibitor,noncancer
busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,1,Launched,DNA inhibitor,chemo
fenticonazole,Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
GDC-0980,C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1,1,Phase 2,"mTOR inhibitor, PI3K inhibitor",targeted cancer
valrubicin,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,1,Launched,"DNA inhibitor, topoisomerase inhibitor",chemo
cobimetinib,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,1,Launched,MEK inhibitor,targeted cancer
sertindole,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,1,Withdrawn,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
famotidine,NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1,1,Launched,histamine receptor antagonist,noncancer
simeprevir,COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C,0,Launched,HCV inhibitor,noncancer
griseofulvin,COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12,0,Launched,tubulin polymerization inhibitor,noncancer
isoxepac,OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1,0,Phase 2,anti-inflammatory agent,noncancer
cafestol,C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3,0,Launched,pregnane X receptor agonist,noncancer
U-0521,CC(C)C(=O)c1ccc(O)c(O)c1,0,Preclinical,catechol O methyltransferase inhibitor,noncancer
L-Theanine,CCNC(=O)CCC(N)C(O)=O,0,Launched,glutamate receptor antagonist,noncancer
ritanserin,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1,0,Phase 3,serotonin receptor antagonist,noncancer
U-50488-(-),CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,0,Preclinical,opioid receptor agonist,noncancer
GR-79236,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12,0,Phase 1,adenosine receptor agonist,noncancer
SB-334867,Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1,0,Preclinical,orexin receptor antagonist,noncancer
U-54494A,CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1,0,Preclinical,opioid receptor agonist,noncancer
SB-258585,COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,0,Preclinical,serotonin receptor antagonist,noncancer
diphenyleneiodonium,[I+]1c2ccccc2-c2ccccc12,1,Preclinical,nitric oxide synthase inhibitor,targeted cancer
SB-239063,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,1,Preclinical,p38 MAPK inhibitor,noncancer
BD-1008,CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1,0,Preclinical,sigma receptor antagonist,noncancer
SB-408124,CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1,0,Preclinical,orexin receptor antagonist,noncancer
GBR-12783,C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1,0,Preclinical,dopamine uptake inhibitor,noncancer
6-iodo-nordihydrocapsaicin,CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I,0,Preclinical,TRPV antagonist,noncancer
GBR-12935,C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1,0,Preclinical,dopamine uptake inhibitor,noncancer
dobutamine,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,0,Launched,adrenergic receptor agonist,noncancer
AMG-517,CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1,0,Phase 1,TRPV antagonist,noncancer
sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,1,Launched,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor",targeted cancer
rolipram,COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1,0,Phase 3,phosphodiesterase inhibitor,noncancer
ifenprodil,CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,0,Launched,"adrenergic receptor antagonist, glutamate receptor antagonist",noncancer
LY215490,OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,0,Phase 1,glutamate receptor antagonist,noncancer
amineptine,OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12,0,Withdrawn,dopamine receptor agonist,noncancer
cimetidine,CN\C(NCCSCc1nc[nH]c1C)=N/C#N,1,Launched,histamine receptor antagonist,targeted cancer
meptazinol,CCC1(CCCCN(C)C1)c1cccc(O)c1,0,Launched,opioid receptor agonist,noncancer
theobromine,Cn1cnc2n(C)c(=O)[nH]c(=O)c12,0,Launched,phosphodiesterase inhibitor,noncancer
warfarin,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,Launched,vitamin K antagonist,noncancer
acivicin,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,1,Phase 2,gamma glutamyltransferase Inhibitors,targeted cancer
efatutazone,Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N,0,Phase 2,PPAR receptor agonist,targeted cancer
taranabant,C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N,0,Phase 3,cannabinoid receptor inverse agonist,noncancer
AT-9283,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,1,Phase 2,"Aurora kinase inhibitor, JAK inhibitor",targeted cancer
probucol,CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,0,Launched,atherogenesis inhibitor,noncancer
levosimendan,C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,0,Launched,calcium sensitizer,noncancer
MK-2206,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,1,Phase 2,AKT inhibitor,targeted cancer
pimozide,Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1,0,Launched,dopamine receptor antagonist,noncancer
palmitoylethanolamide,CCCCCCCCCCCCCCCC(=O)NCCO,1,Launched,cannabinoid receptor agonist,noncancer
dapivirine,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,1,Phase 3,non-nucleoside reverse transcriptase inhibitor,noncancer
biperiden,OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
etomidate,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,0,Launched,GABA receptor modulator,noncancer
XL888,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,1,Phase 1,HSP inhibitor,Unknown
acrivastine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1,0,Launched,histamine receptor antagonist,noncancer
ixabepilone,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,1,Launched,microtubule stabilizing agent,Unknown
canertinib,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,1,Phase 3,EGFR inhibitor,targeted cancer
metoprolol,COCCc1ccc(OCC(O)CNC(C)C)cc1,1,Launched,adrenergic receptor antagonist,noncancer
MDL-73005EF,O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1,0,Phase 1,serotonin receptor antagonist,noncancer
raclopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,1,Launched,dopamine receptor antagonist,noncancer
sulfafurazole,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,0,Launched,bacterial antifolate,noncancer
nepafenac,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,0,Launched,cyclooxygenase inhibitor,Unknown
sumatriptan,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,0,Launched,serotonin receptor agonist,noncancer
favipiravir,NC(=O)c1nc(F)cnc1O,1,Phase 3,RNA polymerase inhibitor,noncancer
palomid-529,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,1,Phase 1,"AKT inhibitor, mTOR inhibitor",targeted cancer
mepivacaine,CN1CCCCC1C(=O)Nc1c(C)cccc1C,1,Launched,"potassium channel blocker, sodium channel blocker",noncancer
azacitidine,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,1,Launched,DNA methyltransferase inhibitor,chemo
balaglitazone,Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O,0,Phase 3,"insulin sensitizer, PPAR receptor partial agonist",noncancer
pentamidine,NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1,1,Launched,anti-pneumocystis agent,noncancer
adarotene,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,1,Phase 1,retinoid receptor agonist,Unknown
orphenadrine,CN(C)CCOC(c1ccccc1)c1ccccc1C,0,Launched,acetylcholine receptor antagonist,noncancer
"2,3-DCPE",OCCNCCCOc1cccc(Cl)c1Cl,1,Preclinical,Bcl-XL downregulator,targeted cancer
metirosine,C[C@](N)(Cc1ccc(O)cc1)C(O)=O,0,Launched,tyrosine hydroxylase inhibitor,noncancer
nTZDpa,OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1,0,Preclinical,PPAR receptor agonist,noncancer
acetyl-11-keto-beta-boswellic-acid,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)C4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)(C5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C,0,Phase 2,lipoxygenase inhibitor,targeted cancer
ZD-2079,O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1,0,Phase 2,adrenergic receptor agonist,noncancer
NTNCB,[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1,0,Preclinical,neuropeptide receptor antagonist,noncancer
proxodolol,Cc1noc(COc2ccccc2OCC(O)CNC(C)(C)C)n1,0,Launched,adrenergic receptor antagonist,noncancer
embelin,CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O,1,Preclinical,"HCV inhibitor, XIAP inhibitor",targeted cancer
BAX-channel-blocker,OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12,0,Preclinical,cytochrome C release inhibitor,noncancer
NSC-23766,CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1,1,Preclinical,Ras GTPase inhibitor,noncancer
"6,_7-dehydro-17-acetoxy-progesterone",CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,0,Preclinical,steroidal progestin,noncancer
AZ-10417808,[O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1,0,Preclinical,caspase inhibitor,noncancer
BVT-948,CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21,1,Preclinical,tyrosine phosphatase inhibitor,noncancer
chlorphenamine,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
vismodegib,Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,1,Launched,"hedgehog pathway inhibitor, smoothened receptor antagonist",targeted cancer
AGI-6780,FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1,0,Preclinical,isocitrate dehydrogenase inhibitor,targeted cancer
diethylcarbamazine,CCN(CC)C(=O)N1CCN(C)CC1,0,Launched,lipoxygenase inhibitor,noncancer
clemizole,Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1,0,Launched,HCV inhibitor,noncancer
ARRY-334543,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,1,Phase 2,EGFR inhibitor,targeted cancer
ciprofloxacin,OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
citalopram,CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
nebivolol,O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1,0,Launched,adrenergic receptor antagonist,noncancer
pioglitazone,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,0,Launched,"insulin sensitizer, PPAR receptor agonist",noncancer
olaparib,Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1,1,Launched,PARP inhibitor,targeted cancer
dipyridamole,OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO,0,Launched,phosphodiesterase inhibitor,noncancer
LY2334737,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,Phase 1,"antitumor agent, ribonucleotide reductase inhibitor",chemo
prazosin,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1,1,Launched,adrenergic receptor antagonist,noncancer
BMS-299897,C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O,0,Phase 1,gamma secretase inhibitor,noncancer
fluvoxamine,COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
ticlopidine,Clc1ccccc1CN1CCc2sccc2C1,0,Launched,purinergic receptor antagonist,Unknown
fluphenazine,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,0,Launched,dopamine receptor antagonist,noncancer
altanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,0,Phase 2,serotonin receptor antagonist,noncancer
ivacaftor,CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C,0,Launched,CFTR channel potentiator,Unknown
ZK-164015,CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1,0,Preclinical,estrogen receptor antagonist,noncancer
SN-6,CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1,0,Preclinical,sodium/calcium exchange inhibitor,noncancer
moprolol,COc1ccccc1OCC(O)CNC(C)C,0,Launched,adrenergic receptor antagonist,noncancer
CMPD-1,Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1,1,Preclinical,p38 MAPK inhibitor,noncancer
GTS21,COc1ccc(\C=C2CCCN=C/2c2cccnc2)c(OC)c1,0,Phase 1/Phase 2,cholinergic receptor agonist,noncancer
4-HQN,Oc1ncnc2ccccc12,0,Preclinical,PARP inhibitor,targeted cancer
BL-5583,OC(=O)c1cc2ccccc2s1,0,Preclinical,hypercalcaemic agent,noncancer
carmoxirole,OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1,0,Phase 2,dopamine receptor agonist,noncancer
tromaril,OC(=O)c1ccccc1NCCc1ccccc1,0,Launched,prostanoid receptor antagonist,noncancer
R-59022,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1,0,Preclinical,"diacylglycerol kinase inhibitor, protein kinase inhibitor",targeted cancer
eliprodil,OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1,0,Phase 3,glutamate receptor antagonist,noncancer
pelanserin,O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1,0,Phase 2,serotonin receptor antagonist,noncancer
CGP-71683,Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12,0,Preclinical,neuropeptide receptor antagonist,noncancer
ameltolide,Cc1cccc(C)c1NC(=O)c1ccc(N)cc1,0,Preclinical,anticonvulsant,noncancer
PD-160170,CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O,0,Preclinical,neuropeptide receptor antagonist,noncancer
sulfadiazine,Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1,0,Launched,bacterial antifolate,noncancer
PNU-22394,Cn1c2CCNCCc2c2ccccc12,0,Phase 2,serotonin receptor agonist,noncancer
bupropion,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,0,Launched,dopamine uptake inhibitor,noncancer
dapsone,Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1,0,Launched,bacterial antifolate,noncancer
luteolin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1,0,Phase 2,glucosidase inhibitor,noncancer
basimglurant,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,0,Phase 2,glutamate receptor antagonist,noncancer
estramustine-phosphate,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,1,Launched,"DNA synthesis inhibitor, microtubule inhibitor",chemo
doxazosin,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1,0,Launched,adrenergic receptor antagonist,noncancer
lisofylline,CC(O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,0,Phase 2,"interleukin receptor antagonist, STAT inhibitor",noncancer
lerisetron,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,1,Phase 3,serotonin receptor antagonist,noncancer
nicotine,CN1CCCC1c1cccnc1,1,Launched,acetylcholine receptor agonist,noncancer
lomerizine,COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC,0,Launched,calcium channel blocker,noncancer
ledipasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1ncc([nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C,0,Launched,HCV inhibitor,noncancer
rifaximin,CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C,0,Launched,RNA synthesis inhibitor,noncancer
telmesteine,CCOC(=O)N1CSCC1C(O)=O,0,Launched,mucolytic agent,noncancer
tipifarnib,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,1,Phase 3,farnesyltransferase inhibitor,targeted cancer
RG2833,Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N,1,Phase 1,HDAC inhibitor,noncancer
lidocaine,CCN(CC)CC(=O)Nc1c(C)cccc1C,1,Launched,histamine receptor agonist,noncancer
diphenidol,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor agonist,noncancer
MK-1775,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,1,Phase 2,WEE1 kinase inhibitor,Unknown
picolinic-acid,O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1,1,Phase 2,chelating agent,noncancer
BIIB021,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C,1,Phase 2,HSP inhibitor,Unknown
zatebradine,COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC,0,Phase 3,HCN channel blocker,noncancer
beta-amyloid-synthesis-inhibitor,Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1,0,Preclinical,beta amyloid synthesis inhibitor,noncancer
TCS2002,Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1,0,Preclinical,glycogen synthase kinase inhibitor,noncancer
LY255283,CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1,0,Preclinical,leukotriene receptor antagonist,noncancer
brucine,COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC,0,Preclinical,glycine receptor antagonist,noncancer
N20C,NC(=O)CNCCC(c1ccccc1)c1ccccc1,0,Preclinical,glutamate receptor antagonist,targeted cancer
BRL-50481,CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,0,Preclinical,phosphodiesterase inhibitor,noncancer
ethaverine,CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC,0,Launched,calcium channel blocker,noncancer
GW-441756,Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12,1,Preclinical,growth factor receptor inhibitor,targeted cancer
dropropizine,OCC(O)CN1CCN(CC1)c1ccccc1,0,Launched,antitussive,noncancer
DMAB-anabaseine,CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1,0,Preclinical,adrenergic receptor agonist,noncancer
fendiline,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,1,Preclinical,calcium channel blocker,noncancer
ACDPP,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,1,Preclinical,glutamate receptor antagonist,noncancer
mebhydrolin,CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1,0,Launched,antihistamine,noncancer
PHCCC,O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1,0,Preclinical,glutamate receptor agonist,targeted cancer
sulfaphenazole,Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1,0,Launched,dihydropteroate synthetase inhibitor,noncancer
CPCCOEt,CCOC(=O)C12CC1\C(=N/O)c1ccccc1O2,0,Preclinical,glutamate receptor antagonist,noncancer
dicloxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
lidoflazine,Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,0,Launched,calcium channel blocker,noncancer
sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,Launched,RNA polymerase inhibitor,noncancer
erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,0,Launched,NFkB pathway inhibitor,noncancer
AZ-628,Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1,1,Preclinical,RAF inhibitor,targeted cancer
etacrynic-acid,CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl,0,Launched,sodium/potassium/chloride transporter inhibitor,noncancer
bupivacaine,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,0,Launched,sodium channel blocker,noncancer
lorcaserin,C[C@H]1CNCCc2ccc(Cl)cc12,0,Launched,serotonin receptor agonist,noncancer
docetaxel,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C,1,Launched,tubulin polymerization inhibitor,chemo
brivudine,OC[C@H]1O[C@H](CC1O)n1cc(\C=C\Br)c(=O)[nH]c1=O,0,Launched,DNA directed DNA polymerase inhibitor,noncancer
fluconazole,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,0,Launched,sterol demethylase inhibitor,noncancer
triflupromazine,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F,0,Launched,dopamine receptor antagonist,noncancer
rilpivirine,Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1,0,Launched,non-nucleoside reverse transcriptase inhibitor,noncancer
DPI-201106,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,1,Phase 2,sodium channel activator,noncancer
acarbose,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,0,Launched,glucosidase inhibitor,noncancer
econazole,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,0,Launched,"lanosterol demethylase inhibitor, sterol demethylase inhibitor",noncancer
JNJ-38877605,Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1,0,Phase 1,tyrosine kinase inhibitor,targeted cancer
everolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO,1,Launched,mTOR inhibitor,targeted cancer
amoxapine,Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1,0,Launched,norepinephrine reputake inhibitor,noncancer
meglitinide,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,1,Phase 2,potassium channel blocker,noncancer
sulfaguanidine,NC(=N)NS(=O)(=O)c1ccc(N)cc1,0,Launched,bacterial antifolate,noncancer
methyllycaconitine,CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14,0,Preclinical,acetylcholine receptor antagonist,noncancer
D-Phenylalanine,N[C@H](Cc1ccccc1)C(O)=O,0,Preclinical,enkephalinase inhibitor,noncancer
CP-93129,O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1,0,Preclinical,serotonin receptor agonist,noncancer
ciprofibrate,CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O,1,Launched,PPAR receptor agonist,noncancer
4-P-PDOT,CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1,0,Preclinical,melatonin receptor antagonist,noncancer
acetanilide,CC(=O)Nc1ccccc1,0,Preclinical,hydrogen peroxide decomposition inhibitor,noncancer
8-M-PDOT,CCC(=O)NC1CCc2cccc(OC)c2C1,0,Preclinical,melatonin receptor agonist,Unknown
todralazine,CCOC(=O)NNc1nncc2ccccc12,0,Launched,antihypertensive agent,noncancer
ZM-241385,Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1,0,Preclinical,adenosine receptor antagonist,targeted cancer
1-EBIO,CCn1c2ccccc2[nH]c1=O,0,Preclinical,potassium channel activator,noncancer
N-methyllidocaine-iodide,CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C,0,Preclinical,antiarrhythmic medication,noncancer
bufexamac,CCCCOc1ccc(CC(=O)NO)cc1,0,Withdrawn,cyclooxygenase inhibitor,noncancer
QX-222,Cc1cccc(C)c1NC(=O)C[N+](C)(C)C,0,Preclinical,sodium channel blocker,noncancer
niflumic-acid,OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
RS-102221,COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O,0,Preclinical,serotonin receptor antagonist,noncancer
coumarin,O=c1ccc2ccccc2o1,0,Launched,vitamin K antagonist,noncancer
A61603,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,1,Preclinical,adrenergic receptor agonist,noncancer
tizanidine,Clc1ccc2nsnc2c1NC1=NCCN1,0,Launched,adrenergic receptor agonist,noncancer
dienogest,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,Launched,progesterone receptor agonist,noncancer
pramipexole,CCCN[C@H]1CCc2nc(N)sc2C1,0,Launched,dopamine receptor agonist,noncancer
Ro-4987655,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,1,Phase 1,MEK inhibitor,targeted cancer
voriconazole,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,0,Launched,cytochrome P450 inhibitor,Unknown
aminocaproic-acid,NCCCCCC(O)=O,0,Launched,plasminogen activator inhibitor,noncancer
nafamostat,NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N,0,Launched,serine protease inhibitor,noncancer
mirtazapine,CN1CCN2C(C1)c1ccccc1Cc1cccnc21,0,Launched,"adrenergic receptor antagonist, serotonin receptor antagonist",noncancer
formoterol,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,0,Launched,adrenergic receptor agonist,noncancer
isbufylline,CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12,0,Phase 2,phosphodiesterase inhibitor,noncancer
oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
cabazitaxel,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,1,Launched,microtubule inhibitor,chemo
trilostane,C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O,0,Launched,3beta-hydroxy-delta5-steroid dehydrogenase inhibitor,noncancer
brexpiprazole,O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1,0,Launched,dopamine receptor partial agonist,noncancer
sarcosine,CNCC(O)=O,0,Phase 2,Glycine transporter 1 inhibitor,noncancer
caffeine,Cn1cnc2n(C)c(=O)n(C)c(=O)c12,0,Launched,"adenosine receptor antagonist, phosphodiesterase inhibitor",noncancer
apocynin,COc1cc(ccc1O)C(C)=O,0,Phase 1,NADPH oxidase inhibitor,noncancer
S18986,O=S1(=O)N[C@H]2CCCN2c2ccccc12,0,Phase 2,glutamate receptor modulator,noncancer
AZD1480,C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1,1,Phase 1,JAK inhibitor,targeted cancer
WIN-64338,CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1,0,Preclinical,bradykinin receptor antagonist,noncancer
BW-723C86,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12,0,Preclinical,serotonin receptor agonist,noncancer
quinpirol-(-),CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12,0,Phase 2,dopamine receptor agonist,noncancer
adiphenine,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
zolantidine,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,1,Preclinical,histamine receptor antagonist,noncancer
bepridil,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,0,Launched,calcium channel blocker,noncancer
AGN-192403,CC(C)[C@@H]1C2CCC(C2)[C@H]1N,0,Preclinical,imidazoline receptor ligand,Unknown
thonzylamine,COc1ccc(CN(CCN(C)C)c2ncccn2)cc1,0,Launched,antihistamine,noncancer
AMPA-(RS),Cc1onc(O)c1CC(N)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
thiamphenicol,CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
SKF-89976A,OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1,0,Preclinical,GABA uptake inhibitor,noncancer
tenoxicam,CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
CFM-2,COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC,0,Preclinical,glutamate receptor antagonist,noncancer
cinnarazine,C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,1,Launched,calcium channel blocker,noncancer
CGP-54626,C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1,1,Preclinical,GABA receptor antagonist,noncancer
betamethasone-dipropionate,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,1,Launched,anti-inflammatory agent,noncancer
8-bromo-cGMP,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,1,Preclinical,PKA activator,noncancer
tebipenem,C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
pirenoxine,OC(=O)c1cc(O)c2c3nc4ccccc4oc3cc(=O)c2n1,0,Launched,AGE inhibitor,noncancer
trimethoprim,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,0,Launched,dihydrofolate reductase inhibitor,noncancer
altrenogest,C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C,0,Launched,progestogen hormone,noncancer
minoxidil,Nc1cc(nc(N)[n+]1[O-])N1CCCCC1,0,Launched,"KATP activator, Kir6 channel (KATP) activator, vasodilator",noncancer
sorbitol,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,Launched,mucolytic agent,noncancer
CPI-613,OC(=O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,0,Phase 2,pyruvate dehydrogenase inhibitor,targeted cancer
lodoxamide,OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N,0,Launched,histamine receptor antagonist,noncancer
fusidic-acid,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
cilostazol,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,0,Launched,phosphodiesterase inhibitor,Unknown
BMS-599626,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12,1,Phase 1,"EGFR inhibitor, protein tyrosine kinase inhibitor",targeted cancer
altretamine,CN(C)c1nc(nc(n1)N(C)C)N(C)C,1,Launched,DNA synthesis inhibitor,chemo
fiacitabine,Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,Phase 2,DNA synthesis inhibitor,noncancer
ORE1001,CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O,0,Phase 1/Phase 2,angiotensin converting enzyme inhibitor,noncancer
ATN-161,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O,0,Phase 2,integrin antagonist,targeted cancer
palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O,1,Launched,CDK inhibitor,targeted cancer
lamivudine,Nc1ccn(C2CSC(CO)O2)c(=O)n1,0,Launched,nucleoside reverse transcriptase inhibitor,Unknown
cinoxacin,CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12,0,Launched,topoisomerase inhibitor,noncancer
alizapride,COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C,0,Launched,dopamine receptor antagonist,noncancer
MK-3207,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,1,Phase 2,calcitonin antagonist,noncancer
ethisterone,CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C#C,0,Launched,progestogen hormone,noncancer
BU226,C1CN=C(N1)c1cc2ccccc2cn1,0,Preclinical,imidazoline receptor ligand,noncancer
meprylcaine,CCCNC(C)(C)COC(=O)c1ccccc1,0,Preclinical,local anesthetic,noncancer
procaterol,CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,0,Launched,adrenergic receptor agonist,noncancer
hycanthone,CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12,0,Launched,RNA synthesis inhibitor,noncancer
CF102,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12,0,Phase 2,adenosine receptor agonist,targeted cancer
methylprednisolone-sodium-succinate,C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12,0,Launched,glucocorticoid receptor agonist,noncancer
otenzepad,CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12,0,Phase 3,acetylcholine receptor antagonist,noncancer
naltrexone,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,1,Launched,opioid receptor antagonist,noncancer
ATPA,CC(C)(C)c1onc(O)c1CC(N)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
prilocaine,CCCNC(C)C(=O)Nc1ccccc1C,0,Launched,local anesthetic,noncancer
GR-103691,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1,0,Preclinical,dopamine receptor antagonist,noncancer
CGP-37157,Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1,0,Preclinical,"mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor",noncancer
AM-281,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1,0,Preclinical,cannabinoid receptor antagonist,noncancer
quipazine,C1CN(CCN1)c1ccc2ccccc2n1,0,Preclinical,serotonin receptor agonist,noncancer
AM-404,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,1,Preclinical,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist",noncancer
homosalate,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,1,Preclinical,HSP inducer,noncancer
AM-251,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,1,Preclinical,cannabinoid receptor antagonist,targeted cancer
levomequitazine,C(C1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12,0,Phase 2,histamine receptor antagonist,noncancer
moclobemide,Clc1ccc(cc1)C(=O)NCCN1CCOCC1,0,Launched,monoamine oxidase inhibitor,noncancer
CI-966,OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1,0,Phase 1,GAT inhibitor,noncancer
PF-04691502,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,1,Phase 2,"mTOR inhibitor, PI3K inhibitor",Unknown
haloperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,0,Launched,dopamine receptor antagonist,noncancer
esmolol,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,0,Launched,adrenergic receptor antagonist,noncancer
metolazone,CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
labetalol,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O,0,Launched,adrenergic receptor antagonist,noncancer
moxidectin,CO\N=C1\C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C,0,Launched,chloride channel antagonist,Unknown
bopindolol,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1,0,Launched,adrenergic receptor antagonist,noncancer
gabapentin,NCC1(CC(O)=O)CCCCC1,0,Launched,calcium channel blocker,noncancer
oxybuprocaine,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,0,Launched,local anesthetic,noncancer
andrographolide,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CCC12,0,Phase 2,tumor necrosis factor production inhibitor,targeted cancer
oxatomide,O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,0,Launched,histamine receptor antagonist,noncancer
anecortave-acetate,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C,0,Launched,angiogenesis inhibitor,noncancer
lersivirine,CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N,0,Phase 2,non-nucleoside reverse transcriptase inhibitor,noncancer
benzylpenicillin,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,penicillin binding protein inhibitor,noncancer
bemegride,CCC1(C)CC(=O)NC(=O)C1,0,Launched,chemoreceptor agonist,noncancer
lafutidine,O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,1,Launched,histamine receptor antagonist,noncancer
alfacalcidol,CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer
AM-630,COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12,0,Preclinical,cannabinoid receptor antagonist,noncancer
naratriptan,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,0,Launched,serotonin receptor agonist,noncancer
telenzepine,CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1,0,Phase 3,acetylcholine receptor antagonist,noncancer
SAR-245409,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,0,Phase 1/Phase 2,PI3K inhibitor,targeted cancer
niguldipine-(S)-(+),COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1,0,Preclinical,adrenergic receptor antagonist,noncancer
AM-1241,CN1CCCCC1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12,0,Preclinical,cannabinoid receptor agonist,noncancer
BRL-54443,CN1CCC(CC1)c1c[nH]c2ccc(O)cc12,0,Preclinical,serotonin receptor agonist,noncancer
KRN-633,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,0,Preclinical,VEGFR inhibitor,targeted cancer
KU14R,CCC1(Cc2ccccc2O1)c1ncc[nH]1,0,Preclinical,imidazoline receptor antagonist,noncancer
BS-181,CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,0,Preclinical,CDK inhibitor,targeted cancer
harmane,Cc1nccc2c3ccccc3[nH]c12,0,Preclinical,monoamine oxidase inhibitor,noncancer
PIK-93,CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO,0,Preclinical,PI3K inhibitor,targeted cancer
L-NIL,CC(=N)NCCCC[C@H](N)C(O)=O,0,Preclinical,nitric oxide synthase inhibitor,noncancer
AT7867,Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1,1,Preclinical,AKT inhibitor,targeted cancer
8-bromo-cAMP,Nc1ncnc2n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c(Br)nc12,0,Preclinical,PKA activator,Unknown
daclatasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,1,Launched,HCV inhibitor,noncancer
ponatinib,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1,1,Launched,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor",targeted cancer
L-733060,FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F,0,Preclinical,tachykinin antagonist,noncancer
dexloxiglumide,CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1,0,Phase 3,CCK receptor antagonist,Unknown
molsidomine,CCOC(=O)Nc1c[n+](no1)N1CCOCC1,0,Launched,guanylate cyclase stimulant,noncancer
roscovitine,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,Phase 2,CDK inhibitor,targeted cancer
NSC-4644,CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12,0,Phase 2,"ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor",noncancer
isofloxythepin,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,1,Phase 2,dopamine receptor antagonist,noncancer
molindone,CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12,0,Launched,dopamine receptor antagonist,noncancer
acecainide,CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1,0,Phase 3,polarization inhibitor,noncancer
milrinone,Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N,0,Launched,phosphodiesterase inhibitor,noncancer
PSI-6130,C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O,0,Phase 1,RNA polymerase inhibitor,noncancer
pyrazinoylguanidine,NC(=N)NC(=O)c1cnccn1,0,Phase 1,diuretic,noncancer
kakonein,OCC1OC(C(O)C(O)C1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O,0,Phase 2,"GABA receptor antagonist, serotonin receptor antagonist",noncancer
ursolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,0,Phase 1,"ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor",targeted cancer
etoposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,1,Launched,topoisomerase inhibitor,chemo
PF-03084014,CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C,0,Phase 2,gamma secretase inhibitor,targeted cancer
fulvestrant,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31,1,Launched,estrogen receptor antagonist,targeted cancer
TAK-715,CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1,1,Phase 2,p38 MAPK inhibitor,noncancer
lofexidine,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,0,Launched,adrenergic receptor agonist,noncancer
methimazole,Cn1cc[nH]c1=S,0,Launched,antithyroid agent,noncancer
roquinimex,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,1,Phase 3,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",targeted cancer
AMG-232,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,1,Phase 1/Phase 2,MDM inhibitor,targeted cancer
org-27569,CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1,0,Preclinical,cannabinoid receptor modulator,noncancer
SKF-96365,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,1,Preclinical,calcium channel blocker,noncancer
iloperidone,COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
SB-203580,CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,0,Preclinical,p38 MAPK inhibitor,noncancer
CP-673451,COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1,1,Preclinical,PDGFR tyrosine kinase receptor inhibitor,targeted cancer
SC-19220,CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12,0,Preclinical,prostanoid receptor antagonist,noncancer
GSK429286A,CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F,1,Preclinical,rho associated kinase inhibitor,noncancer
BRL-15572,OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1,0,Preclinical,serotonin receptor antagonist,noncancer
tie2-kinase-inhibitor,COc1ccc2cc(ccc2c1)-c1nc([nH]c1-c1ccncc1)-c1ccc(cc1)S(C)=O,0,Preclinical,TIE tyrosine kinase inhibitor,targeted cancer
FR-139317,CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O,1,Phase 1,endothelin receptor antagonist,noncancer
hesperadin,CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1,1,Preclinical,Aurora kinase inhibitor,Unknown
ZD-7155,CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nnn[nH]3)C(=O)CCc2c(CC)n1,0,Preclinical,angiotensin receptor antagonist,Unknown
PD-318088,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,1,Preclinical,MEK inhibitor,targeted cancer
PD-98059,COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,1,Preclinical,MEK inhibitor,targeted cancer
SB-525334,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C,1,Preclinical,TGF beta receptor inhibitor,noncancer
SIB-1757,Cc1ccc(O)c(N=Nc2ccccc2)n1,1,Preclinical,glutamate receptor antagonist,noncancer
CCT129202,CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
MRS-1220,Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1,1,Preclinical,adenosine receptor antagonist,noncancer
BIX-02188,CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1,1,Preclinical,MEK inhibitor,targeted cancer
IDRA-21,CC1Nc2ccc(Cl)cc2S(=O)(=O)N1,1,Preclinical,glutamate receptor positive allosteric modulator,noncancer
loxapine,CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
triamcinolone,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
eprosartan,CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O,1,Launched,angiotensin receptor antagonist,noncancer
clozapine,CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
tilmicosin,CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
efaproxiral,Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1,0,Phase 3,haemoglobin oxygen release stimulant,targeted cancer
clorprenaline,CC(C)NCC(O)c1ccccc1Cl,0,Launched,adrenergic receptor agonist,noncancer
conivaptan,Cc1nc2CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc3-c2[nH]1,0,Launched,vasopressin receptor antagonist,noncancer
difluprednate,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,1,Launched,glucocorticoid receptor agonist,noncancer
betulinic-acid,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,1,Phase 1/Phase 2,"apoptosis stimulant, NFkB pathway inhibitor",targeted cancer
eprazinone,CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1,0,Launched,mucolytic agent,noncancer
amfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,1,Launched,cyclooxygenase inhibitor,noncancer
GSK256066,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,1,Phase 2,phosphodiesterase inhibitor,noncancer
bepotastine,OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,Unknown
halobetasol-propionate,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,1,Launched,glucocorticoid receptor agonist,noncancer
torcitabine,Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,0,Phase 2,DNA polymerase inhibitor,noncancer
benzydamine,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,1,Launched,prostanoid receptor antagonist,noncancer
cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC,1,Launched,"RET tyrosine kinase inhibitor, VEGFR inhibitor",targeted cancer
SD-169,NC(=O)c1ccc2[nH]ccc2c1,0,Preclinical,p38 MAPK inhibitor,noncancer
N6022,Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O,0,Phase 1/Phase 2,alcohol dehydrogenase inhibitor,noncancer
ethylenediaminetetraacetic-acid,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,0,Launched,PKC inhibitor,noncancer
sphingosylphosphorylcholine,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C,0,Preclinical,gene expression stimulant,targeted cancer
finasteride,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,0,Launched,5 alpha reductase inhibitor,noncancer
aptiganel,CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12,0,Phase 3,glutamate receptor antagonist,Unknown
AZD1981,CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12,0,Phase 2,CRTH receptor antagonist,noncancer
pimavanserin,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,0,Launched,serotonin receptor inverse agonist,noncancer
FK-888,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,1,Phase 2,tachykinin antagonist,noncancer
bismuth(iii)-trifluoromethanesulfonate,[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F,0,Preclinical,direct substitution catalyst,Unknown
tolbutamide,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,0,Launched,ATP channel blocker,noncancer
R306465,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,1,Phase 1,HDAC inhibitor,Unknown
tecastemizole,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,1,Phase 3,histamine receptor antagonist,noncancer
benznidazole,[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1,0,Launched,DNA synthesis inhibitor,noncancer
epinephrine,CNC[C@H](O)c1ccc(O)c(O)c1,1,Launched,"adrenergic receptor agonist, neurotransmitter",noncancer
pentagastrin,CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1,Launched,CCK receptor agonist,noncancer
tiratricol,OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1,0,Launched,thyroid hormone stimulant,noncancer
"3,3'-diindolylmethane",C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12,0,Phase 3,"CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor",targeted cancer
troxipide,COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1,0,Launched,glucosamine synthetase stimulant,noncancer
tirofiban,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O,0,Launched,"platelet aggregation inhibitor, structural glycoprotein antagonist",noncancer
camptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O,1,Phase 3,topoisomerase inhibitor,Unknown
sevelamer,NCC=C.ClCC1CO1,1,Launched,phosphate antagonist,Unknown
estrone,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O,1,Launched,"estrogen receptor agonist, estrogenic hormone",noncancer
etamsylate,Oc1ccc(O)c(c1)S(O)(=O)=O,0,Launched,haemostatic agent,noncancer
paroxetine,Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
choline,C[N+](C)(C)CCO,0,Phase 3,acetylcholine precursor,noncancer
AMD11070,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12,0,Phase 1/Phase 2,CC chemokine receptor antagonist,targeted cancer
levodropropizine,OC[C@@H](O)CN1CCN(CC1)c1ccccc1,0,Launched,antitussive,noncancer
clonazepam,[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,1,Launched,GABA benzodiazepine site receptor agonist,noncancer
purmorphamine,C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12,0,Preclinical,smoothened receptor agonist,noncancer
genz-644282,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,1,Phase 1,topoisomerase inhibitor,Unknown
pazopanib,CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1,1,Launched,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
rofecoxib,CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1,0,Withdrawn,cyclooxygenase inhibitor,targeted cancer
dutasteride,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F,0,Launched,5 alpha reductase inhibitor,noncancer
nelarabine,COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,Launched,"DNA synthesis inhibitor, T cell inhibitor",chemo
CG-400549,Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O,0,Phase 2,FABI inhibitor,noncancer
telatinib,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,1,Phase 2,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
pimobendan,COc1ccc(cc1)-c1nc2cc(ccc2[nH]1)C1=NNC(=O)CC1C,0,Launched,"calcium sensitizer, phosphodiesterase inhibitor",noncancer
levo-phencynonate,CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
T-5224,OC(=O)CCc1cc(ccc1OCc1ccc2c(O)noc2c1)C(=O)c1ccc(OC2CCCC2)cc1O,0,Phase 2,AP inhibitor,noncancer
metipranolol,CC(C)NCC(O)COc1cc(C)c(OC(C)=O)c(C)c1C,0,Withdrawn,adrenergic receptor antagonist,noncancer
darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,0,Launched,HIV protease inhibitor,noncancer
R547,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,1,Phase 1,CDK inhibitor,Unknown
eupatilin,COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1,0,Launched,mucus protecting agent,targeted cancer
AZD3514,CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1,0,Phase 1,androgen receptor modulator,targeted cancer
radezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,1,Phase 2,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",noncancer
talnetant,CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1,0,Phase 2,tachykinin antagonist,noncancer
prednisone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
androstenone,CC12CCC3C(CCC4CC(=O)CCC34C)C1CC=C2,0,Preclinical,steroid,noncancer
L-Arginine,N[C@H](CCCNC(N)=N)C(O)=O,0,Launched,nitric oxide precursor,noncancer
cilomilast,COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N,0,Phase 3,phosphodiesterase inhibitor,noncancer
adrenalone,CNCC(=O)c1ccc(O)c(O)c1,0,Launched,adrenergic receptor agonist,noncancer
melphalan,N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O,1,Launched,"DNA alkylating agent, DNA inhibitor",chemo
azelnidipine,CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1,0,Launched,calcium channel blocker,noncancer
lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,1,Launched,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
tylosin,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,0,Launched,protein synthesis inhibitor,noncancer
MK-0773,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,1,Phase 2,androgen receptor modulator,noncancer
azatadine,CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12,0,Launched,histamine receptor antagonist,noncancer
atipamezole,CCC1(Cc2ccccc2C1)c1cnc[nH]1,1,Launched,adrenergic receptor antagonist,noncancer
alverine,CCN(CCCc1ccccc1)CCCc1ccccc1,0,Launched,muscle relaxant,noncancer
epirizole,COc1cc(C)nn1-c1nc(C)cc(OC)n1,0,Launched,cyclooxygenase inhibitor,noncancer
reboxetine,CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1,0,Launched,adrenergic receptor antagonist,Unknown
articaine,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,0,Launched,local anesthetic,Unknown
indiplon,CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1,1,Phase 3,benzodiazepine receptor agonist,noncancer
benztropine-mesylate,CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
resiquimod,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,1,Phase 3,toll-like receptor agonist,targeted cancer
azilsartan,CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1,1,Launched,angiotensin receptor antagonist,noncancer
anisodamine,CN1C2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1,0,Phase 3,lipid peroxidase inhibitor,noncancer
refametinib,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,1,Phase 2,MEK inhibitor,targeted cancer
dehydroepiandrosterone,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,0,Launched,protein synthesis stimulant,targeted cancer
benzyldimethylhexadecylammonium,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,1,Preclinical,cationic surfactant,noncancer
aphidicolin,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,1,Phase 1,RNA synthesis inhibitor,Unknown
zalcitabine,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,0,Launched,nucleoside reverse transcriptase inhibitor,noncancer
linsitinib,C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12,1,Phase 3,IGF-1 inhibitor,targeted cancer
imidacloprid,[O-][N+](=O)NC1=NCCN1Cc1ccc(Cl)nc1,0,Launched,acetylcholine receptor antagonist,noncancer
edoxudine,CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O,0,Launched,DNA directed DNA polymerase inhibitor,noncancer
cediranib,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,1,Phase 3,"KIT inhibitor, VEGFR inhibitor",targeted cancer
CTS21166,CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O,0,Phase 1,beta-secretase inhibitor,noncancer
NMS-1286937,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,1,Phase 1,PLK inhibitor,Unknown
NXY-059,CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O,0,Phase 3,free radical scavenger,noncancer
3-(4-methylbenzylidene)camphor,Cc1ccc(cc1)\C=C1\C2CCC(C)(C1=O)C2(C)C,0,Launched,endocrine disruptor,noncancer
ZK-200775,OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F,0,Phase 2,kainate receptor antagonist,noncancer
1-ethyl-2-pyrrolidone,CCN1CCCC1=O,0,Preclinical,transdermal absorption-enhancing compound,noncancer
besifloxacin,N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
CGP-12177,CC(C)(C)NCC(O)COc1cccc2[nH]c(O)nc12,0,Phase 1,adrenergic receptor agonist,noncancer
moguisteine,CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC,0,Phase 2,ATP-sensitive potassium channel inhibitor,noncancer
vinburnine,CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41,0,Launched,adrenergic receptor antagonist,noncancer
methenamine,C1N2CN3CN1CN(C2)C3,0,Launched,bacterial DNA inhibitor,noncancer
ketorolac,OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
brinzolamide,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
ambrisentan,COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1,0,Launched,endothelin receptor antagonist,noncancer
azilsartan-medoxomil,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1,0,Launched,angiotensin receptor antagonist,noncancer
BMS-777607,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,0,Phase 1/Phase 2,"AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor",targeted cancer
butenafine,CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12,0,Launched,fungal squalene epoxidase inhibitor,noncancer
efavirenz,FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1,0,Launched,HIV protease inhibitor,noncancer
gemifloxacin,CO\N=C1/CN(CC1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
danofloxacin,CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
mercaptopurine,S=c1[nH]cnc2nc[nH]c12,1,Launched,"immunosuppressant, protein synthesis inhibitor, purine antagonist",targeted cancer
pyridoxine,Cc1ncc(CO)c(CO)c1O,0,Launched,vitamin B,noncancer
dequalinium,Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12,1,Launched,PKC inhibitor,targeted cancer
biotin,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,0,Launched,vitamin B,noncancer
josamycin,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
AT-7519,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,1,Phase 2,CDK inhibitor,Unknown
otamixaban,COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1,0,Phase 3,coagulation factor inhibitor,noncancer
bromocriptine,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C,0,Launched,dopamine receptor agonist,noncancer
phenacaine,CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1,0,Launched,local anesthetic,noncancer
etoricoxib,Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
exherin,CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O,0,Phase 2,cadherin antagonist,targeted cancer
metrizoic-acid,CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I,0,Launched,radiopaque medium,Unknown
dicoumarol,Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12,0,Launched,NADPH inhibitor,noncancer
picrotin,CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC33C(=O)OC2C13C,0,Phase 2,GABA receptor antagonist,noncancer
ACY-1215,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,1,Phase 1/Phase 2,HDAC inhibitor,targeted cancer
dazoxiben,OC(=O)c1ccc(OCCn2ccnc2)cc1,0,Phase 2,thromboxane synthase inhibitor,noncancer
valsartan,CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O,0,Launched,angiotensin receptor antagonist,noncancer
SB-705498,FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br,0,Phase 2,TRPV antagonist,noncancer
E7449,O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23,1,Phase 1/Phase 2,PARP inhibitor,targeted cancer
tripelennamine,CN(C)CCN(Cc1ccccc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
KW-2478,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,1,Phase 1/Phase 2,HSP inhibitor,targeted cancer
flumequine,CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,topoisomerase inhibitor,noncancer
valproic-acid,CCCC(CCC)C(O)=O,0,Launched,HDAC inhibitor,Unknown
azlocillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,Unknown
balsalazide,OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
methacycline,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,1,Launched,protein synthesis inhibitor,noncancer
org-9768,CC1(CN)Cc2ccccc2C1,0,Phase 1,adrenergic receptor antagonist,noncancer
daphnetin,Oc1ccc2ccc(=O)oc2c1O,0,Preclinical,protein kinase inhibitor,targeted cancer
STA-5326,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,1,Phase 2,interleukin synthesis inhibitor,noncancer
tiotropium,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1,0,Launched,acetylcholine receptor antagonist,Unknown
PK-11195,CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl,0,Phase 1,benzodiazepine receptor antagonist,noncancer
pramiracetam,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,0,Launched,acetylcholine receptor agonist,noncancer
paracetamol,CC(=O)Nc1ccc(O)cc1,0,Launched,cyclooxygenase inhibitor,noncancer
asaraldehyde,COc1cc(OC)c(C=O)cc1OC,0,Preclinical,cyclooxygenase inhibitor,noncancer
flumazenil,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21,0,Launched,benzodiazepine receptor antagonist,noncancer
physostigmine,CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1,0,Launched,cholinesterase inhibitor,noncancer
clindamycin-palmitate,CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)Cl,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
thiocolchicoside,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,1,Launched,GABA receptor antagonist,noncancer
vicriviroc,COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F,0,Phase 3,CC chemokine receptor antagonist,targeted cancer
satraplatin,NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O,1,Phase 3,DNA alkylating agent,chemo
varenicline,C1C2CNCC1c1cc3nccnc3cc21,0,Launched,acetylcholine receptor agonist,noncancer
nedaplatin,N[Pt++]1(N)OCC(=O)O1,0,Launched,DNA inhibitor,chemo
tetracaine,CCCCNc1ccc(cc1)C(=O)OCCN(C)C,0,Launched,membrane integrity inhibitor,noncancer
ardeparin,CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O,0,Withdrawn,thrombin inhibitor,noncancer
Y-26763,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Phase 1,potassium channel activator,noncancer
ripasudil,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,0,Launched,rho associated kinase inhibitor,noncancer
LB-100,CN1CCN(CC1)C(=O)C1[C@H]2CC[C@H](O2)C1C(O)=O,0,Phase 1,protein phosphatase inhibitor,targeted cancer
merbarone,O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O,0,Phase 2,topoisomerase inhibitor,chemo
falecalcitriol,C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,0,Launched,vitamin D receptor agonist,noncancer
bimatoprost,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCc1ccccc1,0,Launched,prostanoid receptor agonist,noncancer
ABT-491,CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C,0,Phase 1,platelet activating factor receptor antagonist,Unknown
methazolamide,CC(=O)N=c1sc(nn1C)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
sangivamycin,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,1,Phase 1,DNA inhibitor,Unknown
afatinib,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1,Launched,EGFR inhibitor,targeted cancer
traxoprodil,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1,0,Phase 2,glutamate receptor antagonist,noncancer
trifluridine,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F,1,Launched,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",chemo
kifunensine,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,1,Phase 1,mannosidase inhibitor,noncancer
trospium,OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
protriptyline,CNCCCC1c2ccccc2C=Cc2ccccc12,0,Launched,tricyclic antidepressant,noncancer
vancomycin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
imipramine,CN(C)CCCN1c2ccccc2CCc2ccccc12,0,Launched,"norepinephrine reputake inhibitor, serotonin reuptake inhibitor",noncancer
tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
cyclobenzaprine,CN(C)CCC=C1c2ccccc2C=Cc2ccccc12,0,Launched,"adrenergic receptor agonist, serotonin receptor agonist",noncancer
anandamide,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO,0,Phase 2,cannabinoid receptor agonist,targeted cancer
ebastine,CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,1,Launched,histamine receptor antagonist,noncancer
butorphanol-(+)-tartrate,Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)c2c1,0,Launched,"opioid receptor agonist, opioid receptor antagonist",noncancer
tasisulam,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,1,Phase 3,apoptosis stimulant,targeted cancer
alexidine,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,1,Preclinical,phosphatidylglycerophosphatase inhibitor,targeted cancer
Y-27152,CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Phase 1,potassium channel activator,noncancer
chlorquinaldol,Cc1ccc2c(Cl)cc(Cl)c(O)c2n1,1,Launched,other antibiotic,noncancer
halcinonide,CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl,1,Launched,glucocorticoid receptor agonist,noncancer
azaperone,Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1,0,Launched,dopamine receptor antagonist,noncancer
PD-153035,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,1,Phase 1,EGFR inhibitor,targeted cancer
prucalopride,COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12,0,Launched,serotonin receptor agonist,noncancer
tolperisone,CC(CN1CCCCC1)C(=O)c1ccc(C)cc1,0,Launched,voltage-gated sodium channel blocker,noncancer
mepacrine,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,0,Launched,"cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator",noncancer
YM-58483,Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F,0,Preclinical,calcium channel blocker,noncancer
ozagrel,OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1,0,Launched,thromboxane synthase inhibitor,noncancer
INCB-003284,COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,0,Phase 2,CC chemokine receptor antagonist,Unknown
amrinone,Nc1cc(c[nH]c1=O)-c1ccncc1,0,Launched,phosphodiesterase inhibitor,noncancer
hypoestoxide,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,1,Phase 1,IKK inhibitor,targeted cancer
bezafibrate,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O,0,Launched,PPAR receptor agonist,noncancer
7-hydroxystaurosporine,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,1,Phase 2,"CDK inhibitor, CHK inhibitor, PKC inhibitor",Unknown
cinepazide,COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1,0,Withdrawn,calcium channel activator,noncancer
echinomycin,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,1,Phase 2,DNA intercalating agent,Unknown
phenazone,Cc1cc(=O)n(-c2ccccc2)n1C,1,Launched,cyclooxygenase inhibitor,noncancer
cefozopran,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
GGTI-298,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,1,Preclinical,GGTase inhibitor,targeted cancer
dantrolene,[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1,0,Launched,calcium channel blocker,noncancer
CID-5458317,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,1,Preclinical,MAP kinase phosphatase inhibitor,noncancer
aprepitant,C[C@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,0,Launched,tachykinin antagonist,noncancer
halofuginone,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,1,Launched,collagenase inhibitor,Unknown
venetoclax,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1,1,Launched,BCL inhibitor,targeted cancer
gallic-acid,OC(=O)c1cc(O)c(O)c(O)c1,0,Preclinical,"beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist",targeted cancer
etofibrate,CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,0,Launched,PPAR receptor agonist,noncancer
mibampator,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,1,Phase 2,glutamate receptor modulator,noncancer
bromfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1,0,Withdrawn,cyclooxygenase inhibitor,noncancer
SR-33805,COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC,1,Phase 1,calcium channel blocker,noncancer
furaltadone,[O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1,0,Launched,bacterial DNA inhibitor,Unknown
loxoprofen,CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1,0,Launched,"cyclooxygenase inhibitor, prostanoid receptor antagonist",noncancer
montelukast,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,0,Launched,leukotriene receptor antagonist,noncancer
cholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,0,Launched,bile acid,noncancer
anisotropine,CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
MLN2480,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F,0,Phase 1,RAF inhibitor,targeted cancer
clopamide,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,1,Launched,sodium/chloride cotransporter inhibitor,noncancer
acetazolamide,CC(=O)Nc1nnc(s1)S(N)(=O)=O,1,Launched,carbonic anhydrase inhibitor,noncancer
defactinib,CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1,1,Phase 2,focal adhesion kinase inhibitor,targeted cancer
carbimazole,CCOC(=O)n1ccn(C)c1=S,0,Launched,antithyroid agent,noncancer
phenothiazine,N1c2ccccc2Sc2ccccc12,0,Preclinical,dopamine receptor antagonist,noncancer
lestaurtinib,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,1,Phase 3,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor",Unknown
valnemulin,CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
ZD-7114,COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,0,Phase 1,adrenergic receptor agonist,noncancer
podophyllotoxin,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,1,Launched,"microtubule inhibitor, tubulin polymerization inhibitor",noncancer
tolfenamic-acid,Cc1c(Cl)cccc1Nc1ccccc1C(O)=O,0,Launched,"cyclooxygenase inhibitor, prostanoid receptor antagonist",noncancer
piribedil,C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1,0,Launched,dopamine receptor agonist,noncancer
balapiravir,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],1,Phase 2,RNA polymerase inhibitor,noncancer
teneligliptin,Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1,0,Launched,dipeptidyl peptidase inhibitor,noncancer
pipemidic-acid,CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1,0,Launched,topoisomerase inhibitor,noncancer
methyldopa,C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O,1,Launched,adrenergic receptor agonist,noncancer
dilazep,COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1,0,Launched,adenosine reuptake inhibitor,noncancer
coumophos,CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1,0,Preclinical,cholinesterase inhibitor,noncancer
faropenem,CC(O)C1C2SC(C3CCCO3)=C(N2C1=O)C(O)=O,0,Launched,lactamase inhibitor,noncancer
dimpylate,CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C,0,Launched,acetylcholinesterase inhibitor,noncancer
torcetrapib,CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F,1,Phase 3,cholesteryl ester transfer protein inhibitor,noncancer
chlorpyrifos,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,1,Launched,acetylcholinesterase inhibitor,noncancer
meclizine,Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1,1,Launched,constitutive androstane receptor (CAR) agonist,noncancer
fenthion,COP(=S)(OC)Oc1ccc(SC)c(C)c1,0,Launched,cholinesterase inhibitor,noncancer
serotonin,NCCc1c[nH]c2ccc(O)cc12,0,Launched,growth factor receptor activator,noncancer
pinacidil,CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C,0,Launched,"ATP channel activator, potassium channel activator",noncancer
dibenzepine,CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O,0,Preclinical,norepinephrine reputake inhibitor,noncancer
dopamine,NCCc1ccc(O)c(O)c1,0,Launched,dopamine receptor agonist,noncancer
ER-27319,Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O,1,Preclinical,"mediator release inhibitor, SYK inhibitor",Unknown
penicillin-v-potassium,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
GW-3965,OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1,1,Preclinical,LXR agonist,noncancer
indoprofen,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,1,Withdrawn,"cyclooxygenase inhibitor, prostanoid receptor antagonist",noncancer
2-pyridylethylamine,NCCc1ccccn1,0,Preclinical,histamine receptor agonist,noncancer
tolnaftate,CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1,0,Launched,fungal squalene epoxidase inhibitor,noncancer
AC-7954-(+/-),CN(C)CCC1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1,0,Preclinical,urotensin receptor agonist,noncancer
dexniguldipine,COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1,0,Phase 2,calmodulin antagonist,targeted cancer
MNITMT,Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O,0,Preclinical,lymphocyte inhibitor,noncancer
nateglinide,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O,0,Launched,insulin secretagogue,noncancer
PNU-120596,COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl,0,Preclinical,acetylcholine receptor agonist,noncancer
trap-101,CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O,0,Preclinical,"nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist",noncancer
PKI-179,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,1,Phase 1,"mTOR inhibitor, PI3K inhibitor",Unknown
talniflumate,FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1,0,Launched,cyclooxygenase inhibitor,noncancer
ziprasidone,Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12,1,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
macitentan,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,0,Launched,endothelin receptor antagonist,Unknown
sasapyrine,OC(=O)c1ccccc1OC(=O)c1ccccc1O,0,Launched,NFkB pathway inhibitor,noncancer
levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,0,Launched,calcium channel blocker,noncancer
dichlorophen,Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O,0,Launched,anticestodal agent,noncancer
pilaralisib,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,1,Phase 2,PI3K inhibitor,targeted cancer
flopropione,CCC(=O)c1c(O)cc(O)cc1O,0,Launched,serotonin receptor antagonist,noncancer
SEP-227900,OC(=O)c1cc2occc2[nH]1,0,Phase 1,D-Amino Acid Oxidase Inhibitor,noncancer
iproniazid,CC(C)NNC(=O)c1ccncc1,1,Withdrawn,monoamine oxidase inhibitor,noncancer
BMS-707035,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,1,Phase 2,HIV integrase inhibitor,noncancer
octopamine,NCC(O)c1ccc(O)cc1,1,Preclinical,trace amine associated receptor agonist,noncancer
rivaroxaban,Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O,0,Launched,coagulation factor inhibitor,noncancer
sulfanilamide,Nc1ccc(cc1)S(N)(=O)=O,1,Launched,carbonic anhydrase inhibitor,noncancer
laropiprant,CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12,0,Launched,prostanoid receptor antagonist,noncancer
ajmaline,CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,1,Launched,sodium channel blocker,noncancer
acipimox,Cc1cnc(c[n+]1[O-])C(O)=O,1,Launched,cholesterol inhibitor,noncancer
acemetacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1,0,Launched,cyclooxygenase inhibitor,noncancer
ibutamoren,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1,0,Phase 2,growth hormone secretagogue receptor agonist,noncancer
gamma-aminobutyric-acid,NCCCC(O)=O,1,Preclinical,benzodiazepine receptor agonist,noncancer
acyclovir,Nc1nc2n(COCCO)cnc2c(=O)[nH]1,0,Launched,DNA polymerase inhibitor,noncancer
fluocinolone-acetonide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
daunorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O,1,Launched,"RNA synthesis inhibitor, topoisomerase inhibitor",Unknown
felbamate,NC(=O)OCC(COC(N)=O)c1ccccc1,1,Launched,glutamate receptor antagonist,noncancer
furazolidone,[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1,0,Launched,bacterial DNA inhibitor,noncancer
niclosamide,Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O,1,Launched,"DNA replication inhibitor, STAT inhibitor",noncancer
crystal-violet,CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C,1,Launched,other antibiotic,Unknown
amcinonide,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C,0,Launched,glucocorticoid receptor agonist,noncancer
glucosamine,N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,0,Launched,glycosylated protein precursor,noncancer
temoporfin,Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,1,Launched,radical formation stimulant,targeted cancer
guaifenesin,COc1ccccc1OCC(O)CO,0,Launched,expectorant,noncancer
asymmetrical-dimethylarginine,CN(C)C(=N)NCCC[C@H](N)C(O)=O,1,Phase 1,nitric oxide synthase inhibitor,noncancer
hexylresorcinol,CCCCCCc1ccc(O)cc1O,1,Launched,local anesthetic,Unknown
sulfadoxine,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,0,Launched,dihydropteroate synthase inhibitor,noncancer
homatropine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
solifenacin-succinate,O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
homatropine-methylbromide,C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1,0,Launched,acetylcholine receptor antagonist,Unknown
BCI-540,Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C,0,Phase 2,glutamate receptor agonist,noncancer
hydrochlorothiazide,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl,0,Launched,thiazide diuretic,noncancer
benurestat,ONC(=O)CNC(=O)c1ccc(Cl)cc1,0,Phase 1,urease inhibitor,noncancer
etofylline,Cn1c2ncn(CCO)c2c(=O)n(C)c1=O,0,Launched,adenosine receptor antagonist,noncancer
benzoxiquine,O=C(Oc1cccc2cccnc12)c1ccccc1,0,Preclinical,antiinfective drug,noncancer
paraxanthine,Cn1cnc2[nH]c(=O)n(C)c(=O)c12,0,Phase 1,adenosine receptor antagonist,noncancer
diadenosine-tetraphosphate,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O,0,Phase 1,adenosine kinase inhibitor,noncancer
ethopabate,CCOc1cc(NC(C)=O)ccc1C(=O)OC,0,Launched,antiprotozoal agent,noncancer
ethotoin,CCN1C(=O)NC(C1=O)c1ccccc1,0,Launched,hydantoin antiepileptic,noncancer
hydrocortisone-valerate,CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
nornicotine,C1CNC(C1)c1cccnc1,0,Preclinical,acetylcholine receptor agonist,noncancer
lobendazole,CCOC(=O)Nc1nc2ccccc2[nH]1,0,Preclinical,anthelmintic agent,noncancer
anabasine,C1CCC(NC1)c1cccnc1,0,Preclinical,acetylcholine receptor agonist,Unknown
methsuximide,CN1C(=O)CC(C)(C1=O)c1ccccc1,0,Launched,T-type calcium channel binder,noncancer
pepstatin,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,1,Preclinical,aspartic protease inhibitor,noncancer
methylatropine-nitrate,C[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1,0,Preclinical,acetylcholine receptor antagonist,noncancer
trolox,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,1,Launched,antioxidant,noncancer
nithiamide,CC(=O)Nc1ncc(s1)[N+]([O-])=O,1,Preclinical,bacterial DNA inhibitor,noncancer
propantheline,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
hydroflumethiazide,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,0,Launched,sodium/potassium/chloride transporter inhibitor,noncancer
hydrocortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C,0,Launched,glucocorticoid receptor agonist,noncancer
glyburide,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,0,Launched,"ATP channel blocker, insulin secretagogue, sulfonylurea",noncancer
tonabersat,CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1,0,Phase 2,"gap junction modulator, nitric oxide production inhibitor",noncancer
barasertib,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,1,Phase 2/Phase 3,Aurora kinase inhibitor,targeted cancer
hyoscyamine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer
idebenone,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,0,Launched,calcium channel modulator,noncancer
iodoquinol,Oc1c(I)cc(I)c2cccnc12,0,Launched,antiseptic,noncancer
AMG-487,CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1,0,Phase 2,CC chemokine receptor antagonist,noncancer
isopropamide-iodide,CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
trimethobenzamide,COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,0,Launched,histamine receptor antagonist,noncancer
isoprenaline,CC(C)NCC(O)c1ccc(O)c(O)c1,0,Launched,adrenergic receptor agonist,noncancer
MK-5108,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,1,Phase 1,Aurora kinase inhibitor,targeted cancer
isoxsuprine,CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,1,Launched,adrenergic receptor agonist,noncancer
homochlorcyclizine,CN1CCCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,0,Launched,antihistamine,noncancer
lactulose,OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,0,Launched,laxative,noncancer
diflunisal,OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F,0,Launched,prostanoid receptor antagonist,noncancer
lincomycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
prednisolone-hemisuccinate,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,1,Preclinical,glucocorticoid receptor agonist,noncancer
ephedrine-(racemic),CNC(C)C(O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
prednisolone-tebutate,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,1,Launched,anti-inflammatory agent,noncancer
rifampin,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C,1,Launched,RNA polymerase inhibitor,noncancer
roxarsone,Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O,0,Launched,antiprotozoal agent,Unknown
cefonicid,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
acepromazine,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O,0,Launched,dopamine receptor antagonist,noncancer
salicylamide,NC(=O)c1ccccc1O,0,Launched,analgesic agent,noncancer
diloxanide,CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1,0,Launched,protein synthesis inhibitor,noncancer
sodium-salicylate,OC(=O)c1ccccc1O,0,Launched,prostanoid receptor antagonist,noncancer
dydrogesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,0,Launched,progesterone receptor agonist,noncancer
salicylic-acid,OC(=O)c1ccccc1O,0,Launched,cyclooxygenase inhibitor,noncancer
penbutolol,CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1,0,Launched,adrenergic receptor antagonist,noncancer
streptozotocin,CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,Launched,DNA alkylating agent,chemo
aminopentamide,CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
sulfabenzamide,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,1,Launched,bacterial antifolate,noncancer
chlorzoxazone,Clc1ccc2oc(=O)[nH]c2c1,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
sulfamerazine,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,0,Launched,bacterial antifolate,Unknown
miglustat,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,0,Launched,Glycosyl transferase inhibitor,noncancer
mafenide,NCc1ccc(cc1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
dolasetron,O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12,0,Launched,serotonin receptor antagonist,noncancer
megestrol-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,0,Launched,progesterone receptor agonist,noncancer
GSK1070916,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,1,Phase 1,Aurora kinase inhibitor,targeted cancer
mepenzolate,C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
esculin,OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O,0,Phase 1,antioxidant,targeted cancer
metaproterenol,CC(C)NCC(O)c1cc(O)cc(O)c1,0,Launched,adrenergic receptor agonist,noncancer
tetradecylthioacetic-acid,CCCCCCCCCCCCCCSCC(O)=O,0,Phase 2,lipid peroxidase inhibitor,targeted cancer
methacholine,CC(C[N+](C)(C)C)OC(C)=O,0,Launched,acetylcholine receptor agonist,noncancer
fenoldopam,Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12,0,Launched,dopamine receptor agonist,noncancer
methicillin,COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
FK-866,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,1,Phase 2,niacinamide phosphoribosyltransferase inhibitor,targeted cancer
methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,1,Launched,dihydrofolate reductase inhibitor,chemo
anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N,1,Launched,aromatase inhibitor,targeted cancer
methoxamine,COc1ccc(OC)c(c1)C(O)C(C)N,0,Launched,adrenergic receptor agonist,noncancer
L-ergothioneine,C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O,0,Phase 2,free radical scavenger,noncancer
dantron,Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12,0,Withdrawn,laxative,noncancer
atomoxetine,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,0,Launched,norepinephrine transporter inhibitor,noncancer
clemastine,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,0,Launched,histamine receptor antagonist,noncancer
clidinium,C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
sulfamethizole,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1,0,Launched,bacterial antifolate,noncancer
cloxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
sulfamethoxazole,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,0,Launched,PABA antagonist,noncancer
cloxyquin,Oc1ccc(Cl)c2cccnc12,0,Preclinical,potassium channel activator,noncancer
sulfapyridine,Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1,0,Launched,PABA antagonist,noncancer
cortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,0,Launched,glucocorticoid receptor agonist,noncancer
sulfathiazole,Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,0,Launched,dihydropteroate synthase inhibitor,targeted cancer
cotinine,CN1[C@@H](CCC1=O)c1cccnc1,0,Phase 2,nicotine metabolite,noncancer
sulfinpyrazone,O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1,0,Launched,uricosuric blocker,noncancer
terbutaline,CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1,Launched,adrenergic receptor agonist,noncancer
cyclopentolate,CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
tetrahydrozoline,C1CN=C(N1)C1CCCc2ccccc12,0,Launched,adrenergic receptor agonist,noncancer
cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,1,Launched,DNA alkylating agent,chemo
tolazoline,C(C1=NCCN1)c1ccccc1,0,Launched,adrenergic receptor antagonist,noncancer
tolmetin,Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C,0,Launched,cyclooxygenase inhibitor,noncancer
mestinon,CN(C)C(=O)Oc1ccc[n+](C)c1,0,Launched,cholinesterase inhibitor,noncancer
deoxycorticosterone-acetate,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,Preclinical,progestogen hormone,noncancer
alprostadil,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,0,Launched,prostanoid receptor agonist,noncancer
testosterone-propionate,CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,0,Launched,androgen receptor agonist,targeted cancer
moxonidine,COc1nc(C)nc(Cl)c1NC1=NCCN1,0,Launched,imidazoline receptor agonist,noncancer
irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Launched,angiotensin receptor antagonist,noncancer
salicylanilide,Oc1ccccc1C(=O)Nc1ccccc1,0,Preclinical,other antibiotic,Unknown
andarine,CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1,0,Phase 1,androgen receptor modulator,noncancer
sodium-oxybate,OCCCC(O)=O,0,Launched,benzodiazepine receptor agonist,Unknown
enoxolone,C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O,0,Launched,gap junction modulator,Unknown
camostat-mesilate,CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1,0,Launched,protease inhibitor,Unknown
atropine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
ofloxacin,CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
mianserin,CN1CCN2C(C1)c1ccccc1Cc1ccccc21,0,Launched,serotonin receptor antagonist,noncancer
benzocaine,CCOC(=O)c1ccc(N)cc1,1,Launched,sodium channel blocker,noncancer
dexamethasone-sodium-phosphate,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O,0,Launched,glucocorticoid receptor agonist,noncancer
dienestrol,C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C,0,Launched,estrogen receptor agonist,noncancer
trichlormethiazide,NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl,0,Launched,chloride channel blocker,noncancer
digitoxin,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,1,Launched,ATPase inhibitor,Unknown
trihexyphenidyl,OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
dioxybenzone,COc1ccc(C(=O)c2ccccc2O)c(O)c1,0,Preclinical,topical sunscreen agent,noncancer
alimemazine,CC(CN(C)C)CN1c2ccccc2Sc2ccccc12,0,Launched,histamine receptor agonist,noncancer
diphenhydramine,CN(C)CCOC(c1ccccc1)c1ccccc1,0,Launched,histamine receptor antagonist,noncancer
trioxsalen,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,0,Launched,DNA synthesis inhibitor,noncancer
doxylamine,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
triprolidine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
dyphylline,Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O,0,Launched,"adenosine receptor antagonist, phosphodiesterase inhibitor",noncancer
tropicamide,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
emetine,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12,1,Phase 2,protein synthesis inhibitor,Unknown
ephedrine,CN[C@@H](C)[C@H](O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
tubocurarine,COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)cc4,0,Launched,acetylcholine receptor antagonist,Unknown
mosapride,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,0,Launched,serotonin receptor agonist,noncancer
nadifloxacin,CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,1,Launched,bacterial DNA gyrase inhibitor,noncancer
gaboxadol,Oc1noc2CNCCc12,0,Phase 3,benzodiazepine receptor agonist,noncancer
betamethasone,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
amodiaquine,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,0,Launched,histamine receptor agonist,Unknown
betamethasone-valerate,CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
GSK923295,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,1,Phase 1,centromere associated protein inhibitor,targeted cancer
bisacodyl,CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1,1,Launched,laxative,noncancer
alagebrium,Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,Phase 2/Phase 3,glycosylation inhibitor,noncancer
bithionol,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,0,Withdrawn,autotaxin inhibitor,noncancer
salirasib,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O,0,Phase 2,mTOR inhibitor,targeted cancer
carbinoxamine,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
lesinurad,OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,0,Launched,uric acid diuretic,noncancer
cefadroxil,CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
perindopril,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC,0,Launched,angiotensin converting enzyme inhibitor,noncancer
cephalothin,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
trientine,NCCNCCNCCN,0,Launched,chelating agent,noncancer
cephapirin,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
travoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F,0,Launched,prostanoid receptor agonist,noncancer
tazobactam,C[C@]1(Cn2ccnn2)C(N2C(CC2=O)S1(=O)=O)C(O)=O,0,Launched,beta lactamase inhibitor,noncancer
chloramphenicol-palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,1,Launched,protein synthesis inhibitor,noncancer
azalomycin-b,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,1,Preclinical,bacterial 50S ribosomal subunit inhibitor,Unknown
pranoprofen,CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1,0,Launched,cyclooxygenase inhibitor,noncancer
atazanavir,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,0,Launched,HIV protease inhibitor,noncancer
rufloxacin,CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
vecuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
tenatoprazole,COc1ccc2[nH]c(nc2n1)S(=O)Cc1ncc(C)c(OC)c1C,0,Phase 2,ATPase inhibitor,noncancer
nanchangmycin,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,1,Preclinical,other antibiotic,noncancer
orbifloxacin,C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
bakuchiol,CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1,0,Phase 2,DNA polymerase inhibitor,noncancer
NSC-9965,CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1,0,Preclinical,acetylcholine receptor antagonist,noncancer
aceclofenac,OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,0,Launched,prostanoid receptor antagonist,noncancer
gambogic-acid,CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C,1,Phase 2,caspase activator,targeted cancer
erdosteine,OC(=O)CSCC(=O)NC1CCSC1=O,0,Launched,mucolytic agent,noncancer
HA-1004,NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12,0,Phase 2,calcium channel blocker,noncancer
ibuproxam,CC(C)Cc1ccc(cc1)C(C)C(=O)NO,0,Launched,"cyclooxygenase inhibitor, prostaglandin inhibitor",noncancer
ethenzamide,CCOc1ccccc1C(N)=O,0,Launched,analgesic agent,noncancer
lirimilast,CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl,0,Phase 2,phosphodiesterase inhibitor,noncancer
chlorhexidine,Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,1,Launched,membrane integrity inhibitor,noncancer
chlorocresol,Cc1cc(O)ccc1Cl,0,Launched,ryanodine receptor activator,noncancer
enprofylline,CCCn1c2nc[nH]c2c(=O)[nH]c1=O,0,Phase 3,phosphodiesterase inhibitor,noncancer
chloroxylenol,Cc1cc(O)cc(C)c1Cl,0,Launched,ATP synthase inhibitor,noncancer
ecabet,CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O,0,Launched,"gastrin inhibitor, urease inhibitor",noncancer
dexchlorpheniramine,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
cevimeline,C[C@H]1O[C@]2(CS1)CN1CCC2CC1.C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,0,Launched,acetylcholine receptor agonist,Unknown
florfenicol,CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl,1,Launched,protein synthesis inhibitor,noncancer
benzamil,NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N,0,Phase 2,sodium channel blocker,noncancer
mifepristone,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C,1,Launched,"glucocorticoid receptor antagonist, progesterone receptor antagonist",noncancer
pasiniazid,NNC(=O)c1ccncc1,0,Launched,cyclooxygenase inhibitor,noncancer
equilin,CC12CCC3C(=CCc4cc(O)ccc34)C1CCC2=O,0,Preclinical,estrogen receptor agonist,noncancer
chenodeoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,"11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist",noncancer
procaine,CCN(CC)CCOC(=O)c1ccc(N)cc1,0,Launched,HMGCR inhibitor,noncancer
RG4733,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O,0,Phase 2,gamma secretase inhibitor,targeted cancer
tetramisole,C1CN2CC(N=C2S1)c1ccccc1,0,Launched,immunostimulant,noncancer
dihomo-gamma-linolenic-acid,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O,0,Phase 2,prostanoid receptor agonist,noncancer
aminothiazole,Nc1nccs1,0,Preclinical,cyclin D inhibitor,noncancer
buthionine-sulfoximine,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,1,Phase 1,glutathione transferase inhibitor,targeted cancer
edelfosine,CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC,0,Phase 2,phospholipase inhibitor,targeted cancer
harringtonine,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,1,Phase 3,protein synthesis inhibitor,Unknown
chromocarb,OC(=O)c1cc(=O)c2ccccc2o1,1,Launched,antispasmodic,noncancer
anguidine,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,1,Phase 2,protein synthesis inhibitor,Unknown
pipenzolate,CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1,0,Launched,cholinergic receptor antagonist,noncancer
icomucret,CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O,0,Phase 3,mucin production enhancer,noncancer
pridinol,OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1,0,Launched,muscle relaxant,noncancer
LTB4,CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O,0,Phase 2,leukocyte activator,targeted cancer
pyrithyldione,CCC1(CC)C(=O)NC=CC1=O,0,Withdrawn,psychoactive drug,noncancer
epoprostenol,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O,0,Launched,prostacyclin analog,noncancer
bromopride,CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,0,Launched,dopamine receptor antagonist,noncancer
secalciferol,C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C,0,Launched,vitamin D receptor agonist,noncancer
citiolone,CC(=O)NC1CCSC1=O,0,Preclinical,"lipotropic, mucolytic agent",noncancer
icosapent,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,0,Launched,platelet aggregation inhibitor,noncancer
heptaminol,CC(N)CCCC(C)(C)O,0,Launched,vasoconstrictor,Unknown
benzotript,OC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1,0,Phase 1,CCK receptor antagonist,noncancer
toltrazuril,Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O,0,Launched,antiprotozoal agent,noncancer
piretanide,NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,1,Launched,glucocorticoid receptor agonist,noncancer
proxymetacaine,CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC,0,Launched,sodium channel blocker,noncancer
fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,0,Launched,"immunosuppressant, sphingosine phosphate receptor agonist",noncancer
pipamperone,NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1,0,Launched,dopamine receptor antagonist,noncancer
urea,NC(N)=O,0,Launched,hydroxy radical formation stimulant,noncancer
pefloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
letrozole,N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1,1,Launched,aromatase inhibitor,targeted cancer
prednisolone-sodium-phosphate,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O,0,Launched,glucocorticoid receptor agonist,noncancer
elacridar,COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC,1,Phase 1,P glycoprotein inhibitor,targeted cancer
pregnenolone-succinate,CC(=O)[C@H]1CCC2C3CC=C4C[C@H](CC[C@]4(C)C3CC[C@]12C)OC(=O)CCC(O)=O,0,Preclinical,GABA receptor negative allosteric modulator,noncancer
armodafinil,NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
meglumine,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,Launched,excipient,noncancer
mecamylamine,CNC1(C)C2CCC(C2)C1(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
desoximetasone,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
ABT-239,C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N,0,Phase 1,histamine receptor antagonist,noncancer
melengestrol-acetate,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,1,Preclinical,progesterone receptor agonist,noncancer
medrysone,C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12,0,Launched,glucocorticoid receptor agonist,noncancer
entacapone,CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O,0,Launched,catechol O methyltransferase inhibitor,noncancer
alpha-linolenic-acid,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,0,Phase 3,omega 3 fatty acid stimulant,noncancer
fipexide,Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1,0,Withdrawn,psychoactive drug,noncancer
gamma-linolenic-acid,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O,0,Phase 2,"cyclooxygenase inhibitor, prostanoid receptor agonist",noncancer
meclofenoxate,CN(C)CCOC(=O)COc1ccc(Cl)cc1,0,Launched,nootropic agent,noncancer
GABA-linoleamide,CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O,0,Phase 2,benzodiazepine receptor agonist,Unknown
nifenazone,Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C,0,Launched,analgesic agent,noncancer
acetyl-farnesyl-cysteine,CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O,0,Launched,methyltransferase inhibitor,noncancer
hexamethonium,C[N+](C)(C)CCCCCC[N+](C)(C)C,0,Preclinical,cholinergic receptor antagonist,noncancer
taurocholate,C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,0,Phase 1,G protein-coupled receptor agonist,noncancer
deoxyepinephrine,CNCCc1ccc(O)c(O)c1,0,Preclinical,"adrenergic receptor agonist, dopamine receptor agonist",noncancer
benzonatate,CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,0,Launched,local anesthetic,noncancer
flupentixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,0,Launched,dopamine receptor antagonist,noncancer
lisuride,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,0,Launched,dopamine receptor agonist,noncancer
xylometazoline,Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C,0,Launched,adrenergic receptor agonist,noncancer
quinelorane,CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12,0,Phase 3,dopamine receptor agonist,noncancer
zomepirac,Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1,0,Withdrawn,prostaglandin synthesis inhibitor,noncancer
talipexole,Nc1nc2CCN(CC=C)CCc2s1,0,Launched,"adrenergic receptor agonist, dopamine receptor agonist",noncancer
phenacetin,CCOc1ccc(NC(C)=O)cc1,0,Withdrawn,cyclooxygenase inhibitor,noncancer
AS-703026,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,1,Phase 2,MEK inhibitor,targeted cancer
erythrosine,OC(=O)c1ccccc1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12,0,Preclinical,coloring agent,noncancer
phenprocoumon,CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O,0,Launched,vitamin K antagonist,noncancer
L-655240,Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12,0,Phase 1,thromboxane receptor antagonist,noncancer
SN-38,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12,1,Launched,topoisomerase inhibitor,Unknown
bephenium-hydroxynaphthoate,C[N+](C)(CCOc1ccccc1)Cc1ccccc1,1,Launched,anthelmintic agent,noncancer
mefloquine,OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F,0,Launched,"adenosine receptor antagonist, hemoglobin antagonist",noncancer
manidipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,0,Launched,calcium channel blocker,noncancer
vincamine,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,1,Withdrawn,adrenergic receptor antagonist,noncancer
"2,4-dinitrophenol",Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O,0,Preclinical,ATP synthase inhibitor,noncancer
nefazodone,CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1,0,Withdrawn,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor",noncancer
butylated-hydroxyanisole,COc1ccc(O)c(c1)C(C)(C)C,0,Preclinical,antioxidant,Unknown
prochlorperazine,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,0,Launched,dopamine receptor antagonist,noncancer
AZD1208,N[C@@H]1CCCN(C1)c1c(cccc1-c1ccccc1)\C=C1/SC(=O)NC1=O,0,Phase 1,Pim kinase inhibitor,targeted cancer
colforsin-daproate,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,1,Launched,adenylyl cyclase activator,noncancer
amperozide,CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,0,Launched,dopamine receptor antagonist,noncancer
strychnine,O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61,0,Preclinical,acetylcholine receptor antagonist,noncancer
spiradoline,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,1,Phase 2,opioid receptor agonist,noncancer
adenosine-phosphate,Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,0,Launched,adenosine receptor agonist,targeted cancer
levallorphan,Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1,0,Launched,opioid antagonist,noncancer
arecoline,COC(=O)C1=CCCN(C)C1,0,Phase 1,acetylcholine receptor agonist,noncancer
BW-180C,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,1,Phase 2,opioid receptor agonist,noncancer
"hydrastine-(1r,-9s)",COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12,0,Preclinical,tyrosine hydroxylase inhibitor,noncancer
FK-33-824,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CCS(C)=O,0,Phase 2,opioid receptor agonist,noncancer
butamben,CCCCOC(=O)c1ccc(N)cc1,1,Withdrawn,sodium channel blocker,noncancer
rivanicline,CNCC\C=C\c1cccnc1,0,Phase 2,acetylcholine receptor agonist,noncancer
cefaclor,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
L-Aspartic-Acid,N[C@@H](CC(O)=O)C(O)=O,0,Launched,metallic radical formation stimulant,noncancer
iodipamide,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,1,Launched,radiopaque medium,noncancer
ACPC,NC1(CC1)C(O)=O,0,Phase 1,glutamate receptor antagonist,noncancer
allantoin,NC(=O)NC1NC(=O)NC1=O,0,Launched,cosmetic,noncancer
eltanolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Phase 3,membrane integrity inhibitor,noncancer
althiazide,NS(=O)(=O)c1cc2c(NC(CSCC=C)NS2(=O)=O)cc1Cl,0,Launched,diuretic,noncancer
benzoquinonium-dibromide,CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1,0,Preclinical,cholinergic receptor antagonist,noncancer
chloropyramine,CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,1,Launched,histamine receptor antagonist,noncancer
L-693403,C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1,0,Preclinical,"sigma receptor agonist, sigma receptor antagonist",noncancer
famprofazone,CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C,0,Preclinical,cyclooxygenase inhibitor,noncancer
SC-10,CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,0,Preclinical,protein kinase activator,noncancer
oxelaidin,CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1,0,Launched,antitussive,noncancer
ML-9,Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1,0,Preclinical,myosin light chain kinase inhibitor,noncancer
MY-5445,Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1,0,Preclinical,"phosphodiesterase inhibitor, platelet aggregation inhibitor",noncancer
oxyphenonium,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,0,Launched,cholinergic receptor antagonist,noncancer
SC-9,Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1,0,Preclinical,protein tyrosine kinase activator,noncancer
nifuroxazide,Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O,0,Launched,bacterial DNA inhibitor,noncancer
4-chlorophenylguanidine,NC(=N)Nc1ccc(Cl)cc1,1,Preclinical,urokinase inhibitor,noncancer
beclamide,ClCCC(=O)NCc1ccccc1,0,Launched,anticonvulsant,noncancer
6-chloromelatonin,COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl,0,Preclinical,melatonin receptor agonist,noncancer
carbetapentane,CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
metaraminol,C[C@H](N)[C@H](O)c1cccc(O)c1,1,Launched,adrenergic receptor agonist,noncancer
L-161982,CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C,0,Preclinical,prostanoid receptor antagonist,noncancer
oxprenolol,CC(C)NCC(O)COc1ccccc1OCC=C,1,Launched,adrenergic receptor antagonist,noncancer
RS-504393,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,1,Preclinical,CC chemokine receptor antagonist,noncancer
aceclidine,CC(=O)OC1CN2CCC1CC2,0,Launched,acetylcholine receptor agonist,noncancer
PD-166793,CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O,0,Preclinical,"collagenase inhibitor, metalloproteinase inhibitor",targeted cancer
methapyrilene,CN(C)CCN(Cc1cccs1)c1ccccn1,0,Withdrawn,histamine receptor antagonist,noncancer
A205804,Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1,0,Preclinical,ICAM1 expression inhibitor,noncancer
hydrastinine,CN1CCc2cc3OCOc3cc2C1O,0,Preclinical,haemostatic agent,noncancer
DPO-1,CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1,0,Preclinical,potassium channel blocker,Unknown
thiostrepton,CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O,1,Launched,"FOXM1 inhibitor, protein synthesis inhibitor",noncancer
domperidone,Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1,1,Launched,dopamine receptor antagonist,noncancer
CD-1530,OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2,0,Preclinical,retinoid receptor agonist,noncancer
SB-218078,O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13,1,Preclinical,CHK inhibitor,noncancer
aurora-a-inhibitor-i,CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
fexaramine,COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1,0,Preclinical,FXR agonist,noncancer
thiazovivin,O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1,0,Preclinical,rho associated kinase inhibitor,noncancer
PSB-06126,Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O,0,Preclinical,NTPDase inhibitor,noncancer
5-carboxamidotryptamine,NCCc1c[nH]c2ccc(cc12)C(N)=O,0,Preclinical,serotonin receptor agonist,noncancer
nialamide,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,0,Withdrawn,monoamine oxidase inhibitor,noncancer
cinanserin,CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1,0,Preclinical,serotonin receptor antagonist,noncancer
capsazepine,Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1,0,Preclinical,TRPV agonist,noncancer
idazoxan,C1CN=C(N1)C1COc2ccccc2O1,1,Phase 3,adrenergic receptor antagonist,noncancer
nitrocaramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,1,Preclinical,cholinergic receptor antagonist,noncancer
ML347,COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,0,Preclinical,ALK tyrosine kinase receptor inhibitor,targeted cancer
UNC1999,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
GZD824,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,1,Preclinical,Bcr-Abl kinase inhibitor,targeted cancer
bucetin,CCOc1ccc(NC(=O)CC(C)O)cc1,0,Withdrawn,analgesic agent,noncancer
repsox,Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1,1,Preclinical,TGF beta receptor inhibitor,noncancer
barbital,CCC1(CC)C(=O)NC(=O)NC1=O,0,Launched,sedative,noncancer
golgicide-a,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,1,Preclinical,ARF inhibitor,Unknown
cortisone,C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
STF-118804,Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1,1,Preclinical,NAMPT inhibitor,Unknown
MGCD-265,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,1,Preclinical,VEGFR inhibitor,targeted cancer
cetirizine,OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,0,Launched,histamine receptor antagonist,noncancer
zamifenacin,C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1,0,Phase 3,acetylcholine receptor antagonist,noncancer
ispinesib,CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1,1,Phase 2,kinesin inhibitor,targeted cancer
lansoprazole,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,0,Launched,ATPase inhibitor,noncancer
pyrazolanthrone,O=C1c2ccccc2-c2n[nH]c3cccc1c23,0,Preclinical,JNK inhibitor,targeted cancer
CFM-1571,COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1,0,Preclinical,guanylate cyclase activator,noncancer
rigosertib,COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1,1,Phase 3,"cell cycle inhibitor, PLK inhibitor",targeted cancer
TCS-359,COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O,0,Preclinical,FLT3 inhibitor,targeted cancer
alfuzosin,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1,0,Launched,adrenergic receptor antagonist,noncancer
PD-198306,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,1,Preclinical,"MAP kinase inhibitor, MEK inhibitor",targeted cancer
AZD6482,C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1,1,Phase 1,PI3K inhibitor,targeted cancer
ryuvidine,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O,1,Preclinical,histone lysine methyltransferase inhibitor,noncancer
KI-8751,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,1,Preclinical,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
cilnidipine,COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,0,Launched,calcium channel blocker,noncancer
tenofovir-disoproxil,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C,0,Launched,nucleoside reverse transcriptase inhibitor,noncancer
WAY-170523,Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO,1,Preclinical,metalloproteinase inhibitor,targeted cancer
clopidogrel,COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl,0,Launched,purinergic receptor antagonist,noncancer
DAPT,C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1,0,Preclinical,gamma secretase inhibitor,targeted cancer
hydroquinidine,CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,0,Launched,antiarrhythmic,noncancer
AZ191,COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1,0,Preclinical,DYRK inhibitor,targeted cancer
pimethixene,CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12,0,Launched,antihistamine,noncancer
adiporon,O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1,0,Preclinical,adiponectin receptor agonist,targeted cancer
efaroxan,CCC1(Cc2ccccc2O1)C1=NCCN1,0,Phase 2,adrenergic receptor antagonist,noncancer
NSC-319726,C\C(c1ccccn1)=N/NC(=S)N1CCC1,1,Preclinical,p53 activator,Unknown
RKI-1447,Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1,1,Preclinical,rho associated kinase inhibitor,targeted cancer
metacetamol,CC(=O)Nc1cccc(O)c1,0,Preclinical,analgesic agent,noncancer
RGFP966,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,1,Preclinical,HDAC inhibitor,targeted cancer
suxibuzone,CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,1,Launched,cyclooxygenase inhibitor,noncancer
AZD2858,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer
SRPIN340,FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1,0,Preclinical,serine arginine protein kinase inhibitor,targeted cancer
paroxypropione,CCC(=O)c1ccc(O)cc1,0,Launched,gonadotropin inhibitor,noncancer
NMS-873,Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O,1,Preclinical,ATPase inhibitor,targeted cancer
WZ4003,CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1,0,Preclinical,AMPK inhibitor,noncancer
PHA-680632,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
NGB-2904,Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl,0,Preclinical,dopamine receptor antagonist,noncancer
droxinostat,Cc1cc(Cl)ccc1OCCCC(=O)NO,0,Preclinical,HDAC inhibitor,noncancer
ST-91,CCc1cccc(CC)c1N=C1NCCN1,0,Preclinical,adrenergic receptor agonist,noncancer
gestodene,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C,0,Launched,contraceptive agent,noncancer
CGK-733,[O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F,0,Preclinical,"ATM kinase inhibitor, ATR kinase inhibitor",targeted cancer
zibotentan,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1,0,Phase 3,endothelin receptor antagonist,targeted cancer
L-368899,Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C,0,Phase 1,oxytocin receptor antagonist,noncancer
etosalamide,CCOCCOc1ccccc1C(N)=O,0,Preclinical,anti-inflammatory agent,noncancer
fananserin,Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1,0,Phase 2,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
NSC-632839,Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1,1,Preclinical,ubiquitin specific protease inhibitor,targeted cancer
AEG3482,NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1,1,Preclinical,HSP inducer,targeted cancer
cloperastine,Clc1ccc(cc1)C(OCCN1CCCCC1)c1ccccc1,0,Launched,antitussive,noncancer
WAY-213613,N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O,0,Preclinical,glutamate inhibitor,noncancer
tulobuterol,CC(C)(C)NCC(O)c1ccccc1Cl,0,Launched,adrenergic receptor agonist,noncancer
pifithrin-mu,NS(=O)(=O)C#Cc1ccccc1,0,Preclinical,HSP inhibitor,targeted cancer
compound-w,OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1,0,Preclinical,beta-secretase inhibitor,noncancer
FLI-06,CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1,1,Preclinical,notch signaling inhibitor,targeted cancer
silibinin,COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O,0,Launched,cytochrome P450 inhibitor,noncancer
C646,CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O,0,Preclinical,histone acetyltransferase inhibitor,targeted cancer
allylthiourea,NC(S)=NCC=C,0,Preclinical,nitrification inhibitor,noncancer
ONX-0914,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,1,Preclinical,proteasome inhibitor,Unknown
dimetridazole,Cc1ncc(n1C)[N+]([O-])=O,0,Launched,bacterial DNA inhibitor,noncancer
bromosporine,CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1,1,Preclinical,bromodomain inhibitor,noncancer
nonivamide,CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,0,Launched,TRPV agonist,noncancer
SGC-CBP30,COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl,0,Preclinical,bromodomain inhibitor,targeted cancer
procodazole,OC(=O)CCc1nc2ccccc2[nH]1,0,Preclinical,immunostimulant,noncancer
4-mu-8C,Cc1cc(=O)oc2c(C=O)c(O)ccc12,0,Preclinical,IRE1 inhibitor,noncancer
TAK-632,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,1,Preclinical,RAF inhibitor,targeted cancer
meticrane,Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O,0,Launched,diuretic,noncancer
EHop-016,CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12,0,Preclinical,Ras GTPase inhibitor,targeted cancer
ergonovine,CC(CO)NC(=O)C1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,0,Launched,"adrenergic receptor agonist, serotonin receptor agonist",noncancer
estradiol-cypionate,C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,1,Launched,estrogen receptor agonist,noncancer
cyclocytidine,OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O,1,Preclinical,"DNA synthesis inhibitor, RNA synthesis inhibitor",chemo
JX-401,COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1,0,Preclinical,p38 MAPK inhibitor,noncancer
UCL-2077,C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1,0,Preclinical,slow afterhyperpolarization channel blocker,noncancer
piperonyl-butoxide,CCCCOCCOCCOCc1cc2OCOc2cc1CCC,0,Launched,cytochrome P450 inhibitor,noncancer
PHTPP,Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1,0,Preclinical,estrogen receptor antagonist,noncancer
zoxazolamine,Nc1nc2cc(Cl)ccc2o1,0,Phase 2,myorelaxant,noncancer
BMS-191011,Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F,0,Preclinical,potassium channel activator,noncancer
betamipron,OC(=O)CCNC(=O)c1ccccc1,0,Launched,panipenem uptake inhibitor,noncancer
TC1,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,1,Preclinical,beta-secretase inhibitor,noncancer
proflavine-hemisulfate,Nc1ccc2cc3ccc(N)cc3nc2c1,1,Phase 2,topical anesthetic,noncancer
Y-134,CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1,0,Preclinical,estrogen receptor antagonist,targeted cancer
cyclandelate,CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1,0,Launched,calcium channel blocker,noncancer
ICG-001,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,1,Preclinical,beta-catenin inhibitor,targeted cancer
CHIR-124,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,1,Preclinical,CHK inhibitor,noncancer
etebenecid,CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O,0,Preclinical,uricosuric blocker,noncancer
LY2109761,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,1,Preclinical,TGF beta receptor inhibitor,targeted cancer
hydroxyprogesterone,CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,0,Launched,progesterone receptor agonist,noncancer
estradiol-valerate,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,0,Launched,estrogen receptor agonist,targeted cancer
pramoxine,CCCCOc1ccc(OCCCN2CCOCC2)cc1,0,Launched,topical anesthetic,noncancer
brompheniramine,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
mephenesin,Cc1ccccc1OCC(O)CO,0,Launched,muscle relaxant,noncancer
ethylnorepinephrine,CCC(N)C(O)c1ccc(O)c(O)c1,0,Preclinical,bronchodilator,noncancer
sulfachlorpyridazine,Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1,0,Launched,bacterial antifolate,noncancer
teniposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12,1,Launched,topoisomerase inhibitor,chemo
sulphadimethoxine,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1,0,Launched,dihydropteroate synthetase inhibitor,noncancer
sulfamonomethoxine,COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1,0,Launched,bacterial antifolate,noncancer
dirithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
sulconazole,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,1,Launched,sterol demethylase inhibitor,noncancer
nilutamide,CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,1,Launched,androgen receptor antagonist,targeted cancer
spiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1,0,Launched,dopamine receptor antagonist,noncancer
trimetozine,COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1,0,Launched,sedative,noncancer
suloctidil,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,0,Withdrawn,adrenergic receptor antagonist,noncancer
metaxalone,Cc1cc(C)cc(OCC2CNC(=O)O2)c1,0,Launched,muscle relaxant,noncancer
ronidazole,Cn1c(COC(N)=O)ncc1[N+]([O-])=O,0,Launched,antiprotozoal agent,noncancer
oxcarbazepine,NC(=O)N1c2ccccc2CC(=O)c2ccccc12,1,Launched,sodium channel blocker,noncancer
carsalam,O=c1[nH]c(=O)c2ccccc2o1,0,Preclinical,analgesic agent,noncancer
PP-121,C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12,1,Preclinical,protein tyrosine kinase inhibitor,noncancer
NU-7441,O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1,0,Preclinical,DNA dependent protein kinase inhibitor,targeted cancer
WAY-100635,COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1,0,Phase 1,serotonin receptor antagonist,noncancer
cinchophen,OC(=O)c1cc(nc2ccccc12)-c1ccccc1,0,Launched,analgesic agent,noncancer
trametinib,CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O,1,Launched,MEK inhibitor,targeted cancer
chiniofon,Oc1c(I)cc(c2cccnc12)S(O)(=O)=O,0,Launched,antiprotozoal agent,noncancer
YO-01027,C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O,1,Preclinical,gamma secretase inhibitor,noncancer
nilvadipine,COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N,0,Launched,calcium channel blocker,noncancer
afalanine,CC(=O)N[C@@H](Cc1ccccc1)C(O)=O,0,Phase 3,dopamine receptor agonist,noncancer
A922500,OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,0,Preclinical,diacylglycerol O acyltransferase inhibitor,noncancer
clorgiline,CN(CCCOc1ccc(Cl)cc1Cl)CC#C,0,Phase 2,monoamine oxidase inhibitor,Unknown
NVP-BSK805,Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1,0,Preclinical,JAK inhibitor,targeted cancer
OSI-027,COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12,1,Phase 1,mTOR inhibitor,targeted cancer
efloxate,CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1,0,Preclinical,vasodilator,noncancer
BMS-806,COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12,0,Phase 1,HIV attachment inhibitor,noncancer
sulfameter,COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1,0,Launched,dihydrofolate reductase inhibitor,Unknown
enrofloxacin,CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
sulfamethoxypyridazine,COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1,0,Withdrawn,bacterial antifolate,noncancer
fenofibric-acid,CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O,0,Launched,cytochrome P450 inhibitor,noncancer
saccharin,O=C1NS(=O)(=O)c2ccccc12,0,Launched,DNA polymerase inhibitor,noncancer
ceftiofur,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
estradiol-benzoate,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,1,Preclinical,contraceptive agent,noncancer
oseltamivir-phosphate,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,Launched,neuraminidase inhibitor,noncancer
flunisolide,CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO,0,Launched,cytochrome P450 inhibitor,noncancer
flumethasone,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
propofol,CC(C)c1cccc(C(C)C)c1O,0,Launched,benzodiazepine receptor agonist,noncancer
xylazine,Cc1cccc(C)c1NC1=NCCCS1,1,Launched,adrenergic receptor agonist,noncancer
mesoridazine,CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O,1,Launched,dopamine receptor antagonist,noncancer
lanatoside-c,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,1,Preclinical,cardiac glycoside,Unknown
flubendazole,COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1,1,Launched,tubulin polymerization inhibitor,noncancer
mesna,OS(=O)(=O)CCS,1,Launched,antioxidant,noncancer
flunixin-meglumin,Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F,0,Launched,prostanoid receptor antagonist,Unknown
phthalylsulfathiazole,OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,0,Launched,dihydropteroate synthetase inhibitor,noncancer
clorsulon,Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O,0,Launched,glycolysis inhibitor,noncancer
isaxonine,CC(C)Nc1ncccn1,0,Withdrawn,nerve growth factor agonist,noncancer
SNX-5422,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1,1,Phase 1/Phase 2,HSP inhibitor,Unknown
A-769662,Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12,0,Preclinical,AMPK activator,noncancer
synephrine,CNCC(O)c1ccc(O)cc1,0,Launched,adrenergic receptor agonist,noncancer
LY411575,C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O,0,Preclinical,gamma secretase inhibitor,noncancer
sulbentine,S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1,0,Preclinical,other antifungal,noncancer
fostamatinib,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC,0,Launched,SYK inhibitor,noncancer
troxerutin,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,0,Launched,antioxidant,noncancer
NPS-2143,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,0,Preclinical,calcium receptor antagonist,noncancer
ouabain,C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O,1,Launched,ATPase inhibitor,Unknown
GSK2126458,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,1,Phase 1,"mTOR inhibitor, PI3K inhibitor",Unknown
methylphenidate,COC(=O)C(C1CCCCN1)c1ccccc1,1,Launched,dopamine-norepinephrine reuptake inhibitor,noncancer
PF-3845,FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1,1,Preclinical,FAAH inhibitor,noncancer
bromperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1,0,Launched,dopamine receptor antagonist,noncancer
WAY-600,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,1,Preclinical,mTOR inhibitor,targeted cancer
isoetharine,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1,1,Launched,adrenergic receptor agonist,noncancer
LY2603618,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,1,Phase 2,CHK inhibitor,targeted cancer
5-hydroxymethyl-tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C,1,Phase 1,acetylcholine receptor antagonist,noncancer
succinylsulfathiazole,OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,0,Phase 2,dihydrofolate reductase inhibitor,noncancer
estropipate,C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O,0,Launched,estrogen receptor agonist,noncancer
suramin,Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O,0,Launched,DNA synthesis inhibitor,noncancer
ceftibuten,Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
cefuroxime,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
sibutramine,CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1,0,Withdrawn,serotonin-norepinephrine reuptake inhibitor (SNRI),noncancer
narasin,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,1,Launched,antiprotozoal agent,noncancer
deracoxib,COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
proadifen,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,0,Preclinical,nitric oxide synthase inhibitor,noncancer
canrenone,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,1,Withdrawn,mineralocorticoid receptor antagonist,noncancer
cycloheximide,C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1,1,Preclinical,protein synthesis inhibitor,targeted cancer
hydroxychloroquine,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,0,Launched,antimalarial agent,noncancer
tinidazole,CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O,0,Launched,antiprotozoal agent,noncancer
trandolapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
ethosuximide,CCC1(C)CC(=O)NC1=O,0,Launched,succinimide antiepileptic,noncancer
telithromycin,CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC,0,Launched,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",noncancer
troleandomycin,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](OC3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,0,Launched,protein synthesis inhibitor,noncancer
crotamiton,CCN(C(=O)\C=C\C)c1ccccc1C,0,Launched,antipruritic,noncancer
ascorbic-acid,OC[C@H](O)[C@H]1OC(=O)C(=O)C1O,0,Launched,antioxidant,noncancer
nonoxynol-9,CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1,1,Launched,membrane integrity inhibitor,noncancer
nizatidine,CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O,1,Launched,histamine receptor antagonist,noncancer
ADX-47273,Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1,0,Preclinical,glutamate receptor modulator,noncancer
CH5132799,CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1,1,Phase 1,PI3K inhibitor,targeted cancer
decamethonium,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,0,Launched,acetylcholine receptor agonist,noncancer
CP-91149,CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,0,Preclinical,glycogen phosphorylase inhibitor,noncancer
ethamivan,CCN(CC)C(=O)c1ccc(O)c(OC)c1,0,Preclinical,respiratory stimulant,noncancer
tyrphostin-AG-1478,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,1,Preclinical,EGFR inhibitor,targeted cancer
butyl-paraben,CCCCOC(=O)c1ccc(O)cc1,0,Preclinical,DNA synthesis inhibitor,noncancer
tubastatin-a,CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO,0,Preclinical,HDAC inhibitor,targeted cancer
tocainide,CC(N)C(=O)Nc1c(C)cccc1C,0,Launched,sodium channel blocker,noncancer
CCT128930,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,1,Preclinical,AKT inhibitor,targeted cancer
A-674563,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,1,Preclinical,AKT inhibitor,Unknown
enilconazole,Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1,0,Launched,sterol demethylase inhibitor,noncancer
AS-604850,FC1(F)Oc2ccc(cc2O1)\C=C1/SC(=O)NC1=O,0,Preclinical,PI3K inhibitor,targeted cancer
pentetic-acid,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O,0,Phase 2,chelating agent,noncancer
TAK-901,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,1,Phase 1,Aurora kinase inhibitor,targeted cancer
SB-415286,Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl,0,Preclinical,glycogen synthase kinase inhibitor,noncancer
salicin,OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 1,anti-inflammatory agent,noncancer
carbadox,COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-],0,Launched,other antibiotic,noncancer
monensin,CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C,1,Launched,bacterial permeability inducer,noncancer
alpha-tochopheryl-acetate,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1,0,Launched,antioxidant,noncancer
chlormadinone-acetate,CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,0,Launched,5 alpha reductase inhibitor,noncancer
diaveridine,COc1ccc(Cc2cnc(N)nc2N)cc1OC,1,Launched,dihydrofolate reductase inhibitor,noncancer
riboflavin,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,1,Launched,vitamin B2,noncancer
lornoxicam,CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
firocoxib,CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O,0,Launched,cyclooxygenase inhibitor,Unknown
iohexol,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,Unknown
mometasone-furoate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,0,Launched,glucocorticoid receptor agonist,noncancer
nifursol,Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O,0,Launched,bacterial DNA inhibitor,noncancer
paliperidone,Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12,1,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
levobunolol-(+/-),CC(C)(C)NCC(O)COc1cccc2C(=O)CCCc12,0,Preclinical,adrenergic receptor antagonist,noncancer
quinestrol,C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C,0,Launched,estrogen receptor agonist,noncancer
securinine,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,1,Preclinical,"GABA receptor antagonist, TP53 activator",noncancer
roxatidine-acetate,CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1,0,Launched,histamine receptor antagonist,noncancer
lufenuron,FC(C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl,0,Launched,chitin inhibitor,noncancer
PF-05212384,CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1,1,Phase 2,"mTOR inhibitor, PI3K inhibitor",targeted cancer
A66,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C,0,Preclinical,PI3K inhibitor,targeted cancer
isobutamben,CC(C)COC(=O)c1ccc(N)cc1,0,Preclinical,local anesthetic,noncancer
WYE-125132,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,1,Preclinical,mTOR inhibitor,targeted cancer
diethyltoluamide,CCN(CC)C(=O)c1cccc(C)c1,0,Launched,ionotropic receptor IR40a activator,noncancer
CAY10505,Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1,0,Preclinical,PI3K inhibitor,Unknown
tapentadol,CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1,0,Launched,opioid receptor agonist,Unknown
TG-101209,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,1,Preclinical,JAK inhibitor,noncancer
tilorone,CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1,0,Launched,interferon inducer,noncancer
GSK1838705A,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12,1,Preclinical,insulin growth factor receptor inhibitor,targeted cancer
astemizole,COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,1,Withdrawn,histamine receptor antagonist,noncancer
AMG900,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,1,Phase 1,Aurora kinase inhibitor,targeted cancer
ethionamide,CCc1cc(ccn1)C(S)=N,0,Launched,mycolic synthesis inhibitor,noncancer
VUF10166,CN1CCN(CC1)c1nc2ccccc2nc1Cl,0,Preclinical,serotonin receptor antagonist,noncancer
hygromycin-b,CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@@H]3OC4(O[C@@H]3[C@@H]2O)O[C@H](C(N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O,0,Preclinical,polypeptide synthesis inhibitor,noncancer
flumethasone-pivalate,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,1,Launched,glucocorticoid receptor agonist,noncancer
stemregenin-1,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,1,Preclinical,aryl hydrocarbon receptor antagonist,noncancer
proguanil,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,0,Launched,dihydrofolate reductase inhibitor,noncancer
tirapazamine,Nc1n[n+]([O-])c2ccccc2[n+]1[O-],1,Phase 3,DNA inhibitor,chemo
pindolol,CC(C)NCC(O)COc1cccc2[nH]ccc12,1,Launched,adrenergic receptor antagonist,noncancer
"16,16-dimethylprostaglandin-e2",CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,0,Phase 2,prostanoid receptor agonist,targeted cancer
pimecrolimus,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC,0,Launched,calcineurin inhibitor,noncancer
oglemilast,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,0,Phase 2,phosphodiesterase inhibitor,noncancer
chlorpropamide,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,1,Launched,ATP channel blocker,noncancer
trimebutine,CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1,1,Launched,opioid receptor agonist,noncancer
theophylline,Cn1c2nc[nH]c2c(=O)n(C)c1=O,1,Launched,adenosine receptor antagonist,noncancer
zaleplon,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,1,Launched,benzodiazepine receptor agonist,noncancer
honokiol,Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O,0,Phase 3,AKT inhibitor,targeted cancer
imatinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,1,Launched,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor",targeted cancer
clonidine,Clc1cccc(Cl)c1N=C1NCCN1,0,Launched,adrenergic receptor agonist,noncancer
thiomersal,CC[Hg]Sc1ccccc1C(O)=O,1,Launched,other antibiotic,noncancer
oxaprozin,OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,Unknown
pirfenidone,Cc1ccc(=O)n(c1)-c1ccccc1,0,Launched,TGF beta receptor inhibitor,noncancer
ST-1859,Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12,0,Phase 1,antiamyloidogenic agent,noncancer
naftifine,CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12,1,Launched,fungal squalene epoxidase inhibitor,noncancer
safinamide,C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,0,Launched,"dopamine uptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor",noncancer
U-104,NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,0,Preclinical,carbonic anhydrase inhibitor,targeted cancer
chlorthalidone,NS(=O)(=O)c1cc(ccc1Cl)C1(O)NC(=O)c2ccccc12,0,Launched,carbonic anhydrase inhibitor,noncancer
tolimidone,Cc1cccc(Oc2cnc(=O)[nH]c2)c1,0,Phase 2,src activator,noncancer
IOX2,OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,0,Preclinical,hypoxia inducible factor inhibitor,noncancer
teriflunomide,CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F,1,Launched,dihydroorotate dehydrogenase inhibitor,noncancer
zaltoprofen,CC(C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1,0,Launched,cyclooxygenase inhibitor,noncancer
ornidazole,Cc1ncc(n1CC(O)CCl)[N+]([O-])=O,0,Launched,antiprotozoal agent,noncancer
vildagliptin,OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N,0,Launched,dipeptidyl peptidase inhibitor,noncancer
osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,1,Launched,EGFR inhibitor,targeted cancer
WHI-P154,COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC,1,Preclinical,JAK inhibitor,targeted cancer
temsirolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,1,Launched,mTOR inhibitor,targeted cancer
IKK-16,O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1,1,Preclinical,IKK inhibitor,noncancer
lacidipine,CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC,0,Launched,calcium channel blocker,noncancer
ruxolitinib-(S),N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,0,Preclinical,JAK inhibitor,targeted cancer
voreloxin,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,1,Phase 3,topoisomerase inhibitor,chemo
go-6983,COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1,0,Preclinical,protein kinase inhibitor,targeted cancer
benzthiazide,NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
sitaxentan,Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl,0,Withdrawn,endothelin receptor antagonist,noncancer
CYT-997,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,1,Phase 2,tubulin polymerization inhibitor,Unknown
isradipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C,0,Launched,calcium channel blocker,noncancer
apremilast,CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O,0,Launched,phosphodiesterase inhibitor,Unknown
mesulergine,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1,0,Phase 2,dopamine receptor agonist,noncancer
thalidomide,O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12,0,Launched,tumor necrosis factor production inhibitor,Unknown
sacubitril,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O,0,Launched,neprilysin inhibitor,noncancer
indoximod,Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12,0,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",targeted cancer
lomitapide,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,1,Launched,microsomal trigylceride transfer protein inhibitor,noncancer
taltirelin,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,1,Launched,thyrotropin releasing hormone receptor agonist,noncancer
tosedostat,CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1,1,Phase 2,peptidase inhibitor,targeted cancer
stavudine,Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O,0,Launched,"DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor",noncancer
torasemide,CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1,1,Launched,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",noncancer
ipriflavone,CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O,0,Launched,bone resorption inhibitor,noncancer
cepharanthine,COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34,0,Phase 2,NFkB pathway inhibitor,targeted cancer
ingenol-mebutate,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,1,Launched,PKC activator,noncancer
propafenone,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,0,Launched,antiarrhythmic,noncancer
dihydroergocristine,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,1,Launched,"adrenergic receptor antagonist, prolactin inhibitor",noncancer
enzastaurin,Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12,0,Phase 3,PKC inhibitor,targeted cancer
tadalafil,CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O,0,Launched,phosphodiesterase inhibitor,noncancer
tomelukast,CCCc1c(OCCCCc2nnn[nH]2)ccc(C(C)=O)c1O,0,Phase 3,leukotriene receptor antagonist,noncancer
temazepam,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,1,Withdrawn,benzodiazepine receptor agonist,noncancer
SB-742457,O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1,0,Phase 3,serotonin receptor antagonist,noncancer
genistein,Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,0,Phase 2/Phase 3,tyrosine kinase inhibitor,targeted cancer
WZ811,C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1,0,Preclinical,CC chemokine receptor antagonist,targeted cancer
AMG-837,CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1,0,Phase 1,free fatty acid receptor agonist,noncancer
PF-4981517,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,1,Preclinical,cytochrome P450 inhibitor,noncancer
anacetrapib,COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,0,Phase 3,cholesteryl ester transfer protein inhibitor,noncancer
amoxicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O,1,Launched,penicillin binding protein inhibitor,noncancer
2-methoxyestradiol,COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O,1,Phase 2,hypoxia inducible factor inhibitor,targeted cancer
CTEP,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,0,Preclinical,glutamate receptor antagonist,noncancer
pidotimod,OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1,0,Launched,"interferon receptor agonist, interleukin receptor agonist",noncancer
TG-100713,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,1,Preclinical,PI3K inhibitor,targeted cancer
saracatinib,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,1,Phase 2/Phase 3,src inhibitor,targeted cancer
tyrphostin-A9,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,1,Preclinical,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",targeted cancer
pentobarbital,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,0,Withdrawn,"barbiturate antiepileptic, GABA receptor modulator",noncancer
PF-477736,Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O,1,Phase 1,CHK inhibitor,targeted cancer
grazoprevir,COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C,0,Launched,HCV inhibitor,noncancer
icotinib,C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,1,Launched,EGFR inhibitor,targeted cancer
dinaciclib,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,1,Phase 3,CDK inhibitor,Unknown
KW-2449,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,1,Phase 1,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor",targeted cancer
carbenoxolone,CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O,0,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,noncancer
bifonazole,c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1,0,Launched,sterol demethylase inhibitor,noncancer
baicalin,O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O,1,Launched,beta glucuronidase inhibitor,noncancer
digoxin,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,1,Launched,ATPase inhibitor,Unknown
nicardipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1,0,Launched,calcium channel blocker,noncancer
etanidazole,OCCNC(=O)Cn1ccnc1[N+]([O-])=O,0,Phase 3,bacterial cell wall synthesis inhibitor,targeted cancer
CI-976,CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC,0,Phase 1,ACAT inhibitor,noncancer
diosmin,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1,0,Launched,"aryl hydrocarbon receptor agonist, capillary stabilizing agent",noncancer
bisoprolol,CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,0,Launched,adrenergic receptor antagonist,noncancer
LY2811376,C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1,0,Phase 1,beta-secretase inhibitor,noncancer
phentolamine,Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1,0,Launched,adrenergic receptor antagonist,noncancer
trapidil,CCN(CC)c1cc(C)nc2ncnn12,1,Launched,PDGFR tyrosine kinase receptor inhibitor,noncancer
noscapine,COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12,0,Launched,"bradykinin receptor antagonist, tubulin polymerization inhibitor",noncancer
darifenacin,NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer
VX-765,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,1,Phase 2,caspase inhibitor,noncancer
oxandrolone,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,androgen receptor agonist,noncancer
rutin,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,1,Launched,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",noncancer
ribavirin,NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,1,Launched,antiviral,noncancer
clenbuterol,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,1,Launched,adrenergic receptor agonist,noncancer
tamoxifen,CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1,1,Launched,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",targeted cancer
piceatannol,Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1,0,Preclinical,SYK inhibitor,noncancer
amfepramone,CCN(CC)C(C)C(=O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
VU0364770,Clc1cccc(NC(=O)c2ccccn2)c1,1,Preclinical,glutamate receptor positive allosteric modulator,noncancer
glafenine,OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12,0,Withdrawn,DeltaF508-CFTR Correctors,noncancer
ZM-323881,Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,0,Preclinical,VEGFR inhibitor,targeted cancer
lapatinib,CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1,Launched,EGFR inhibitor,targeted cancer
JNJ-7777120,CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1,0,Preclinical,histamine receptor antagonist,noncancer
ganetespib,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,1,Phase 3,HSP inhibitor,targeted cancer
clevudine,Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O,0,Launched,DNA polymerase inhibitor,noncancer
AEE788,CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1,1,Phase 1/Phase 2,"EGFR inhibitor, VEGFR inhibitor",targeted cancer
ML130,Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12,0,Preclinical,NOD1 inhibitor,noncancer
perampanel,O=c1c(cc(cn1-c1ccccc1)-c1ccccn1)-c1ccccc1C#N,0,Launched,glutamate receptor antagonist,noncancer
PJ-34,CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,1,Preclinical,PARP inhibitor,targeted cancer
buparlisib,Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,1,Phase 3,PI3K inhibitor,targeted cancer
ZM-306416,COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC,1,Preclinical,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor",targeted cancer
sparfloxacin,C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1,1,Withdrawn,bacterial DNA gyrase inhibitor,noncancer
ki16198,COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)OC(C)c1ccccc1Cl,0,Preclinical,lipoprotein antagonist,targeted cancer
trimipramine,CC(CN(C)C)CN1c2ccccc2CCc2ccccc12,0,Launched,"norepinephrine reputake inhibitor, tricyclic antidepressant",noncancer
CHIR-99021,Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl,1,Preclinical,glycogen synthase kinase inhibitor,noncancer
LY2784544,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,1,Phase 2,JAK inhibitor,noncancer
AZD2014,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,1,Phase 2,mTOR inhibitor,targeted cancer
PH-797804,CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O,0,Phase 2,p38 MAPK inhibitor,noncancer
HC-030031,CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1,0,Phase 1,TRPA1 channel blocker,noncancer
phentermine,CC(C)(N)Cc1ccccc1,0,Launched,"dopamine uptake inhibitor, serotonin reuptake inhibitor",noncancer
EX-527,NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21,0,Phase 2,SIRT inhibitor,noncancer
tobramycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
edoxaban,CN(C)C(=O)[C@@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@H](C1)NC(=O)c1nc2CCN(C)Cc2s1,0,Launched,coagulation factor inhibitor,noncancer
bexarotene,Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,1,Launched,retinoid receptor agonist,targeted cancer
telmisartan,CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C,0,Launched,angiotensin receptor antagonist,noncancer
FPL-55712,CCCc1c(OCC(O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O,0,Phase 1,leukotriene receptor antagonist,noncancer
indibulin,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,1,Phase 1/Phase 2,tubulin polymerization inhibitor,chemo
AV-608,FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12,0,Phase 2,tachykinin antagonist,noncancer
ibutilide,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,1,Launched,potassium channel blocker,noncancer
tezacaftor,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,1,Launched,CFTR channel agonist,noncancer
ganaxolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Phase 3,GABA receptor modulator,noncancer
ciglitazone,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1,0,Phase 2,PPAR receptor agonist,noncancer
tiabendazole,c1nc(cs1)-c1nc2ccccc2[nH]1,0,Launched,angiogenesis inhibitor,noncancer
nisoxetine,CNCCC(Oc1ccccc1OC)c1ccccc1,1,Phase 1,norepinephrine reuptake inhibitor,noncancer
nimesulide,CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O,0,Launched,cyclooxygenase inhibitor,noncancer
PF-04136309,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,1,Phase 2,CC chemokine receptor antagonist,targeted cancer
ciclopirox,Cc1cc(C2CCCCC2)n(O)c(=O)c1,1,Launched,membrane integrity inhibitor,noncancer
siramesine,Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12,0,Phase 2,sigma receptor antagonist,targeted cancer
GNF-2,NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1,0,Preclinical,Bcr-Abl kinase inhibitor,targeted cancer
toremifene,CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1,1,Launched,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",Unknown
ML161,CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1,0,Preclinical,protease-activated receptor inhibitor,noncancer
fosinopril,CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C,0,Launched,angiotensin converting enzyme inhibitor,noncancer
thiamine,Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N,1,Launched,vitamin B,noncancer
pterostilbene,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,1,Phase 2/Phase 3,"cyclooxygenase inhibitor, PPAR receptor agonist",targeted cancer
ethambutol,CC[C@@H](CO)NCCN[C@@H](CC)CO,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
ritonavir,CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,0,Launched,HIV protease inhibitor,noncancer
desloratadine,Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1,0,Launched,histamine receptor antagonist,noncancer
metronidazole,Cc1ncc(n1CCO)[N+]([O-])=O,1,Launched,DNA inhibitor,noncancer
doxycycline,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12,1,Launched,metalloproteinase inhibitor,noncancer
nandrolone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O,0,Launched,imidazoline receptor agonist,noncancer
diphemanil,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer
bifemelane,CNCCCCOc1ccccc1Cc1ccccc1,1,Launched,acetylcholine release enhancer,noncancer
guanidine,NC(N)=N,1,Launched,HSP inhibitor,noncancer
cromoglicic-acid,OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O,0,Launched,immunosuppressant,noncancer
schisandrin-b,COc1cc2C[C@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC,0,Preclinical,antioxidant,noncancer
levocetirizine,OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,1,Launched,histamine receptor antagonist,noncancer
etodolac,CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12,0,Launched,cyclooxygenase inhibitor,noncancer
droperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O,0,Launched,dopamine receptor antagonist,noncancer
etravirine,Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N,0,Launched,non-nucleoside reverse transcriptase inhibitor,noncancer
amiloride,NC(=N)NC(=O)c1nc(Cl)c(N)nc1N,0,Launched,sodium channel blocker,noncancer
anidulafungin,CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(NC(=O)C(NC(=O)C2CC(O)CN2C(=O)C(NC1=O)C(C)O)C(O)C(O)c1ccc(O)cc1)C(C)O,0,Launched,"fungal 1,3-beta-D-glucan synthase inhibitor",Unknown
melatonin,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,Launched,"melatonin receptor agonist, nitric oxide synthase inhibitor",noncancer
rimantadine,CC(N)C12CC3CC(CC(C3)C1)C2,0,Launched,"antiviral, RNA synthesis inhibitor",noncancer
mepyramine,COc1ccc(cc1)CN(CCN(C)C)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
disopyramide,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,0,Launched,sodium channel blocker,noncancer
melperone,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
metoclopramide,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
amiprilose,CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO,0,Phase 3,CD antagonist,noncancer
tioguanine,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,1,Phase 2,purine antagonist,targeted cancer
ranolazine,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,0,Launched,sodium channel blocker,noncancer
inosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12,1,Launched,neurotrophic agent,noncancer
hesperidin,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1,0,Launched,flavanone glycoside,noncancer
regadenoson,CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1,0,Launched,adenosine receptor agonist,noncancer
brequinar,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,1,Phase 2,dihydroorotate dehydrogenase inhibitor,targeted cancer
betrixaban,COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1,0,Launched,coagulation factor inhibitor,noncancer
tetrabenazine,COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC,0,Launched,vesicular monoamine transporter inhibitor,noncancer
pregnenolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,glutamate receptor modulator,noncancer
hydroxyzine,OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,0,Launched,antihistamine,noncancer
GDC-0941,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,1,Phase 2,PI3K inhibitor,targeted cancer
cinchocaine,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,0,Launched,sodium channel blocker,noncancer
gallopamil,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC,0,Launched,L-type calcium channel blocker,noncancer
sulfacetamide,CC(=O)NS(=O)(=O)c1ccc(N)cc1,0,Launched,PABA antagonist,noncancer
mitiglinide,OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,0,Launched,insulin secretagogue,noncancer
methyclothiazide,CN1C(CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O,0,Launched,chloride reabsorption inhibitor,noncancer
amlodipine,CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC,0,Launched,calcium channel blocker,noncancer
ropivacaine,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,0,Launched,sodium channel blocker,noncancer
clomipramine,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12,0,Launched,serotonin transporter (SERT) inhibitor,noncancer
amidopyrine,CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O,0,Launched,analgesic agent,noncancer
baricitinib,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,1,Phase 3,JAK inhibitor,noncancer
lithocholic-acid,C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Preclinical,"FXR antagonist, vitamin D receptor agonist",targeted cancer
ondansetron,Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C,0,Launched,serotonin receptor antagonist,noncancer
fadrozole,N#Cc1ccc(cc1)C1CCCc2cncn12,0,Launched,aromatase inhibitor,targeted cancer
olsalazine,OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
MK-0752,OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1,0,Phase 1/Phase 2,gamma secretase inhibitor,targeted cancer
fasudil,O=S(=O)(N1CCCNCC1)c1cccc2cnccc12,0,Launched,rho associated kinase inhibitor,noncancer
buspirone,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,0,Launched,serotonin receptor agonist,Unknown
ramelteon,CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12,0,Launched,melatonin receptor agonist,noncancer
asenapine,CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
homoharringtonine,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,1,Launched,protein synthesis inhibitor,Unknown
letermovir,COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F,0,Phase 3,CMV terminase inhibitor,noncancer
tibolone,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)C12,0,Launched,"androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist",noncancer
istaroxime,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O,0,Phase 2,ATPase inhibitor,noncancer
topiroxostat,N#Cc1cc(ccn1)-c1n[nH]c(n1)-c1ccncc1,0,Launched,xanthine oxidase inhibitor,noncancer
sertaconazole,Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,0,Launched,sterol demethylase inhibitor,noncancer
vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,1,Launched,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor",targeted cancer
thiothixene,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C/CCN3CCN(C)CC3)c2c1,0,Launched,dopamine receptor antagonist,noncancer
naphazoline,C(C1=NCCN1)c1cccc2ccccc12,0,Launched,adrenergic receptor agonist,noncancer
goserelin-acetate,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,Launched,gonadotropin releasing factor hormone receptor agonist,Unknown
ebselen,O=c1n([se]c2ccccc12)-c1ccccc1,0,Phase 2/Phase 3,"cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor",noncancer
suvorexant,C[C@@H]1CCN(CCN1C(=O)c1cc(C)ccc1-n1nccn1)c1nc2cc(Cl)ccc2o1,0,Launched,orexin receptor antagonist,noncancer
doramapimod,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C,0,Phase 2,p38 MAPK inhibitor,noncancer
deferasirox,OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,1,Launched,chelating agent,noncancer
crizotinib,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,1,Launched,ALK tyrosine kinase receptor inhibitor,targeted cancer
eflornithine,NCCCC(N)(C(F)F)C(O)=O,0,Launched,ornithine decarboxylase inhibitor,noncancer
valganciclovir,CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O,0,Launched,DNA synthesis inhibitor,noncancer
amitriptyline,CN(C)CCC=C1c2ccccc2CCc2ccccc12,0,Launched,"norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin-norepinephrine reuptake inhibitor (SNRI)",noncancer
acetylcholine,CC(=O)OCC[N+](C)(C)C,0,Launched,acetylcholine receptor agonist,noncancer
camicinal,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1,0,Phase 2,motilin receptor agonist,noncancer
gadodiamide,CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,0,Launched,radiopaque medium,noncancer
empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1,0,Launched,sodium/glucose cotransporter inhibitor,noncancer
albendazole-oxide,CCCS(=O)c1ccc2nc(NC(=O)OC)[nH]c2c1,0,Launched,anthelmintic agent,noncancer
elvitegravir,COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C,0,Launched,HIV integrase inhibitor,noncancer
oxibendazole,CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1,1,Launched,tubulin polymerization inhibitor,noncancer
LXR-623,Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F,0,Phase 1,LXR agonist,noncancer
cefditoren-pivoxil,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1,1,Launched,bacterial cell wall synthesis inhibitor,noncancer
WAY-362450,CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1,0,Phase 1,FXR agonist,noncancer
pranlukast,O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1,0,Launched,leukotriene receptor antagonist,noncancer
dosulepin,CN(C)CC\C=C1/c2ccccc2CSc2ccccc12,0,Launched,"norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant",noncancer
dapoxetine,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
selinexor,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,1,Phase 2/Phase 3,exportin antagonist,Unknown
esomeprazole,COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C,0,Launched,ATPase inhibitor,noncancer
metatinib,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,1,Phase 1,Bcr-Abl kinase inhibitor,targeted cancer
perhexiline,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1,0,Launched,carnitine palmitoyltransferase inhibitor,noncancer
LY2157299,Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O,0,Phase 2/Phase 3,TGF beta receptor inhibitor,targeted cancer
RS-127445,CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12,0,Phase 1,serotonin receptor antagonist,noncancer
menadione,CC1=CC(=O)c2ccccc2C1=O,1,Launched,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor",noncancer
canagliflozin,Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,Launched,sodium/glucose cotransporter inhibitor,noncancer
imexon,N=C1NC(=O)N2CC12,0,Phase 2,"apoptosis stimulant, ribonucleotide reductase inhibitor",targeted cancer
AGP-103,CCCCCCCCCCCCCCCCCCCCCC(O)=O,0,Launched,membrane permeability inhibitor,noncancer
glycitein,COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O,0,Phase 3,tumor necrosis factor release inhibitor,noncancer
nikethamide,CCN(CC)C(=O)c1cccnc1,0,Withdrawn,immunostimulant,noncancer
nefopam,CN1CCOC(c2ccccc2)c2ccccc2C1,0,Launched,cyclooxygenase inhibitor,noncancer
alaproclate,CC(N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1,0,Phase 2,serotonin receptor antagonist,noncancer
broxuridine,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O,0,Phase 2,antimetabolite,targeted cancer
PF-562271,CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O,1,Phase 1,focal adhesion kinase inhibitor,Unknown
idalopirdine,FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1,0,Phase 3,serotonin receptor antagonist,noncancer
ostarine,C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F,0,Phase 3,androgen receptor modulator,targeted cancer
ipratropium,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
bosentan,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,1,Launched,endothelin receptor antagonist,noncancer
piperidolate,CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
olmesartan-medoxomil,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,0,Launched,angiotensin receptor antagonist,Unknown
benzoic-acid,OC(=O)c1ccccc1,0,Launched,food preservative,noncancer
R-428,Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1,0,Phase 1,AXL kinase inhibitor,targeted cancer
edrophonium,CC[N+](C)(C)c1cccc(O)c1,0,Launched,acetylcholinesterase inhibitor,noncancer
propylthiouracil,CCCc1cc(=O)[nH]c(=S)[nH]1,0,Launched,thyroid peroxidase inhibitor,noncancer
oxolinic-acid,CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12,0,Preclinical,bacterial DNA gyrase inhibitor,noncancer
mestranol,COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1,0,Launched,estrogen receptor agonist,noncancer
pentylenetetrazol,C1CCc2nnnn2CC1,0,Withdrawn,GABA receptor antagonist,noncancer
10-DEBC,CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12,0,Preclinical,AKT inhibitor,targeted cancer
alprenolol,CC(C)NCC(O)COc1ccccc1CC=C,0,Launched,adrenergic receptor antagonist,noncancer
bitopertin,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,1,Phase 3,"glycine transporter inhibitor, GlyT-1 inhibitor",noncancer
desoxypeganine,C1CN2Cc3ccccc3N=C2C1,0,Phase 1,"acetylcholinesterase inhibitor, monoamine oxidase inhibitor",noncancer
evans-blue,Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(c(C)c1)\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O,0,Launched,glutamate receptor negative allosteric modulator,targeted cancer
tafamidis-meglumine,OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1,0,Launched,transthyretin amyloid inhibitor,noncancer
diflorasone-diacetate,C[C@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O,0,Launched,glucocorticoid receptor agonist,noncancer
SB-683698,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1,0,Phase 1,integrin antagonist,noncancer
zolmitriptan,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,1,Launched,serotonin receptor agonist,noncancer
marimastat,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,1,Phase 3,matrix metalloprotease inhibitor,targeted cancer
albendazole,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,1,Launched,tubulin polymerization inhibitor,noncancer
rupatadine,Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1,0,Launched,"histamine receptor antagonist, platelet activating factor receptor antagonist",noncancer
midodrine,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,1,Launched,adrenergic receptor agonist,noncancer
spironolactone,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12,1,Launched,mineralocorticoid receptor antagonist,noncancer
nesbuvir,CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1,0,Phase 2,RNA polymerase inhibitor,noncancer
EMD-1214063,CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1,0,Phase 1,hepatocyte growth factor receptor inhibitor,targeted cancer
bendroflumethiazide,NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F,1,Launched,sodium/potassium/chloride transporter inhibitor,noncancer
ketoprofen,CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1,1,Launched,cyclooxygenase inhibitor,Unknown
sodium-gualenate,CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O,0,Launched,antacid,noncancer
malotilate,CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1,0,Launched,protein synthesis stimulant,noncancer
phenylephrine,CNC[C@H](O)c1cccc(O)c1,0,Launched,adrenergic receptor agonist,noncancer
timonacic,OC(=O)C1CSCN1,0,Launched,antioxidant,Unknown
cinaciguat,OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O,0,Phase 2,guanylate cyclase activator,noncancer
alvimopan,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1,0,Launched,opioid receptor antagonist,noncancer
vardenafil,CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1,0,Launched,phosphodiesterase inhibitor,noncancer
bretazenil,CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21,0,Phase 2,GABA benzodiazepine site receptor partial agonist,Unknown
rizatriptan,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,0,Launched,serotonin receptor agonist,noncancer
3-deazaadenosine,Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)C(O)C1O,0,Phase 2,adenosylhomocysteinase inhibitor,noncancer
cyanocobalamin,C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12,0,Launched,"methylmalonyl CoA mutase stimulant, vitamin B",noncancer
PI-103,Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,1,Preclinical,"mTOR inhibitor, PI3K inhibitor",targeted cancer
berberine,COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC,1,Phase 2/Phase 3,LDL receptor activator,targeted cancer
nomifensine,CN1CC(c2ccccc2)c2cccc(N)c2C1,0,Withdrawn,"dopamine uptake inhibitor, noradrenaline uptake inhibitor",noncancer
torin-1,CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1,1,Preclinical,mTOR inhibitor,Unknown
hydroxyamphetamine,CC(N)Cc1ccc(O)cc1,0,Launched,trace amine associated receptor agonist,noncancer
zileuton,CC(N(O)C(N)=O)c1cc2ccccc2s1,0,Launched,"leukotriene synthesis inhibitor, lipoxygenase inhibitor",noncancer
butylated-hydroxytoluene,Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,0,Phase 1,carbonic anhydrase inhibitor,noncancer
tramadol,COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C,0,Launched,"norepinephrine reputake inhibitor, opioid receptor agonist, serotonin reuptake inhibitor",noncancer
cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,1,Launched,cytochrome P450 inhibitor,noncancer
nocodazole,COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1,1,Preclinical,tubulin polymerization inhibitor,targeted cancer
halofantrine,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,1,Launched,antimalarial agent,noncancer
dextroamphetamine,C[C@H](N)Cc1ccccc1,0,Launched,monoamine oxidase inhibitor,noncancer
TIC10,Cc1ccccc1CN1CC2=C(CCN(Cc3ccccc3)C2=O)N2CCN=C12,0,Phase 2,"AKT inhibitor, TRAIL modulator",targeted cancer
formestane,C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O,1,Launched,aromatase inhibitor,targeted cancer
bardoxolone-methyl,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,1,Phase 3,"nuclear factor erythroid derived, like (NRF2) activator",Unknown
L-NAME,COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O,0,Phase 2/Phase 3,nitric oxide synthase inhibitor,noncancer
sertraline,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
nevirapine,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,0,Launched,non-nucleoside reverse transcriptase inhibitor,noncancer
aclidinium,OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1,0,Launched,acetylcholine receptor antagonist,noncancer
tesaglitazar,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O,0,Phase 3,"insulin sensitizer, PPAR receptor agonist",noncancer
gatifloxacin,COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1,0,Withdrawn,bacterial DNA gyrase inhibitor,noncancer
papaverine,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,1,Launched,phosphodiesterase inhibitor,noncancer
cefdinir,Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,1,Launched,bacterial cell wall synthesis inhibitor,noncancer
CP-724714,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,1,Phase 2,"EGFR inhibitor, protein tyrosine kinase inhibitor",targeted cancer
rebamipide,OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1,0,Launched,free radical scavenger,noncancer
entinostat,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,1,Phase 3,HDAC inhibitor,targeted cancer
clotrimazole,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1,Launched,"cytochrome P450 inhibitor, imidazoline receptor ligand",noncancer
decitabine,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,1,Launched,DNA methyltransferase inhibitor,targeted cancer
LX1031,COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,0,Phase 2,tryptophan hydroxylase inhibitor,noncancer
naftidrofuryl,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,1,Launched,adrenergic receptor antagonist,noncancer
liranaftate,COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1,0,Launched,fungal squalene epoxidase inhibitor,noncancer
avasimibe,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C,0,Phase 3,ACAT inhibitor,targeted cancer
terbinafine,CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12,0,Launched,fungal squalene epoxidase inhibitor,noncancer
HMN-214,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,1,Phase 1,PLK inhibitor,Unknown
ataluren,OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F,0,Launched,"CFTR channel agonist, dystrophin stimulant",noncancer
DUP-697,CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1,0,Phase 1,cyclooxygenase inhibitor,noncancer
climbazole,CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1,0,Launched,enzyme inducer,noncancer
SQ-22536,Nc1ncnc2n(cnc12)C1CCCO1,0,Preclinical,adenylyl cyclase inhibitor,noncancer
omeprazole,COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C,1,Launched,ATPase inhibitor,noncancer
BMY-45778,OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1,0,Preclinical,IP1 prostacyclin receptor agonist,noncancer
orantinib,Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O,1,Phase 3,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
SKF-81297,Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1,0,Preclinical,dopamine receptor agonist,noncancer
AP26113,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,1,Phase 2,ALK tyrosine kinase receptor inhibitor,targeted cancer
GR-127935,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1,0,Preclinical,serotonin receptor antagonist,noncancer
LGX818,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,1,Phase 3,RAF inhibitor,targeted cancer
oleoylethanolamide,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,1,Preclinical,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist",noncancer
AZD8931,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,1,Phase 2,EGFR inhibitor,targeted cancer
terazosin,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1,0,Launched,adrenergic receptor antagonist,noncancer
cladribine,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,1,Launched,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",chemo
FR-122047,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,1,Preclinical,cyclooxygenase inhibitor,noncancer
fenoterol,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,0,Withdrawn,adrenergic receptor agonist,noncancer
GW-9662,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1,0,Preclinical,PPAR receptor antagonist,noncancer
netupitant,CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1,0,Launched,tachykinin antagonist,noncancer
telbivudine,Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O,0,Launched,DNA polymerase inhibitor,Unknown
amtolmetin-guacil,COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C,0,Launched,cyclooxygenase inhibitor,noncancer
Z160,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,0,Phase 2,N-type calcium channel blocker,noncancer
epothilone-b,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,1,Phase 3,"microtubule stabilizing agent, tubulin polymerization inhibitor",chemo
fentiazac,OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
etizolam,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,0,Launched,benzodiazepine receptor agonist,noncancer
abiraterone-acetate,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1,1,Launched,androgen biosynthesis inhibitor,targeted cancer
SB-743921,CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1,1,Phase 1/Phase 2,kinesin-like spindle protein inhibitor,targeted cancer
oxymetazoline,Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C,1,Launched,adrenergic receptor agonist,noncancer
12-O-tetradecanoylphorbol-13-acetate,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,1,Phase 2,PKC activator,targeted cancer
rimexolone,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer
REV-5901,CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1,0,Phase 2,"leukotriene receptor antagonist, lipoxygenase inhibitor",noncancer
atrasentan,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1,0,Phase 3,endothelin receptor antagonist,targeted cancer
lidamidine,CNC(=N)NC(=O)Nc1c(C)cccc1C,1,Launched,adrenergic receptor agonist,noncancer
azathioprine,Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O,1,Launched,dehydrogenase inhibitor,noncancer
BTS-54505,CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1,1,Withdrawn,dopamine reuptake inhibitor,noncancer
setiptiline,CN1CCC2=C(C1)c1ccccc1Cc1ccccc21,0,Launched,adrenergic receptor antagonist,Unknown
lumacaftor,Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O,0,Launched,CFTR channel agonist,noncancer
dorzolamide,CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,1,Launched,carbonic anhydrase inhibitor,noncancer
clofazimine,CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1,1,Launched,GK0582 inhibitor,noncancer
SR-59230A,CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12,0,Preclinical,adrenergic receptor antagonist,noncancer
Y-39983,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,1,Phase 2,rho associated kinase inhibitor,noncancer
SB-205384,CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N,1,Preclinical,GABA receptor modulator,noncancer
indomethacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1,0,Launched,cyclooxygenase inhibitor,noncancer
CGP-7930,CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,0,Preclinical,GABA receptor modulator,noncancer
cilengitide,CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,0,Phase 3,integrin antagonist,targeted cancer
CGP-13501,CC(C)(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C=O,0,Preclinical,GABA receptor modulator,noncancer
fidaxomicin,CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O,0,Launched,RNA polymerase inhibitor,noncancer
SDZ-21009,CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1,0,Preclinical,"adrenergic receptor antagonist, serotonin receptor antagonist",noncancer
indapamide,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,0,Launched,thiazide diuretic,noncancer
5-iodo-A-85380,Ic1cncc(OC[C@@H]2CCN2)c1,0,Phase 2,acetylcholine receptor agonist,noncancer
oseltamivir-carboxylate,CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O,0,Launched,neuraminidase inhibitor,noncancer
eletriptan,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,0,Launched,serotonin receptor agonist,noncancer
RAF265,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,1,Phase 2,"RAF inhibitor, VEGFR inhibitor",targeted cancer
DCPIB,CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1,0,Preclinical,"chloride channel blocker, gap junction modulator, glutamate inhibitor",noncancer
quercetin,Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O,0,Launched,polar auxin transport inhibitor,noncancer
BAY-K-8644-(s)-(-),COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,1,Preclinical,L-type calcium channel activator,noncancer
itopride,COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,0,Launched,dopamine receptor antagonist,noncancer
VLX600,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,1,Phase 1,ubiquitin C-terminal hydrolase inhibitor,targeted cancer
thioctic-acid,OC(=O)CCCCC1CCSS1,0,Launched,reducing agent,Unknown
EVP-6124,Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2,0,Phase 3,acetylcholine receptor agonist,noncancer
ibudilast,CC(C)C(=O)c1c(nn2ccccc12)C(C)C,0,Launched,"leukotriene receptor antagonist, phosphodiesterase inhibitor",noncancer
afloqualone,Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O,0,Launched,acetylcholine receptor antagonist,noncancer
metixene,CN1CCCC(CC2c3ccccc3Sc3ccccc23)C1,0,Launched,acetylcholine receptor antagonist,noncancer
quetiapine,OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
diazepam,CN1c2ccc(Cl)cc2C(=NCC1=O)c1ccccc1,0,Launched,benzodiazepine receptor agonist,noncancer
pinitol,COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O,0,Phase 2,gamma secretase inhibitor,noncancer
zaprinast,CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1,0,Phase 2,phosphodiesterase inhibitor,noncancer
diltiazem,COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,0,Launched,calcium channel blocker,noncancer
butoconazole,Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
amantadine,NC12CC3CC(CC(C3)C1)C2,0,Launched,glutamate receptor antagonist,noncancer
regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,1,Launched,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor",targeted cancer
aripiprazole,Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl,1,Launched,"serotonin receptor agonist, serotonin receptor antagonist",noncancer
azelastine,CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O,0,Launched,histamine receptor antagonist,noncancer
levocabastine,C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1,0,Launched,histamine receptor antagonist,noncancer
mericitabine,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,1,Phase 2,HCV inhibitor,noncancer
SNX-2112,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,1,Phase 1,HSP inhibitor,Unknown
lisinopril,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
AT13387,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,1,Phase 2,HSP antagonist,Unknown
hyperin,OCC1OC(Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)C(O)C(O)C1O,0,Preclinical,aldose reductase inhibitor,targeted cancer
reparixin,CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O,0,Phase 3,CC chemokine receptor antagonist,targeted cancer
quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,1,Phase 3,FLT3 inhibitor,targeted cancer
NM107,CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O,0,Phase 2,RNA polymerase inhibitor,noncancer
TAK-875,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1,0,Phase 3,insulin secretagogue,noncancer
ilepcimide,O=C(C=Cc1ccc2OCOc2c1)N1CCCCC1,0,Phase 3,anticonvulsant,noncancer
chlorprothixene,CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12,0,Launched,dopamine receptor antagonist,noncancer
ritodrine,C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1,1,Launched,adrenergic receptor agonist,noncancer
cis-urocanic-acid,OC(=O)\C=C\c1c[nH]cn1,0,Phase 2,serotonin receptor agonist,Unknown
naproxen,COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O,1,Launched,cyclooxygenase inhibitor,noncancer
ipidacrine,Nc1c2CCCc2nc2CCCCc12,0,Phase 3,acetylcholinesterase inhibitor,noncancer
PA-824,[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1,0,Phase 3,nitric oxide donor,noncancer
relcovaptan,COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl,0,Phase 2,vasopressin receptor antagonist,targeted cancer
tiracizine,CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1,0,Withdrawn,sodium channel blocker,noncancer
mycophenolic-acid,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O,1,Launched,"dehydrogenase inhibitor, inositol monophosphatase inhibitor",noncancer
PRX-08066,Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N,0,Phase 2,serotonin receptor antagonist,noncancer
BAY-87-2243,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,1,Phase 1,hypoxia inducible factor inhibitor,targeted cancer
sotrastaurin,CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1,0,Phase 2,PKC inhibitor,targeted cancer
trazodone,Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1,0,Launched,"adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor",noncancer
clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
estramustine,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,1,Launched,DNA alkylating agent,chemo
linagliptin,CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1,0,Launched,dipeptidyl peptidase inhibitor,noncancer
lacosamide,COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1,0,Launched,"collapsin response mediator protein inhibitor, collapsin response mediator protein stimulant, sodium channel blocker",noncancer
filgotinib,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,1,Phase 2,JAK inhibitor,noncancer
bevirimat-dimeglumine,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,0,Phase 2,HIV capsid assembly inhibitor,noncancer
BIBX-1382,CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,1,Phase 1,EGFR inhibitor,targeted cancer
protirelin,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,1,Launched,thyrotropin releasing hormone receptor agonist,noncancer
birinapant,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC,1,Phase 2,XIAP inhibitor,targeted cancer
oxfendazole,COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1,0,Launched,anthelmintic agent,noncancer
pinaverium,COc1cc(Br)c(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC,0,Launched,T-type calcium channel blocker,noncancer
tracazolate,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,0,Phase 2,GABA receptor modulator,noncancer
ranitidine,CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O,1,Launched,histamine receptor antagonist,noncancer
urapidil,COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,0,Launched,adrenergic receptor antagonist,noncancer
ZK-93426,CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C,1,Phase 1,benzodiazepine receptor antagonist,noncancer
targinine,CNC(=N)NCCC[C@H](N)C(O)=O,0,Phase 3,nitric oxide synthase inhibitor,noncancer
maribavir,CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,0,Phase 3,"cytomegalovirus inhibitor, protein kinase inhibitor",noncancer
bunazosin,CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1,0,Launched,adrenergic receptor antagonist,noncancer
cyproterone-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,1,Launched,androgen receptor antagonist,targeted cancer
isoconazole,Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,0,Launched,fungal lanosterol demethylase inhibitor,noncancer
asiatic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,0,Preclinical,apoptosis stimulant,targeted cancer
ubenimex,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O,1,Launched,leukotriene synthesis inhibitor,targeted cancer
CGS-21680,CCNC(=O)[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12,0,Preclinical,adenosine receptor agonist,noncancer
GSK1292263,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,1,Phase 2,glucose dependent insulinotropic receptor agonist,noncancer
AZ960,C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1,1,Preclinical,JAK inhibitor,targeted cancer
paricalcitol,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,1,Launched,vitamin D receptor agonist,noncancer
aloe-emodin,OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,0,Preclinical,anticancer agent,noncancer
safingol,CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO,0,Phase 1,PKC inhibitor,targeted cancer
azomycin-(2-nitroimidazole),[O-][N+](=O)c1ncc[nH]1,1,Preclinical,protein synthesis inhibitor,noncancer
talazoparib,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,1,Phase 3,PARP inhibitor,targeted cancer
tandospirone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1,0,Launched,serotonin receptor agonist,noncancer
probenecid,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O,0,Launched,uricosuric blocker,noncancer
taltobulin,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,1,Phase 1,tubulin polymerization inhibitor,chemo
bendamustine,Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl,1,Launched,DNA inhibitor,chemo
zafirlukast,COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C,0,Launched,leukotriene receptor antagonist,noncancer
chloroxine,Oc1c(Cl)cc(Cl)c2cccnc12,1,Launched,opioid receptor antagonist,noncancer
GDC-0068,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,1,Phase 2,AKT inhibitor,targeted cancer
LY2874455,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,1,Phase 1,FGFR antagonist,targeted cancer
acexamic-acid,CC(=O)NCCCCCC(O)=O,0,Launched,5 alpha reductase inhibitor,noncancer
carprofen,CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21,0,Launched,cyclooxygenase inhibitor,noncancer
quinapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
VGX-1027,OC(=O)CC1CC(=NO1)c1ccccc1,0,Phase 1,tumor necrosis factor receptor antagonist,noncancer
flumatinib,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,1,Phase 3,Bcr-Abl kinase inhibitor,targeted cancer
bambuterol,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,0,Launched,adrenergic receptor agonist,noncancer
metergoline,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13,0,Launched,"dopamine receptor agonist, serotonin receptor antagonist",noncancer
choline-alfoscerate,C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO,0,Launched,acetylcholine precursor,noncancer
clofarabine,Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,1,Launched,ribonucleotide reductase inhibitor,chemo
carbamazepine,NC(=O)N1c2ccccc2C=Cc2ccccc12,0,Launched,carboxamide antiepileptic,noncancer
adoprazine,Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1,0,Phase 2,"dopamine receptor antagonist, serotonin receptor agonist",noncancer
D-Serine,N[C@H](CO)C(O)=O,1,Launched,glutamate receptor agonist,noncancer
GDC-0152,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,1,Phase 1,XIAP inhibitor,targeted cancer
amitifadine,Clc1ccc(cc1Cl)C12CC1CNC2,0,Phase 3,serotonin transporter (SERT) inhibitor,noncancer
PHA-848125,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,1,Phase 2,"CDK inhibitor, growth factor receptor inhibitor",targeted cancer
ramosetron,Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12,0,Launched,serotonin receptor antagonist,noncancer
testosterone,C[C@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@@H]2O,0,Launched,androgen receptor agonist,noncancer
fosamprenavir,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,0,Launched,HIV protease inhibitor,noncancer
MK-8033,Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1,0,Phase 1,c-Met inhibitor,targeted cancer
gadobutrol,OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2,0,Launched,radiopaque medium,noncancer
AGI-5198,Cc1nccn1CC(=O)N(C(C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1,0,Preclinical,isocitrate dehydrogenase inhibitor,targeted cancer
frentizole,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,1,Phase 1,immunosuppressant,noncancer
MD-920,C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O,0,Phase 1,NFkB pathway inhibitor,targeted cancer
boceprevir,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,0,Launched,HCV inhibitor,noncancer
enzalutamide,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,1,Launched,androgen receptor antagonist,targeted cancer
CB-03-01,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO,0,Phase 3,androgen receptor antagonist,noncancer
cariprazine,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1,0,Launched,dopamine receptor antagonist,noncancer
dexamethasone-acetate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,1,Launched,glucocorticoid receptor agonist,noncancer
clinafloxacin,NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1,0,Phase 3,bacterial DNA gyrase inhibitor,noncancer
NKP-1339,Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1,0,Phase 1,HSP inhibitor,noncancer
talinolol,CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1,0,Launched,adrenergic receptor antagonist,noncancer
firategrast,CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(O)=O)cc2)c(OC)c1,0,Phase 2,integrin antagonist,noncancer
tacalcitol,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer
ciclesonide,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,1,Launched,glucocorticoid receptor agonist,noncancer
levonorgestrel,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,1,Launched,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist",noncancer
talmapimod,C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C,1,Phase 2,p38 MAPK inhibitor,targeted cancer
fexofenadine,CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1,0,Launched,histamine receptor antagonist,noncancer
amiodarone,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,0,Launched,potassium channel blocker,noncancer
PF-04217903,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,1,Phase 1,c-Met inhibitor,targeted cancer
ibuprofen,CC(C)Cc1ccc(cc1)C(C)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
adatanserin,O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2,0,Phase 2,"serotonin receptor agonist, serotonin receptor antagonist",noncancer
JTC-801,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1,1,Phase 2,opioid receptor antagonist,noncancer
pevonedistat,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,1,Phase 2,nedd activating enzyme inhibitor,targeted cancer
belinostat,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,1,Launched,HDAC inhibitor,targeted cancer
ENMD-2076,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,1,Phase 2,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor",targeted cancer
PD-123319,CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C,0,Phase 1,angiotensin antagonist,noncancer
lasalocid,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,1,Launched,bacterial permeability inducer,noncancer
glimepiride,CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,0,Launched,insulin secretagogue,noncancer
CEP-37440,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,1,Phase 1,ALK tyrosine kinase receptor inhibitor,targeted cancer
CGS-20625,COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O,1,Phase 1,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist",noncancer
volasertib,CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O,1,Phase 3,PLK inhibitor,targeted cancer
delanzomib,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O,1,Phase 1/Phase 2,proteasome inhibitor,Unknown
XL-147,Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1,0,Phase 2,PI3K inhibitor,targeted cancer
ABT-724,C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1,0,Phase 2,dopamine receptor agonist,noncancer
BAY-K-8644-(+/-),COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1C(F)(F)F)[N+]([O-])=O,0,Preclinical,L-type calcium channel activator,noncancer
PF-03758309,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,1,Phase 1,p21 activated kinase inhibitor,targeted cancer
isoniazid,NNC(=O)c1ccncc1,0,Launched,FABI inhibitor,noncancer
rucinol,CCCCc1ccc(O)cc1O,1,Phase 1,tyrosinase inhibitor,noncancer
thioridazine,CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1,0,Withdrawn,dopamine receptor antagonist,targeted cancer
narlaprevir,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,1,Phase 2/Phase 3,HCV inhibitor,noncancer
bergenin,COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O,0,Preclinical,interleukin inhibitor,noncancer
ketoconazole,CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1,1,Launched,sterol demethylase inhibitor,noncancer
AG-14361,CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23,1,Preclinical,PARP inhibitor,targeted cancer
lupanine,O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3,0,Phase 1,sodium channel blocker,noncancer
NVP-BHG712,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,1,Preclinical,ephrin inhibitor,targeted cancer
lamotrigine,Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl,0,Launched,"serotonin receptor antagonist, sodium channel blocker",noncancer
PP242,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12,1,Preclinical,mTOR inhibitor,targeted cancer
rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,0,Withdrawn,"insulin sensitizer, PPAR receptor agonist",noncancer
fesoterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
lenalidomide,Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,1,Launched,anticancer agent,targeted cancer
cyclosporin-a,CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,1,Launched,calcineurin inhibitor,noncancer
indirubin,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,1,Phase 2/Phase 3,"CDK inhibitor, glycogen synthase kinase inhibitor",targeted cancer
zosuquidar,O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F,0,Phase 3,P glycoprotein inhibitor,targeted cancer
retapamulin,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C,0,Launched,protein synthesis inhibitor,noncancer
masitinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1,1,Launched,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor",noncancer
artesunate,C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,Launched,DNA synthesis inhibitor,noncancer
AZD5438,CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1,1,Phase 1,CDK inhibitor,Unknown
LY2886721,NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F,0,Phase 1/Phase 2,beta-secretase inhibitor,noncancer
SGI-1776,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,1,Phase 1,Pim kinase inhibitor,targeted cancer
phensuximide,CN1C(=O)CC(C1=O)c1ccccc1,0,Launched,succinimide antiepileptic,noncancer
moxisylyte,CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C,0,Withdrawn,adrenergic receptor antagonist,noncancer
bosutinib,COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl,1,Launched,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor",Unknown
glycopyrrolate,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
gimeracil,Oc1cc(=O)[nH]cc1Cl,1,Launched,dihydropyrimidine dehydrogenase inhibitor,targeted cancer
atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1,1,Launched,HMGCR inhibitor,noncancer
rotundine,COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC,0,Launched,serotonin receptor agonist,noncancer
VT-464,CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1,0,Phase 2,cytochrome P450 inhibitor,targeted cancer
PF-03814735,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21,1,Phase 1,Aurora kinase inhibitor,targeted cancer
doxofylline,Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O,0,Launched,adenosine receptor antagonist,noncancer
doxepin,CN(C)CC\C=C1\c2ccccc2COc2ccccc12,0,Launched,histamine receptor antagonist,Unknown
AZ3146,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1,1,Preclinical,monopolar spindle 1 kinase inhibitor,noncancer
bumetanide,CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O,1,Launched,solute carrier family member inhibitor,noncancer
CHIR-98014,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,1,Preclinical,glycogen synthase kinase inhibitor,noncancer
metenkephalin,CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccc(O)cc1)C(O)=O,0,Phase 2,immunostimulant,targeted cancer
PF-5274857,Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O,0,Preclinical,smoothened receptor antagonist,targeted cancer
rabeprazole,COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,Launched,"ATPase inhibitor, gastrin inhibitor",noncancer
A-803467,COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1,1,Preclinical,sodium channel blocker,noncancer
cathepsin-inhibitor-1,Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C,0,Preclinical,cathepsin inhibitor,noncancer
quiflapon,CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,0,Phase 2,leukotriene synthesis inhibitor,Unknown
teroxirone,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,1,Phase 1,DNA inhibitor,chemo
MPEP,Cc1cccc(n1)C#Cc1ccccc1,0,Preclinical,glutamate receptor antagonist,noncancer
reserpine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,0,Launched,vesicular monoamine transporter inhibitor,noncancer
JNJ-1661010,O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1,0,Preclinical,FAAH inhibitor,noncancer
diminazene-aceturate,NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1,0,Phase 3,angiotensin converting enzyme activator,noncancer
tacrolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,1,Launched,calcineurin inhibitor,noncancer
SR-95639A,C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1,0,Preclinical,acetylcholine receptor agonist,noncancer
fdcyd,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,1,Phase 2,DNA methyltransferase inhibitor,targeted cancer
triptolide,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O,1,Phase 3,RNA polymerase inhibitor,Unknown
mephentermine,CNC(C)(C)Cc1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
semagacestat,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O,0,Phase 3,gamma secretase inhibitor,noncancer
budipine,CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1,0,Launched,glutamate receptor antagonist,noncancer
tolvaptan,Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc23)c(C)c1,0,Launched,vasopressin receptor antagonist,noncancer
NVP-BEZ235,Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1,1,Phase 2,"mTOR inhibitor, PI3K inhibitor",targeted cancer
elesclomol,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,1,Phase 3,oxidative stress inducer,targeted cancer
estriol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O,0,Launched,estrogen receptor agonist,noncancer
saxagliptin,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,1,Launched,dipeptidyl peptidase inhibitor,noncancer
folic-acid,Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1,0,Launched,folate receptor ligand,noncancer
almitrine,Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1,0,Launched,neurotransmitter agonist,noncancer
ZD-7288,CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1,0,Phase 2,HCN channel blocker,noncancer
navitoclax,CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1,1,Phase 2,BCL inhibitor,targeted cancer
tamibarotene,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,1,Launched,retinoid receptor agonist,targeted cancer
rimcazole,C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1,0,Phase 1,sigma receptor antagonist,targeted cancer
omecamtiv-mecarbil,COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,0,Phase 2,cardiac myosin activator,noncancer
linsidomine,Nc1c[n+](no1)N1CCOCC1,0,Launched,nitric oxide donor,noncancer
erlotinib,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,1,Launched,EGFR inhibitor,targeted cancer
luliconazole,Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1,0,Launched,sterol demethylase inhibitor,noncancer
deoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,0,Launched,"biliverdin reductase A activator, G protein-coupled receptor agonist",noncancer
SC-12267,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,1,Phase 2,dihydroorotate dehydrogenase inhibitor,noncancer
CT-7758,OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1,0,Phase 2,integrin antagonist,noncancer
fenobam,CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1,0,Phase 2,glutamate receptor antagonist,noncancer
betazole,NCCc1cc[nH]n1,0,Launched,histamine receptor agonist,noncancer
lonafarnib,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,1,Phase 3,farnesyltransferase inhibitor,targeted cancer
amyleine,CCC(C)(CN(C)C)OC(=O)c1ccccc1,0,Preclinical,local anesthetic,noncancer
triamcinolone-acetonide,CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,1,Launched,"glucocorticoid receptor agonist, immunosuppressant",noncancer
acetylsalicylsalicylic-acid,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,1,Preclinical,cyclooxygenase inhibitor,noncancer
triclosan,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,0,Launched,antibacterial agent,noncancer
thioproperazine,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,1,Launched,dopamine receptor antagonist,noncancer
abacavir,Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1,0,Launched,nucleoside reverse transcriptase inhibitor,noncancer
6-benzylaminopurine,N(Cc1ccccc1)c1ncnc2nc[nH]c12,0,Preclinical,purinergic receptor activator,noncancer
mycophenolate-mofetil,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1,1,Launched,"dehydrogenase inhibitor, inositol monophosphatase inhibitor",noncancer
scopolamine-n-oxide,C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,0,Preclinical,acetylcholine receptor antagonist,noncancer
GSK461364,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,1,Phase 1,PLK inhibitor,targeted cancer
chlorphensin-carbamate,NC(=O)OCC(O)COc1ccc(Cl)cc1,0,Preclinical,muscle relaxant,noncancer
allopurinol,O=c1[nH]cnc2[nH]ncc12,0,Launched,xanthine oxidase inhibitor,noncancer
clodronic-acid,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,0,Launched,bone resorption inhibitor,targeted cancer
vorinostat,ONC(=O)CCCCCCC(=O)Nc1ccccc1,1,Launched,HDAC inhibitor,targeted cancer
mizoribine,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O,0,Launched,"immunosuppressant, inosine monophosphate dehydrogenase inhibitor",noncancer
acadesine,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N,0,Phase 3,AMPK activator,targeted cancer
ibandronate,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,0,Launched,bone resorption inhibitor,Unknown
carmofur,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,1,Launched,thymidylate synthase inhibitor,targeted cancer
foscarnet,OC(=O)P(O)(O)=O,1,Launched,DNA polymerase inhibitor,noncancer
usniacin-(+),CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O,1,Preclinical,MAP kinase activator,targeted cancer
alogliptin,Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O,1,Launched,dipeptidyl peptidase inhibitor,noncancer
mechlorethamine,CN(CCCl)CCCl,1,Launched,DNA inhibitor,chemo
tideglusib,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,1,Phase 2,glycogen synthase kinase inhibitor,noncancer
oxaliplatin,O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O,1,Launched,DNA inhibitor,chemo
carboplatin,N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1,1,Launched,"DNA alkylating agent, DNA inhibitor",chemo
norepinephrine,NC[C@H](O)c1ccc(O)c(O)c1,1,Launched,adrenergic receptor agonist,noncancer
L-Cysteinesulfinic-acid,N[C@@H](CS(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
methoxyflurane,COC(F)(F)C(Cl)Cl,1,Launched,membrane permeability inhibitor,noncancer
vatalanib,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,1,Phase 3,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
isoflurane,FC(F)OC(Cl)C(F)(F)F,0,Launched,inhaled anaesthetic,noncancer
dimercaptosuccinic-acid,OC(=O)[C@@H](S)[C@@H](S)C(O)=O,0,Launched,chelating agent,noncancer
SNAP,CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-],0,Phase 2,nitric oxide donor,targeted cancer
3-bromopyruvate,OC(=O)C(=O)CBr,0,Preclinical,hexokinase inhibitor,targeted cancer
doconexent-ethyl-ester,CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,0,Launched,omega 3 fatty acid stimulant,noncancer
doxercalciferol,CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer
UNC669,Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1,0,Preclinical,L3MBTL antagonist,noncancer
etidronic-acid,CC(O)(P(O)(O)=O)P(O)(O)=O,0,Launched,bone resorption inhibitor,noncancer
zanamivir,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,0,Launched,neuraminidase inhibitor,noncancer
acitretin,COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C,0,Launched,retinoid receptor agonist,noncancer
penicillamine-(D),CC(C)(S)[C@@H](N)C(O)=O,1,Launched,chelating agent,noncancer
tolcapone,Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O,0,Withdrawn,catechol O methyltransferase inhibitor,noncancer
norfloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1,1,Launched,bacterial DNA gyrase inhibitor,noncancer
RITA,OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1,1,Preclinical,MDM inhibitor,targeted cancer
morin,Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O,1,Preclinical,cytochrome P450 inhibitor,noncancer
7-aminocephalosporanic-acid,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O,1,Preclinical,beta lactamase inhibitor,noncancer
CCG-50014,Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O,1,Preclinical,G protein signaling inhibitor,noncancer
didanosine,OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12,0,Launched,nucleoside reverse transcriptase inhibitor,noncancer
IEM1754,NCCCCCNCC12CC3CC(CC(C3)C1)C2,1,Preclinical,glutamate receptor antagonist,noncancer
perflubron,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br,0,Launched,contrast agent,noncancer
pergolide,CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13,0,Withdrawn,dopamine receptor agonist,noncancer
enflurane,FC(F)OC(F)(F)C(F)Cl,0,Launched,membrane permeability inhibitor,noncancer
lycopene,CC(C)=CCC\C(C)=C\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C=C(/C)CCC=C(C)C,0,Phase 3,free radical scavenger,noncancer
HA14-1,CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC,1,Preclinical,BCL inhibitor,targeted cancer
bucillamine,CC(C)(S)C(=O)N[C@@H](CS)C(O)=O,0,Launched,immunosuppressant,noncancer
MPI-0479605,Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1,1,Preclinical,mitotic kinase inhibitor,targeted cancer
SCMC-Lys,N[C@@H](CSCC(O)=O)C(O)=O,0,Launched,mucolytic agent,Unknown
K-Ras(G12C)-inhibitor-6,SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl,1,Preclinical,K-ras inhibitor,noncancer
VX-702,NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F,1,Phase 2,p38 MAPK inhibitor,noncancer
cyclovirobuxin-d,CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C,1,Preclinical,calcium channel modulator,noncancer
azodicarbonamide,NC(=O)\N=N\C(N)=O,1,Phase 2,DNA synthesis inhibitor,noncancer
colfosceril-palmitate,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,1,Launched,pulmonary surfactant,noncancer
prednisolone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer
LY2140023,N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,0,Phase 3,glutamate receptor agonist,noncancer
M-344,CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO,1,Preclinical,HDAC inhibitor,targeted cancer
phenylbutazone,CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,1,Withdrawn,"cyclooxygenase inhibitor, prostanoid receptor antagonist",noncancer
OG-L002,N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1,0,Preclinical,histone lysine demethylase inhibitor,noncancer
captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,1,Launched,"chelating agent, topoisomerase inhibitor",noncancer
PMPA,OC(=O)CCC(CP(O)(O)=O)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer
5-hydroxytryptophan,NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O,0,Launched,neurotransmitter,noncancer
docosanol,CCCCCCCCCCCCCCCCCCCCCCO,0,Launched,lipase clearing factor inhibitor,noncancer
nicorandil,[O-][N+](=O)OCCNC(=O)c1cccnc1,1,Launched,"nitric oxide donor, potassium channel activator",noncancer
droxidopa,N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O,0,Launched,norepinephrine precursor,noncancer
alendronate,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,0,Launched,bone resorption inhibitor,noncancer
baclofen-(R),NC[C@H](CC(O)=O)c1ccc(Cl)cc1,0,Preclinical,benzodiazepine receptor agonist,noncancer
dichloroacetate,[Na].OC(=O)C(Cl)Cl,1,Phase 3,pyruvate dehydrogenase kinase inhibitor,Unknown
FPA-124,Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O,0,Preclinical,AKT inhibitor,Unknown
methscopolamine,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer
LDN-57444,CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12,1,Preclinical,ubiquitin C-terminal hydrolase inhibitor,noncancer
mirabegron,Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,0,Launched,adrenergic receptor agonist,noncancer
ditiocarb-sodium-trihydrate,CCN(CC)C(S)=S,0,Phase 3,immunostimulant,noncancer
methoxyamine,CON,0,Phase 2,DNA repair enzyme inhibitor,targeted cancer
linalool,CC(C)=CCCC(C)(O)C=C,1,Phase 1,anticonvulsant,noncancer
isobutyramide,CC(C)C(N)=O,0,Phase 2,gene expression stimulant,noncancer
M-14157,CCCCCC(O)CCCC(O)=O,0,Phase 2,ATP-sensitive potassium channel antagonist,noncancer
bethanechol,CC(C[N+](C)(C)C)OC(N)=O,0,Launched,acetylcholine receptor agonist,noncancer
broxyquinoline,Oc1c(Br)cc(Br)c2cccnc12,1,Phase 1,antiprotozoal agent,noncancer
levodopa,N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O,0,Launched,dopamine precursor,noncancer
trichostatin-a,C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C,1,Preclinical,HDAC inhibitor,Unknown
triapine,NC(=S)N\N=C\c1ncccc1N,1,Phase 2,ribonucleotide reductase inhibitor,chemo
IU1,Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1,0,Preclinical,ubiquitin C-terminal hydrolase inhibitor,noncancer
daptomycin,CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
gallamine-triethiodide,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,0,Launched,acetylcholine receptor antagonist,noncancer
caffeic-acid,OC(=O)\C=C\c1ccc(O)c(O)c1,1,Preclinical,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor",noncancer
streptomycin,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
aminosalicylate,Nc1ccc(C(O)=O)c(O)c1,0,Launched,cyclooxygenase inhibitor,noncancer
agmatine,NCCCCNC(N)=N,0,Phase 3,nitric oxide synthase inhibitor,noncancer
polydatin,OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,Phase 2,ICAM1 expression inhibitor,noncancer
AZD4282,NCC(O)=O,0,Phase 1,glutamate receptor antagonist,noncancer
dalcetrapib,CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C,1,Phase 3,cholesteryl ester transfer protein inhibitor,noncancer
SYM-2081,C[C@H](C[C@H](N)C(O)=O)C(O)=O,0,Preclinical,kainate receptor antagonist,noncancer
balofloxacin,CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
glutathione,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,0,Phase 3,antioxidant,noncancer
ilomastat,CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO,1,Phase 3,matrix metalloprotease inhibitor,noncancer
gossypol,CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,1,Phase 2,"BCL inhibitor, MCL1 inhibitor",targeted cancer
TW-37,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O,1,Preclinical,BCL inhibitor,targeted cancer
ornithine,NCCCC(N)C(O)=O,1,Launched,NFkB pathway modulator,noncancer
tazemetostat,CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1,1,Phase 2,histone lysine methyltransferase inhibitor,targeted cancer
merbromin,O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12,0,Launched,antiseptic,noncancer
eltrombopag,CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1,1,Launched,thrombopoietin receptor agonist,noncancer
phenylmercuric-acetate,CC(=O)O[Hg]c1ccccc1,1,Preclinical,other antifungal,Unknown
mesalazine,Nc1ccc(O)c(c1)C(O)=O,0,Launched,"cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist",noncancer
evacetrapib,Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1,1,Phase 3,cholesteryl ester transfer protein inhibitor,noncancer
telaprevir,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,0,Launched,HCV inhibitor,noncancer
novobiocin,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C,1,Launched,bacterial DNA gyrase inhibitor,noncancer
liothyronine,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,0,Launched,thyroid hormone stimulant,Unknown
vigabatrin,NC(CCC(O)=O)C=C,0,Launched,GABA aminotransferase inhibitor,noncancer
dexfosfoserine,N[C@@H](COP(O)(O)=O)C(O)=O,0,Preclinical,membrane integrity inhibitor,noncancer
pancuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
palifosfamide,OP(=O)(NCCCl)NCCCl,0,Phase 3,DNA alkylating agent,chemo
dianhydrogalactitol,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,1,Phase 1,DNA alkylating agent,chemo
mezlocillin,CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
oxaloacetate,OC(=O)CC(=O)C(O)=O,0,Phase 2/Phase 3,glutamate release inhibitor,targeted cancer
AMG458,COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1,1,Preclinical,MET inhibitor,targeted cancer
moexipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
beclomethasone-dipropionate,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer
allylisothiocyanate,C=CCN=C=S,0,Preclinical,TRPV agonist,noncancer
fluroxene,FC(F)(F)COC=C,1,Preclinical,local anesthetic,noncancer
R406,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC,1,Phase 1,SYK inhibitor,targeted cancer
acamprosate,CC(=O)NCCCS(O)(=O)=O,0,Launched,glutamate receptor antagonist,noncancer
tetrandrine,COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34,1,Preclinical,calcium channel blocker,targeted cancer
halothane,FC(F)(F)C(Cl)Br,0,Launched,glutamate receptor antagonist,noncancer
adenosine-triphosphate,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,0,Phase 2,adenosine receptor agonist,noncancer
dimercaprol,OCC(S)CS,0,Launched,chelating agent,noncancer
sodium-butyrate,CCCC(O)=O,0,Phase 2,HDAC inhibitor,targeted cancer
pyrithione-zinc,O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1,1,Launched,ATP synthase inhibitor,Unknown
hydroxyurea,NC(=O)NO,1,Launched,ribonucleotide reductase inhibitor,chemo
CGP-37849,C\C(CP(O)(O)=O)=C/C(N)C(O)=O,1,Phase 1,glutamate receptor antagonist,noncancer
PACOCF3,CCCCCCCCCCCCCCCC(=O)C(F)(F)F,0,Preclinical,phospholipase inhibitor,noncancer
neridronic-acid,NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,0,Launched,bone resorption inhibitor,noncancer
silodosin,C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F,0,Launched,adrenergic receptor antagonist,noncancer
apatinib,O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1,1,Phase 3,RET tyrosine kinase inhibitor,targeted cancer
WP1130,CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1,1,Preclinical,deubiquitinase inhibitor,Unknown
peramivir,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O,0,Launched,neuraminidase inhibitor,noncancer
BMS-387032,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,1,Phase 1,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor",noncancer
4E1RCat,OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O,1,Preclinical,protein synthesis inhibitor,noncancer
SCH-900776,Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1,1,Phase 2,CHK inhibitor,targeted cancer
isopropyl-palmitate,CCCCCCCCCCCCCCCC(=O)OC(C)C,0,Launched,cosmetic moisturizer,noncancer
tanespimycin,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O,1,Phase 3,HSP inhibitor,targeted cancer
tariquidar,COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC,0,Phase 3,P glycoprotein inhibitor,targeted cancer
S-Nitrosoglutathione,N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O,0,Phase 1,nitric oxide stimulant,noncancer
sevoflurane,FCOC(C(F)(F)F)C(F)(F)F,1,Launched,membrane integrity inhibitor,noncancer
amylene-hydrate,CCC(C)(C)O,0,Preclinical,local anesthetic,noncancer
piromidic-acid,CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1,0,Phase 2,bacterial DNA gyrase inhibitor,noncancer
dichlorvos,COP(=O)(OC)OC=C(Cl)Cl,1,Launched,acetylcholinesterase inhibitor,noncancer
MG-132,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O,1,Preclinical,proteasome inhibitor,Unknown
tetraethylenepentamine,NCCNCCNCCNCCN,0,Phase 2/Phase 3,superoxide dismutase inhibitor,targeted cancer
danusertib,CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1,1,Phase 2,"Aurora kinase inhibitor, growth factor receptor inhibitor",targeted cancer
ABT-751,COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1,1,Phase 2,tubulin polymerization inhibitor,chemo
NVP-TAE226,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl,1,Preclinical,protein tyrosine kinase inhibitor,targeted cancer
dexlansoprazole,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,0,Launched,ATPase inhibitor,noncancer
loteprednol,CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl,0,Launched,"glucocorticoid receptor agonist, phospholipase inhibitor",noncancer
curcumin,COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1,1,Launched,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor",targeted cancer
benfotiamine,C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1,1,Launched,antioxidant,noncancer
amygdalin,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 2,caspase activator,targeted cancer
10-hydroxycamptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O,1,Preclinical,topoisomerase inhibitor,Unknown
AZD7762,NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1,1,Phase 1,CHK inhibitor,targeted cancer
acetohydroxamic-acid,CC(=O)NO,0,Launched,urease inhibitor,noncancer
cidofovir,Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1,1,Launched,DNA polymerase inhibitor,noncancer
cephalosporin-c-zn,CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[Zn]OC2=O)C3=O,0,Preclinical,bacterial cell wall synthesis inhibitor,noncancer
tenofovir,C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O,0,Launched,"HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor",noncancer
betaine,C[N+](C)(C)CC(O)=O,0,Launched,nitric oxide donor,noncancer
phenazopyridine,Nc1ccc(\N=N\c2ccccc2)c(N)n1,0,Launched,local anesthetic,noncancer
carmustine,[O-][N+]N(CCCl)C(=O)NCCCl,1,Launched,"DNA alkylating agent, DNA inhibitor",chemo
equol,Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1,1,Launched,estrogen receptor agonist,noncancer
urethane,CCOC(N)=O,0,Preclinical,local anesthetic,noncancer
tanshinone-i,Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,1,Phase 2,AP inhibitor,targeted cancer
cisplatin,N[Pt](N)(Cl)Cl,1,Launched,"DNA alkylating agent, DNA synthesis inhibitor",chemo
pamidronate,NCCC(O)(P(O)(O)=O)P(O)(O)=O,0,Launched,bone resorption inhibitor,targeted cancer
piperine,O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1,1,Phase 1,monoamine oxidase inhibitor,targeted cancer
sodium-stibogluconate,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,1,Launched,tyrosine phosphatase inhibitor,noncancer
trans-4-Hydroxycrotonic-acid,OC\C=C\C(O)=O,1,Preclinical,gamma hydroxybutyric acid ligand,noncancer
flurbiprofen-(S)-(+),C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
azacyclonol,OC(C1CCNCC1)(c1ccccc1)c1ccccc1,0,Preclinical,histamine receptor antagonist,noncancer
nafcillin,CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,1,Launched,bacterial cell wall synthesis inhibitor,noncancer
ethacridine-lactate-monohydrate,CCOc1ccc2nc3cc(N)ccc3c(N)c2c1,1,Preclinical,DNA intercalating agent,noncancer
SB-939,CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO,1,Phase 2,HDAC inhibitor,targeted cancer
GDC-0349,CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1,1,Phase 1,Pim kinase inhibitor,targeted cancer
laquinimod,CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,0,Phase 3,immunosuppressant,noncancer
WP1066,C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1,1,Phase 1,STAT inhibitor,Unknown
AZD3463,COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1,1,Preclinical,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor",targeted cancer
sesamin,C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1,0,Preclinical,NFkB pathway inhibitor,noncancer
chlorogenic-acid,O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O,1,Launched,antioxidant,noncancer
FG-4592,Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12,1,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,noncancer
crenolanib,CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,1,Phase 2,PDGFR tyrosine kinase receptor inhibitor,Unknown
PFI-1,COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1,1,Preclinical,bromodomain inhibitor,targeted cancer
OSI-930,FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1,1,Phase 1,"KIT inhibitor, VEGFR inhibitor",targeted cancer
cytochalasin-b,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,1,Phase 2,microtubule inhibitor,noncancer
LCL-161,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,1,Phase 2,XIAP inhibitor,targeted cancer
nemonapride,CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C,1,Launched,dopamine receptor antagonist,Unknown
2-iminobiotin,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12,0,Phase 2,nitric oxide synthase inhibitor,noncancer
TAK-285,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,1,Phase 1,EGFR inhibitor,targeted cancer
galeterone,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,1,Phase 3,androgen receptor modulator,targeted cancer
gliquidone,COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C,0,Launched,sulfonylurea,noncancer
arbutin,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 2/Phase 3,melanin inhibitor,noncancer
clofibric-acid,CC(C)(Oc1ccc(Cl)cc1)C(O)=O,0,Launched,PPAR receptor agonist,noncancer
I-BET-762,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,1,Phase 2,bromodomain inhibitor,targeted cancer
erteberel,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,1,Phase 2,estrogen receptor agonist,noncancer
racecadotril,CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1,1,Launched,enkephalinase inhibitor,noncancer
inositol,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,0,Launched,insulin sensitizer,noncancer
balicatib,CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N,0,Phase 2,cathepsin inhibitor,noncancer
SB-242235,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,1,Phase 1,p38 MAPK inhibitor,noncancer
DMP-777,CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1,0,Phase 2,elastase inhibitor,Unknown
sitagliptin,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F,0,Launched,dipeptidyl peptidase inhibitor,noncancer
gemcitabine,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,Launched,ribonucleotide reductase inhibitor,chemo
bekanamycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,1,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
tipiracil,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,1,Launched,thymidine phosphorylase inhibitor,targeted cancer
lorazepam,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,1,Launched,benzodiazepine receptor agonist,noncancer
cefepime,CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
flunarizine,Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,0,Launched,calcium channel blocker,noncancer
glipizide,Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,0,Launched,sulfonylurea,noncancer
fenbufen,OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
nutlin-3,COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1,1,Preclinical,MDM inhibitor,targeted cancer
fenofibrate,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1,1,Launched,PPAR receptor agonist,noncancer
L-Citrulline,NC(CCCNC(N)=O)C(O)=O,0,Launched,nitric oxide stimulant,noncancer
fenoprofen,CC(C(O)=O)c1cccc(Oc2ccccc2)c1,1,Launched,prostaglandin inhibitor,noncancer
carfilzomib,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,1,Launched,proteasome inhibitor,Unknown
flufenamic-acid,OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,1,Preclinical,chloride channel blocker,noncancer
milnacipran,CCN(CC)C(=O)C1(CC1CN)c1ccccc1,0,Launched,serotonin-norepinephrine reuptake inhibitor (SNRI),noncancer
fenbendazole,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1,1,Launched,tubulin polymerization inhibitor,noncancer
maxacalcitol,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],1,Launched,vitamin D receptor agonist,noncancer
entecavir,Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1,0,Launched,"DNA replication inhibitor, nucleoside reverse transcriptase inhibitor",noncancer
CX-4945,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,1,Phase 1/Phase 2,casein kinase inhibitor,targeted cancer
diclofenac,OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,0,Launched,cyclooxygenase inhibitor,noncancer
tacrine,Nc1c2CCCCc2nc2ccccc12,0,Launched,acetylcholinesterase inhibitor,noncancer
nilotinib,Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,1,Launched,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor",targeted cancer
irinotecan,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12,1,Launched,topoisomerase inhibitor,chemo
VTP-27999,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,1,Phase 1,renin inhibitor,noncancer
ramatroban,OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,1,Launched,prostanoid receptor antagonist,noncancer
meloxicam,CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O,1,Launched,cyclooxygenase inhibitor,noncancer
imiloxan,CCn1ccnc1CC1COc2ccccc2O1,1,Phase 1,adrenergic receptor antagonist,noncancer
triclabendazole,CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1,1,Launched,microtubule inhibitor,noncancer
3-amino-benzamide,NC(=O)c1cccc(N)c1,1,Phase 2,PARP inhibitor,targeted cancer
tasquinimod,COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12,0,Phase 3,"angiogenesis inhibitor, S100A9 inhibitor",targeted cancer
maprotiline,CNCCCC12CCC(c3ccccc13)c1ccccc21,1,Launched,"norepinephrine reputake inhibitor, tricyclic antidepressant",noncancer
vortioxetine,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,0,Launched,"serotonin receptor agonist, serotonin receptor antagonist",noncancer
vernakalant,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,0,Launched,potassium channel blocker,noncancer
ALX-5407,CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O,0,Phase 1,Glycine transporter 1 inhibitor,noncancer
dronedarone,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,1,Launched,adrenergic receptor antagonist,noncancer
fenspiride,O=C1NCC2(CCN(CCc3ccccc3)CC2)O1,0,Launched,bronchodilator,noncancer
sulbutiamine,CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O,0,Launched,acetylcholine receptor antagonist,noncancer
mefenamic-acid,Cc1cccc(Nc2ccccc2C(O)=O)c1C,0,Launched,cyclooxygenase inhibitor,noncancer
exalamide,CCCCCCOc1ccccc1C(N)=O,0,Launched,membrane permeability inhibitor,noncancer
puromycin,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,1,Preclinical,protein synthesis inhibitor,noncancer
TG-100801,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl,0,Phase 2,"src inhibitor, VEGFR inhibitor",targeted cancer
mefexamide,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,1,Preclinical,psychoactive drug,noncancer
veliparib,C[C@]1(CCCN1)c1nc2c(cccc2[nH]1)C(N)=O,0,Phase 3,PARP inhibitor,targeted cancer
propoxycaine,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,1,Launched,local anesthetic,noncancer
CX-5461,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,1,Phase 1,RNA polymerase inhibitor,targeted cancer
mebeverine,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1,0,Launched,acetylcholine receptor antagonist,noncancer
swainsonine,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,0,Phase 2,alpha mannosidase inhibitor,targeted cancer
meclocycline-sulfosalicylate,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
PCI-24781,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,1,Phase 1/Phase 2,HDAC inhibitor,targeted cancer
ammonium-glycyrrhizinate,C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O,0,Launched,thrombin inhibitor,noncancer
methylergometrine,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",Unknown
penfluridol,OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F,1,Launched,T-type calcium channel blocker,noncancer
iguratimod,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,0,Launched,"cyclooxygenase inhibitor, NFkB pathway inhibitor",noncancer
isosorbide-mononitrate,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O,0,Launched,nitric oxide stimulant,noncancer
naringenin,Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,0,Phase 1,"aromatase inhibitor, TRPV antagonist",targeted cancer
tramiprosate,NCCCS(O)(=O)=O,0,Phase 3,beta amyloid protein neurotoxicity inhibitor,noncancer
DU-728,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,1,Phase 1,structural glycoprotein antagonist,targeted cancer
XBD173,CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1,1,Phase 2,benzodiazepine receptor ligand,noncancer
D-4476,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1,1,Preclinical,TGF beta receptor inhibitor,noncancer
MEK162,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,1,Phase 3,MEK inhibitor,targeted cancer
palonosetron,O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2,0,Launched,serotonin receptor antagonist,noncancer
ginkgolide-b,C[C@@H]1C(=O)OC2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,0,Phase 3,platelet activating factor receptor antagonist,noncancer
azelaic-acid,OC(=O)CCCCCCCC(O)=O,0,Launched,tyrosinase inhibitor,noncancer
miconazole,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
deforolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O,1,Phase 3,mTOR inhibitor,targeted cancer
SB-271046,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1,0,Phase 1,serotonin receptor antagonist,noncancer
"CP-945,598",CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,1,Phase 3,cannabinoid receptor antagonist,noncancer
vinpocetine,CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41,0,Launched,"phosphodiesterase inhibitor, sodium channel blocker",noncancer
CEP-32496,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,1,Phase 1/Phase 2,RAF inhibitor,targeted cancer
tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,1,Phase 3,VEGFR inhibitor,targeted cancer
maraviroc,CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,0,Launched,CC chemokine receptor antagonist,noncancer
minocycline,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C,1,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
cisapride,COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC,0,Withdrawn,serotonin receptor agonist,noncancer
nadide,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,1,Launched,electron acceptor,noncancer
YM-976,CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1,1,Phase 1,phosphodiesterase inhibitor,noncancer
emedastine,CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1,0,Launched,histamine receptor antagonist,noncancer
naloxone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,1,Launched,opioid receptor antagonist,noncancer
pomalidomide,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,1,Launched,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",targeted cancer
nitrofurazone,NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O,0,Launched,bacterial DNA inhibitor,noncancer
valdecoxib,Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1,0,Withdrawn,cyclooxygenase inhibitor,noncancer
noretynodrel,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,1,Launched,progestogen hormone,noncancer
buphenine,CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1,1,Launched,adrenergic receptor agonist,noncancer
perillyl-alcohol,CC(=C)C1CCC(CO)=CC1,0,Phase 2,"apoptosis stimulant, farnesyltransferase inhibitor",targeted cancer
oxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
oxyquinoline,Oc1cccc2cccnc12,1,Launched,chelating agent,noncancer
mepazine,CN1CCCC(CN2c3ccccc3Sc3ccccc23)C1,0,Phase 2,MALT1 inhibitor (JH),targeted cancer
clioquinol,Oc1c(I)cc(Cl)c2cccnc12,0,Withdrawn,chelating agent,noncancer
loratadine,CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12,0,Launched,histamine receptor antagonist,noncancer
norethindrone-acetate,CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,1,Launched,progesterone receptor agonist,noncancer
repaglinide,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O,1,Launched,insulin secretagogue,noncancer
merimepodib,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,1,Phase 2,inosine monophosphate dehydrogenase inhibitor,noncancer
nizofenone,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,1,Launched,ion channel antagonist,noncancer
flecainide,FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1,0,Launched,sodium channel blocker,noncancer
rosuvastatin,CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O,0,Launched,HMGCR inhibitor,noncancer
SR-57227A,NC1CCN(CC1)c1cccc(Cl)n1,1,Phase 2,serotonin receptor agonist,noncancer
mirodenafil,CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1,0,Launched,phosphodiesterase inhibitor,noncancer
TAS-103,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,1,Phase 1,topoisomerase inhibitor,chemo
doxifluridine,C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O,1,Launched,thymidylate synthase inhibitor,targeted cancer
levofloxacin,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
risperidone,Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
5-fluorouracil,Fc1c[nH]c(=O)[nH]c1=O,1,Launched,thymidylate synthase inhibitor,chemo
tacedinaline,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N,1,Phase 3,HDAC inhibitor,targeted cancer
sufentanil,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,1,Launched,opioid receptor modulator,noncancer
cabaletta,OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 2,pharmacological chaperone,noncancer
PD-184352,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,1,Phase 2,MEK inhibitor,targeted cancer
parachlorophenol,Oc1ccc(Cl)cc1,1,Launched,antiinfective drug,noncancer
pargyline,CN(CC#C)Cc1ccccc1,0,Launched,monoamine oxidase inhibitor,noncancer
phenacemide,NC(=O)NC(=O)Cc1ccccc1,0,Launched,sodium channel blocker,noncancer
gadoterate-meglumine,OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1,0,Launched,radiopaque medium,noncancer
phenelzine,NNCCc1ccccc1,1,Launched,monoamine oxidase inhibitor,noncancer
pheniramine,CN(C)CCC(c1ccccc1)c1ccccn1,1,Launched,histamine receptor antagonist,noncancer
adaprev,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,1,Phase 3,TGF beta receptor inhibitor,noncancer
phenolphthalein,Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1,0,Withdrawn,indicator dye,noncancer
"1s,2r-phenylpropanolamine",C[C@@H](N)[C@@H](O)c1ccccc1,0,Withdrawn,adrenergic receptor agonist,noncancer
colistin-b-sulfate,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,1,Launched,bacterial permeability inducer,noncancer
piperazine,C1CNCCN1,1,Launched,benzodiazepine receptor agonist,noncancer
enocitabine,CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,Launched,DNA synthesis inhibitor,chemo
prednisolone,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO,1,Launched,glucocorticoid receptor agonist,noncancer
avagacestat,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1,0,Phase 2,gamma secretase inhibitor,noncancer
verapamil,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC,0,Launched,calcium channel blocker,noncancer
palovarotene,CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12,0,Phase 2,retinoid receptor agonist,noncancer
mibefradil,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,1,Withdrawn,T-type calcium channel blocker,noncancer
JNJ-26481585,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,1,Phase 2,HDAC inhibitor,Unknown
forskolin,CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C,1,Launched,adenylyl cyclase activator,targeted cancer
MLN-8054,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,1,Phase 1,Aurora kinase inhibitor,targeted cancer
varespladib,CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1,0,Phase 3,secretory phospholipase inhibitor,noncancer
masoprocol,CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1,0,Launched,lipoxygenase inhibitor,noncancer
tipranavir,CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1,1,Launched,HIV protease inhibitor,noncancer
candesartan,CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,1,Launched,angiotensin receptor antagonist,noncancer
dabrafenib,CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F,1,Launched,RAF inhibitor,targeted cancer
ercalcitriol,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Phase 1,vitamin D receptor agonist,noncancer
argatroban,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)c1cccc2CC(C)CNc12,0,Launched,thrombin inhibitor,noncancer
methylprednisolone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,Launched,glucocorticoid receptor agonist,noncancer
odanacatib,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,1,Phase 3,cathepsin inhibitor,targeted cancer
erythromycin-ethylsuccinate,CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,0,Launched,"cytochrome P450 inhibitor, protein synthesis inhibitor",noncancer
sulmazole,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,1,Phase 1,adenosine receptor antagonist,noncancer
guanadrel,NC(=N)NCC1COC2(CCCCC2)O1,0,Launched,adrenergic inhibitor,noncancer
dasabuvir,COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1,0,Launched,HCV inhibitor,noncancer
CPP,OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1,1,Phase 2,glutamate receptor antagonist,noncancer
procyclidine,OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
promazine,CN(C)CCCN1c2ccccc2Sc2ccccc12,0,Launched,dopamine receptor antagonist,noncancer
oxonic-acid,OC(=O)c1nc(=O)[nH]c(=O)[nH]1,1,Preclinical,uricase inhibitor,noncancer
eszopiclone,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)c2nccnc12)c1ccc(Cl)cn1,0,Launched,benzodiazepine receptor agonist,noncancer
eglumetad,N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,0,Phase 2,glutamate receptor agonist,noncancer
nabumetone,COc1ccc2cc(CCC(C)=O)ccc2c1,0,Launched,cyclooxygenase inhibitor,noncancer
terfenadine,CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1,1,Withdrawn,histamine receptor antagonist,noncancer
midafotel,OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1,0,Phase 3,glutamate receptor antagonist,noncancer
mephenytoin,CCC1(NC(=O)N(C)C1=O)c1ccccc1,1,Launched,hydantoin antiepileptic,noncancer
diazooxonorleucine,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,1,Phase 2,glutamate receptor antagonist,noncancer
adefovir,Nc1ncnc2n(CCOCP(O)(O)=O)cnc12,0,Launched,DNA polymerase inhibitor,noncancer
iodixanol,CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,noncancer
2-cyanopyrimidine,N#Cc1ncccn1,0,Preclinical,cathepsin inhibitor,noncancer
agomelatine,COc1ccc2cccc(CCNC(C)=O)c2c1,0,Launched,"melatonin receptor agonist, serotonin receptor antagonist",noncancer
propranolol,CC(C)NCC(O)COc1cccc2ccccc12,1,Launched,adrenergic receptor antagonist,noncancer
pilocarpine,CC[C@H]1[C@@H](Cc2cncn2C)COC1=O,1,Launched,acetylcholine receptor agonist,noncancer
pelitinib,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,1,Phase 2,EGFR inhibitor,targeted cancer
riociguat,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,1,Launched,guanylate cyclase stimulant,noncancer
sulfasalazine,OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1,1,Launched,cyclooxygenase inhibitor,noncancer
dideoxyadenosine,Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1,0,Phase 1,nucleoside reverse transcriptase inhibitor,noncancer
sodium-tanshinone-ii-a-sulfonate,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,1,Phase 2,potassium channel activator,noncancer
tiludronate,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,1,Launched,"bone resorption inhibitor, osteoclast inhibitor",noncancer
almorexant,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,1,Phase 3,orexin receptor antagonist,noncancer
IOWH032,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,1,Phase 2,CFTR channel antagonist,noncancer
APD668,CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O,0,Phase 1,glucose dependent insulinotropic receptor agonist,noncancer
clindamycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,0,Launched,protein synthesis inhibitor,noncancer
senicapoc,NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1,0,Phase 3,intermediate conductance potassium channel blocker,noncancer
dinoprost,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,0,Launched,prostacyclin analog,noncancer
chrysin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1,0,Phase 1,breast cancer resistance protein inhibitor,targeted cancer
tetrindole,C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1,0,Phase 3,monoamine oxidase inhibitor,noncancer
trovafloxacin,N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F,1,Withdrawn,bacterial DNA gyrase inhibitor,noncancer
ioversol,OCCN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,noncancer
ioxilan,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,noncancer
terconazole,CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1,1,Launched,sterol demethylase inhibitor,noncancer
dofetilide,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,1,Withdrawn,potassium channel blocker,noncancer
acetophenazine,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,1,Launched,dopamine receptor antagonist,noncancer
UNC2250,CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1,1,Preclinical,MER tyrosine kinase inhibitor,targeted cancer
cefpiramide,Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1,1,Launched,bacterial cell wall synthesis inhibitor,noncancer
aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,1,Launched,bacterial cell wall synthesis inhibitor,noncancer
piperacetazine,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,1,Launched,dopamine receptor antagonist,noncancer
fluvastatin,CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12,1,Launched,HMGCR inhibitor,noncancer
quinethazone,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,1,Launched,thiazide diuretic,noncancer
tiletamine,CCNC1(CCCCC1=O)c1cccs1,1,Launched,glutamate receptor antagonist,noncancer
butacaine,CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1,0,Launched,local anesthetic,Unknown
latanoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,Launched,prostanoid receptor agonist,noncancer
otilonium,CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC,0,Launched,acetylcholine receptor antagonist,noncancer
granisetron,CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12,0,Launched,serotonin receptor antagonist,noncancer
sobetirome,CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O,1,Phase 1,thyroid hormone receptor agonist,noncancer
carvedilol,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,Launched,adrenergic receptor antagonist,noncancer
idoxuridine,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O,1,Launched,DNA directed DNA polymerase inhibitor,noncancer
ICI-162846,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,1,Phase 1,histamine receptor antagonist,noncancer
piketoprofen,CC(C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
CPI-1189,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,1,Phase 2,tumor necrosis factor release inhibitor,noncancer
neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,1,Phase 3,EGFR inhibitor,targeted cancer
gemfibrozil,Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1,0,Launched,lipoprotein lipase activator,noncancer
sulbactam,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O,0,Launched,beta lactamase inhibitor,noncancer
MK-0812,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,1,Phase 2,CC chemokine receptor antagonist,noncancer
venlafaxine,COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1,0,Launched,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)",noncancer
DPCPX,CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)C1CCCC1,0,Phase 1,adenosine receptor antagonist,noncancer
orteronel,CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12,0,Phase 3,"androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor",targeted cancer
iopanic-acid,CCC(Cc1c(I)cc(I)c(N)c1I)C(O)=O,0,Preclinical,thyroid hormone inhibitor,noncancer
mexiletine,CC(N)COc1c(C)cccc1C,1,Launched,sodium channel blocker,noncancer
oxyphencyclimine,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,1,Launched,cholinergic receptor antagonist,noncancer
chlormidazole,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,1,Launched,fungal lanosterol demethylase inhibitor,noncancer
ramifenazone,CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O,1,Launched,cyclooxygenase inhibitor,noncancer
eprobemide,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,1,Launched,monoamine oxidase inhibitor,noncancer
tetrahydrouridine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,1,Phase 2,cytidine deaminase inhibitor,targeted cancer
iniparib,NC(=O)c1ccc(I)c(c1)[N+]([O-])=O,0,Phase 3,PARP inhibitor,targeted cancer
alectinib,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1,1,Launched,ALK tyrosine kinase receptor inhibitor,targeted cancer
PF-04457845,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,1,Phase 2,FAAH inhibitor,noncancer
phenformin,NC(=N)NC(=N)NCCc1ccccc1,0,Withdrawn,AMPK activator,noncancer
nicaraven,CC(CNC(=O)c1cccnc1)NC(=O)c1cccnc1,0,Phase 3,free radical scavenger,noncancer
aspirin,CC(=O)Oc1ccccc1C(O)=O,1,Launched,cyclooxygenase inhibitor,noncancer
cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1,0,Launched,dopamine receptor agonist,noncancer
benzbromarone,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,0,Launched,chloride channel blocker,noncancer
OTS167,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,1,Phase 1,maternal embryonic leucine zipper kinase inhibitor,Unknown
salvinorin-a,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,1,Phase 1,opioid receptor agonist,noncancer
tirasemtiv,CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C,0,Phase 2,troponin activator,noncancer
ethinyl-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C,1,Launched,"estrogen receptor agonist, estrogenic hormone",noncancer
lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,1,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
adenosine,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,0,Launched,adenosine receptor agonist,noncancer
TG-101348,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C,1,Phase 3,"FLT3 inhibitor, JAK inhibitor",targeted cancer
CUDC-907,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,1,Phase 2,PI3K inhibitor,Unknown
INC-280,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,1,Phase 2,c-Met inhibitor,targeted cancer
PAC-1,Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1,1,Phase 1,caspase activator,targeted cancer
I-BET151,COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C,1,Preclinical,bromodomain inhibitor,targeted cancer
RG108,OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O,1,Preclinical,DNA methyltransferase inhibitor,targeted cancer
epiandrosterone,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,1,Preclinical,steroid,noncancer
copanlisib,COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12,0,Launched,PI3K inhibitor,targeted cancer
epalrestat,CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1,0,Launched,aldose reductase inhibitor,noncancer
anethole-trithione,COc1ccc(cc1)-c1cc(=S)ss1,0,Launched,glutathione transferase stimulant,noncancer
nitazoxanide,CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O,0,Launched,pyruvate ferredoxin oxidoreductase inhibitor,noncancer
AGN-194310,CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O,0,Phase 3,retinoid receptor antagonist,noncancer
caspofungin-acetate,CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN,0,Launched,"fungal 1,3-beta-D-glucan synthase inhibitor",noncancer
quinagolide,CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC,0,Launched,dopamine receptor agonist,noncancer
fosaprepitant-dimeglumine,C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,0,Launched,tachykinin antagonist,noncancer
plerixafor,C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1,0,Launched,CC chemokine receptor antagonist,targeted cancer
vinblastine,CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC,1,Launched,"microtubule inhibitor, tubulin polymerization inhibitor",chemo
GDC-0810,CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,Phase 2,selective estrogen receptor destabilizer,targeted cancer
spiramycin,CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
palosuran,Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1,0,Phase 2,urotensin receptor antagonist,noncancer
ponesimod,CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,0,Phase 3,sphingosine 1 phosphate receptor agonist,noncancer
isovaleramide,CC(C)CC(N)=O,0,Phase 2,alcohol dehydrogenase inhibitor,noncancer
motesanib,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12,1,Phase 3,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",Unknown
beta-lapachone,CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O,1,Phase 2,topoisomerase inhibitor,chemo
GSK163090,Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1,0,Phase 2,serotonin receptor antagonist,noncancer
estradiol-acetate,CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1,0,Launched,estrogen receptor agonist,noncancer
abafungin,Cc1ccc(Oc2ccccc2-c2csc(N=C3NCCCN3)n2)c(C)c1,0,Phase 3,sterol methyltransferase inhibitor,noncancer
clofedanol,CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl,0,Launched,histamine receptor antagonist,noncancer
cortodoxone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,0,Phase 3,androgen receptor antagonist,noncancer
lisadimate,Nc1ccc(cc1)C(=O)OCC(O)CO,0,Launched,topical sunscreen agent,noncancer
polythiazide,CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O,0,Launched,sodium/chloride cotransporter inhibitor,noncancer
gabapentin-enacarbil,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1,0,Launched,adrenergic receptor agonist,noncancer
fosphenytoin,OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1,0,Launched,sodium channel blocker,noncancer
desoxycorticosterone-pivalate,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,corticosteroid agonist,noncancer
secoisolariciresinol-diglucoside,COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O,0,Phase 2,antioxidant,noncancer
alcaftadine,CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12,0,Launched,histamine receptor antagonist,noncancer
ravuconazole,C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,0,Phase 2,sterol demethylase inhibitor,noncancer
MK-2295,FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1,0,Phase 2,TRPV antagonist,noncancer
propylhexedrine,CNC(C)CC1CCCCC1,0,Launched,adrenergic receptor agonist,noncancer
carumonam,NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
methoxyphenamine,CNC(C)Cc1ccccc1OC,0,Launched,adrenergic receptor agonist,noncancer
tropesin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(C(O)=O)c3ccccc3)c2c1,0,Launched,cyclooxygenase inhibitor,noncancer
metharbital,CCC1(CC)C(=O)NC(=O)N(C)C1=O,0,Launched,GABA receptor modulator,noncancer
darglitazone,Cc1oc(nc1CCC(=O)c1ccc(Cc2sc(O)nc2O)cc1)-c1ccccc1,0,Phase 2,PPAR receptor antagonist,noncancer
pregabalin,CC(C)C[C@H](CN)CC(O)=O,0,Launched,voltage-gated calcium channel ligand,noncancer
ferulic-acid,COc1cc(\C=C\C(O)=O)ccc1O,0,Phase 2,antioxidant,noncancer
icatibant-acetate,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,0,Launched,bradykinin receptor antagonist,noncancer
evatanepag,CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1,0,Phase 2,prostaglandin inhibitor,noncancer
paritaprevir,Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1,0,Launched,HCV inhibitor,noncancer
JNJ-42165279,FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1,0,Phase 2,FAAH inhibitor,noncancer
niraparib,NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1,1,Launched,PARP inhibitor,targeted cancer
deferoxamine-mesylate,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,0,Launched,chelating agent,noncancer
mavoglurant,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1,0,Phase 2,glutamate receptor antagonist,noncancer
vesnarinone,COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1,0,Launched,phosphodiesterase inhibitor,noncancer
OC000459,Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O,0,Phase 2,CRTH receptor antagonist,noncancer
bupranolol,Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1,0,Launched,adrenergic receptor antagonist,noncancer
epicatechin-gallate-(-),Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1,0,Phase 2,bacterial DNA gyrase inhibitor,targeted cancer
broxaterol,CC(C)(C)NCC(O)c1cc(Br)no1,0,Phase 3,adrenergic receptor agonist,noncancer
crisaborole,OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12,0,Phase 3,phosphodiesterase inhibitor,noncancer
eltoprazine,C1CN(CCN1)c1cccc2OCCOc12,0,Phase 2,serotonin receptor agonist,noncancer
bacampicillin,CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
FK-962,CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1,0,Phase 2,somatostatin receptor agonist,noncancer
VE-822,CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C,1,Phase 2,ATR kinase inhibitor,targeted cancer
NPC-01,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O,0,Phase 3,steroid,noncancer
tasimelteon,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12,0,Launched,melatonin receptor agonist,noncancer
schisandrol-b,COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC,0,Phase 3,lipid peroxidase inhibitor,Unknown
pruvanserin,Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1,0,Phase 2,serotonin receptor antagonist,noncancer
deslanoside,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,0,Launched,Na/K-ATPase inhibitor,Unknown
ibrolipim,CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC,0,Phase 2,lipoprotein lipase activator,noncancer
pipecuronium,CC(=O)OC1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1,0,Launched,neuromuscular blocker,noncancer
lorlatinib,C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,1,Phase 2,ALK tyrosine kinase receptor inhibitor,Unknown
leuprolide,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,Launched,gonadotropin releasing factor hormone receptor agonist,targeted cancer
floctafenine,OCC(O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
itacitinib,Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,0,Phase 2,JAK inhibitor,targeted cancer
enciprazine,COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1,0,Phase 3,GABA receptor modulator,noncancer
elafibranor,CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1,0,Phase 3,PPAR receptor agonist,targeted cancer
gadoteridol,CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3,0,Launched,radiopaque medium,noncancer
17-alpha-methyltestosterone,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,aromatase inhibitor,targeted cancer
calcifediol,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C,0,Launched,vitamin D receptor agonist,noncancer
UNC0631,COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
clobetasone-butyrate,CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl,0,Launched,corticosteroid agonist,noncancer
ceftriaxone,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
L-365260,CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1,0,Phase 2,CCK receptor antagonist,noncancer
pentostatin,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12,1,Launched,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",chemo
estetrol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,0,Phase 3,selective estrogen receptor modulator (SERM),targeted cancer
lorediplon,CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1,0,Phase 2,GABA receptor modulator,noncancer
proquazone,CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
eluxadoline,COc1ccc(CN([C@@H](C)c2ncc([nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O,0,Launched,opioid receptor modulator,noncancer
PF-3274167,COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1,0,Phase 2,oxytocin receptor antagonist,noncancer
apricitabine,Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1,0,Phase 3,nucleoside reverse transcriptase inhibitor,noncancer
gemcadiol,CC(C)(CO)CCCCCCC(C)(C)CO,0,Phase 2,antilipemic,noncancer
didox,ONC(=O)c1ccc(O)c(O)c1,0,Launched,ribonucleotide reductase inhibitor,chemo
titanocene-dichloride,Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1,0,Phase 2,apoptosis stimulant,targeted cancer
ranirestat,Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O,0,Phase 3,aldose reductase inhibitor,noncancer
tiprenolol,CSc1ccccc1OCC(O)CNC(C)C,0,Phase 2,adrenergic receptor antagonist,noncancer
napabucasin,CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,1,Phase 3,STAT inhibitor,targeted cancer
TAK-063,COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1,0,Phase 2,phosphodiesterase inhibitor,noncancer
xibenolol,Cc1cccc(OCC(O)CNC(C)(C)C)c1C,0,Phase 3,adrenergic receptor antagonist,noncancer
corosolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,0,Phase 2,"PKC inhibitor, protein tyrosine kinase inhibitor",targeted cancer
JNJ-26990990,NS(=O)(=O)NCc1csc2ccccc12,0,Phase 2,anticonvulsant,noncancer
LY2606368,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1,1,Phase 2,CHK inhibitor,targeted cancer
gavestinel,OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1,0,Phase 3,glutamate receptor antagonist,noncancer
BMS-833923,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1,0,Phase 2,smoothened receptor antagonist,targeted cancer
methylprednisolone-aceponate,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O,0,Launched,"anti-inflammatory agent, glucocorticoid receptor agonist",noncancer
LY3023414,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,1,Phase 2,"PI3K inhibitor, mTOR inhibitor",targeted cancer
hydrocortisone-butyrate,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO,0,Launched,glucocorticoid receptor agonist,Unknown
netilmicin,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O,0,Launched,protein synthesis inhibitor,noncancer
beclomethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
eprodisate,OS(=O)(=O)CCCS(O)(=O)=O,0,Phase 3,"antiamyloidogenic agent, amyloid protein inhibitor",noncancer
cinepazet,CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1,0,Launched,vasodilator,noncancer
dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,0,Launched,androgen receptor agonist,noncancer
tafenoquine,COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(NC(C)CCCN)c2n1,0,Phase 3,antimalarial agent,noncancer
garenoxacin,C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1,0,Launched,topoisomerase inhibitor,noncancer
valethamate,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
MK-6096,C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1,0,Phase 2,orexin receptor antagonist,noncancer
foropafant,CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C,0,Phase 3,platelet activating factor receptor antagonist,noncancer
FG-2216,OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O,0,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,noncancer
ONC201,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,1,Phase 2,"AKT inhibitor, MAP kinase inhibitor",targeted cancer
INCB-024360,NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O,0,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",targeted cancer
AMG-319,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,0,Phase 2,PI3K inhibitor,targeted cancer
suritozole,Cn1nc(-c2cccc(F)c2)n(C)c1=S,0,Phase 2,GABA receptor inverse agonist,noncancer
ufenamate,CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
org-26576,O=C1N2CCC[C@H]2COc2ncccc12,0,Phase 2,glutamate receptor modulator,noncancer
idronoxil,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,1,Phase 3,XIAP inhibitor,targeted cancer
picartamide,CNC(=S)C1(CCCS1)c1ccccn1,0,Phase 2,H+/K+-ATPase inhibitor,noncancer
etilevodopa,CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,0,Phase 3,dopamine receptor agonist,noncancer
F351,Cc1ccc(=O)n(c1)-c1ccc(O)cc1,0,Phase 2,TGF beta receptor inhibitor,noncancer
diroximel-fumarate,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,0,Phase 3,anti-inflammatory agent,noncancer
emorfazone,CCOc1c(cnn(C)c1=O)N1CCOCC1,0,Launched,"antiinflammatory agent, cyclooxygenase inhibitor",noncancer
lofemizole,Cc1nc[nH]c1-c1ccc(Cl)cc1,0,Phase 3,cyclooxygenase inhibitor,noncancer
ozolinone,CN1C(=O)C(S\C1=C/C(O)=O)N1CCCCC1,0,Phase 3,diuretic,noncancer
fosfosal,OC(=O)c1ccccc1OP(O)(O)=O,0,Launched,phosphodiesterase inhibitor,noncancer
tiaprofenic-acid,CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
alclofenac,OC(=O)Cc1ccc(OCC=C)c(Cl)c1,0,Launched,cyclooxygenase inhibitor,noncancer
piroximone,CCc1[nH]c(O)nc1C(=O)c1ccncc1,0,Phase 2,phosphodiesterase inhibitor,noncancer
isodibut,OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23,0,Phase 2,aldehyde reductase inhibitor,noncancer
nifenalol,CC(C)NCC(O)c1ccc(cc1)[N+]([O-])=O,0,Launched,adrenergic receptor antagonist,noncancer
PNU-142633,CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1,0,Phase 2,serotonin receptor agonist,noncancer
morinidazole,Cc1ncc(n1CC(O)CN1CCOCC1)[N+]([O-])=O,0,Launched,other antibiotic,noncancer
bay-w-9798,COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC,0,Phase 2,antioxidant,targeted cancer
calcipotriol,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,0,Launched,vitamin D receptor agonist,noncancer
fenoverine,O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12,0,Launched,acetylcholine receptor antagonist,noncancer
avibactam,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O,0,Launched,beta lactamase inhibitor,noncancer
darusentan,COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1,0,Phase 3,endothelin receptor antagonist,noncancer
gonadorelin,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,0,Launched,gonadotropin releasing factor hormone receptor agonist,noncancer
halopemide,Oc1nc2cc(Cl)ccc2n1C1CCN(CCNC(=O)c2ccc(F)cc2)CC1,0,Phase 2,phospholipase inhibitor,noncancer
SQ-109,CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2,0,Phase 3,bacterial cell wall synthesis inhibitor,noncancer
cimetropium,C[N+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
talampanel,C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1,0,Phase 2,glutamate receptor antagonist,targeted cancer
7-keto-DHEA,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1,0,Launched,steroid,noncancer
relebactam,OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O,0,Phase 3,beta lactamase inhibitor,noncancer
perphenazine,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,0,Launched,dopamine receptor antagonist,noncancer
naloxegol,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45,0,Launched,opioid receptor antagonist,noncancer
propiverine,CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
cefotiam,CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
RS-0481,CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1,0,Phase 2,immunostimulant,targeted cancer
tolonidine,Cc1ccc(NC2=NCCN2)c(Cl)c1,0,Launched,adrenergic receptor antagonist,noncancer
betamethasone-acetate,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,0,Launched,glucocorticoid receptor agonist,noncancer
pozanicline,Cc1ncccc1OC[C@@H]1CCCN1,0,Phase 2,acetylcholine receptor antagonist,noncancer
dexamethasone,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
sulbactam-pivoxil,CC(C)(C)C(=O)OCOC(=O)C1N2C(CC2=O)S(=O)(=O)C1(C)C,0,Launched,beta lactamase inhibitor,noncancer
pyridoxamine,Cc1ncc(CO)c(CN)c1O,0,Phase 3,AGE inhibitor,noncancer
7-methoxytacrine,COc1ccc2nc3CCCCc3c(N)c2c1,0,Phase 2,acetylcholinesterase inhibitor,noncancer
khellin,COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12,0,Phase 2,vasodilator,noncancer
cinflumide,Fc1cccc(c1)\C=C\C(=O)NC1CC1,0,Phase 2,muscle relaxant,noncancer
bipenamol,NCc1ccccc1Sc1ccccc1CO,0,Phase 2,dipeptidyl peptidase inhibitor,noncancer
bivalirudin,[2H]N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O,0,Launched,thrombin inhibitor,noncancer
toloxatone,Cc1cccc(c1)N1CC(CO)OC1=O,0,Launched,monoamine oxidase inhibitor,noncancer
cridanimod,OC(=O)Cn1c2ccccc2c(=O)c2ccccc12,0,Launched,progesterone receptor agonist,targeted cancer
melevodopa,COC(=O)C(N)Cc1ccc(O)c(O)c1,0,Launched,"dopamine precursor, dopamine receptor agonist",noncancer
nerbacadol,Cc1oncc1C(=O)N1CCCCC1,0,Phase 3,cyclooxygenase inhibitor,noncancer
ceritinib,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0,Launched,ALK tyrosine kinase receptor inhibitor,Unknown
fenretinide,CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1,1,Phase 3,"apoptosis stimulant, retinoid receptor agonist",targeted cancer
SLV-320,O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1,0,Phase 2,adenosine receptor antagonist,Unknown
alarelin,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,0,Launched,gonadotropin releasing factor hormone receptor antagonist,noncancer
ocinaplon,O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1,0,Phase 3,GABA receptor modulator,noncancer
mupirocin,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O,0,Launched,isoleucyl-tRNA synthetase inhibitor,noncancer
flibanserin,FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1,0,Launched,serotonin receptor agonist,noncancer
carazolol,CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12,0,Launched,adrenergic receptor antagonist,noncancer
opicapone,Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O,0,Phase 3,catechol O methyltransferase inhibitor,noncancer
sulmetozine,COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1,0,Launched,gastrin inhibitor,noncancer
TMC647055,COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O,0,Phase 2,RNA polymerase inhibitor,noncancer
igmesine,CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1,0,Phase 2,sigma receptor agonist,noncancer
tedizolid-phosphate,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O,1,Launched,protein synthesis inhibitor,noncancer
ezutromid,CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1,0,Phase 2,utrophin enhancer,noncancer
huperzine-a,C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2,0,Phase 2,acetylcholinesterase inhibitor,noncancer
nuclomedone,Clc1ccc(CC2C(=O)N=C3SCCN3C2=O)cc1,0,Phase 3,immunosuppressant,noncancer
terutroban,Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1,0,Phase 3,prostanoid receptor antagonist,noncancer
fmoc-l-leucine,CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O,0,Phase 2,PPAR receptor agonist,noncancer
pexidartinib,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,0,Phase 3,tyrosine kinase inhibitor,targeted cancer
cibenzoline,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,1,Launched,sodium channel blocker,noncancer
diphencyprone,O=c1c(c1-c1ccccc1)-c1ccccc1,0,Phase 2,immunostimulant,targeted cancer
somatostatin,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N,0,Launched,somatostatin receptor agonist,noncancer
tasuldine,C(Sc1ncccn1)c1cccnc1,0,Phase 3,mucolytic agent,noncancer
cetrorelix,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,0,Launched,gonadotropin releasing factor hormone receptor antagonist,noncancer
tryptophan,N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O,0,Launched,serotonin receptor partial agonist,noncancer
terlipressin,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0,Launched,vasopressin receptor agonist,noncancer
phenindione,O=C1C(C(=O)c2ccccc12)c1ccccc1,0,Launched,vitamin K antagonist,noncancer
zotarolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1,0,Launched,mTOR inhibitor,noncancer
enalaprilat,C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,Unknown
oxytocin,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,0,Launched,oxytocin receptor agonist,noncancer
hexamethylenebisacetamide,CC(=O)NCCCCCCNC(C)=O,0,Phase 2,"AKT inhibitor, differentiation inducer, NFKB pathway inhibitor",targeted cancer
examorelin,C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,0,Phase 2,growth hormone releasing factor agonist,noncancer
7-methylxanthine,Cn1cnc2nc(O)nc(O)c12,0,Phase 2,adenosine receptor antagonist,noncancer
semapimod,NC(=N)NNC(=C)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(=C)NNC(N)=N)C(=C)NNC(N)=N)cc(c1)C(=C)NNC(N)=N,0,Phase 2,"cytokine production inhibitor, p38 MAPK inhibitor",targeted cancer
debrisoquin,NC(=N)N1CCc2ccccc2C1,0,Launched,adrenergic neuron blocker,noncancer
vindesine,CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,1,Launched,tubulin polymerization inhibitor,chemo
abametapir,Cc1ccc(nc1)-c1ccc(C)cn1,0,Phase 3,metalloproteinase inhibitor,noncancer
cefminox,CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
piperazinedione,O=C1CNC(=O)CN1,0,Phase 2,DNA synthesis inhibitor,noncancer
pemetrexed,Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1,0,Launched,"dihydrofolate reductase inhibitor, thymidylate synthase inhibitor",targeted cancer
PI3K-IN-2,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,1,Phase 2,PI3K inhibitor,targeted cancer
sumanirole,CN[C@@H]1Cc2cccc3nc(O)n(C1)c23,0,Phase 3,dopamine receptor agonist,noncancer
BNC105,COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O,1,Phase 2,tubulin polymerization inhibitor,chemo
terodiline,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,0,Phase 3,cholinergic receptor antagonist,noncancer
CHF5074,OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1,0,Phase 2,gamma secretase modulator,noncancer
metazosin,COC(C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1,0,Phase 2,adrenergic receptor antagonist,noncancer
topotecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O,1,Launched,topoisomerase inhibitor,chemo
PF-04937319,CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1,0,Phase 2,glucokinase activator,noncancer
forodesine,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O,1,Phase 2,purinergic receptor antagonist,targeted cancer
gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,1,Phase 3,FLT3 inhibitor,targeted cancer
resveratrol,Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1,0,Launched,"cytochrome P450 inhibitor, SIRT activator",targeted cancer
chidamide,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,1,Launched,HDAC inhibitor,targeted cancer
acetohexamide,CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,0,Launched,ATP channel blocker,noncancer
miocamycin,CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C,0,Launched,other antibiotic,noncancer
MK-571,CN(C)C(=O)CCSC(SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,0,Phase 2,leukotriene receptor antagonist,noncancer
isepamicin,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O,0,Launched,protein synthesis inhibitor,noncancer
promethazine,CC(CN1c2ccccc2Sc2ccccc12)N(C)C,0,Launched,histamine receptor antagonist,noncancer
pantethine,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,0,Launched,coenzyme A precursor,noncancer
fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,0,Phase 3,VEGFR inhibitor,targeted cancer
cis-urocanic acid,OC(=O)\C=C/c1c[nH]cn1,0,Phase 2,serotonin receptor agonist,targeted cancer
indocyanine-green,CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12,0,Launched,contrast agent,noncancer
omeprazole-magnesium,COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)S(=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C,0,Launched,proton pump inhibitor,noncancer
gepefrine,CC(N)Cc1cccc(O)c1,0,Launched,adrenergic receptor agonist,noncancer
lercanidipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1,0,Launched,calcium channel blocker,noncancer
medronic-acid,OP(O)(=O)CP(O)(O)=O,0,Launched,bone resorption inhibitor,noncancer
ergocalciferol,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C,0,Launched,vitamin analog,noncancer
carbendazim,COC(=O)Nc1nc2ccccc2[nH]1,0,Launched,"microtubule inhibitor, tubulin polymerization inhibitor",noncancer
verubulin,COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12,1,Phase 2,tubulin polymerization inhibitor,chemo
pralidoxime-chloride,C[n+]1ccccc1C[N+][O-],0,Launched,acetylcholinesterase inhibitor,noncancer
cyclovalone,COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1,1,Launched,breast cancer resistance protein inhibitor,noncancer
butofilolol,CCCC(=O)c1cc(F)ccc1OCC(O)CNC(C)(C)C,0,Phase 2,adrenergic receptor antagonist,noncancer
L-methionine,CSCC[C@H](N)C(O)=O,0,Launched,voltage-gated calcium channel ligand,noncancer
indisulam,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,1,Phase 2,CDK inhibitor,targeted cancer
L-proline,OC(=O)[C@@H]1CCCN1,0,Launched,glutamate receptor agonist,noncancer
mitoflaxone,OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1,0,Phase 2,antitumor agent,targeted cancer
procysteine,OC(=O)[C@@H]1CSC(=O)N1,0,Phase 3,glutathione synthase stimulant,noncancer
desipramine,CNCCCN1c2ccccc2CCc2ccccc12,0,Launched,tricyclic antidepressant,noncancer
JTE-607,CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O,1,Phase 2,cytokine production inhibitor,noncancer
F-11440,Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O,0,Phase 2,serotonin receptor agonist,noncancer
delamanid,C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
nalfurafine,CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1,0,Launched,opioid receptor agonist,noncancer
salvianolic-acid-B,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,1,Phase 2,"metalloproteinase inhibitor, EGFR inhibitor",noncancer
TRV130,COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1,0,Phase 3,opioid receptor agonist,noncancer
pyronaridine,COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1,0,Phase 3,antimalarial agent,noncancer
citicoline,C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O,0,Launched,"membrane permeability enhancer, glutathione transferase stimulant",noncancer
nitrofurantoin,[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1,0,Launched,DNA inhibitor,noncancer
pipotiazine-palmitate,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
prulifloxacin,CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
vinflunine,CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC,1,Launched,microtubule inhibitor,chemo
paromomycin,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
niceritrol,O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1,0,Launched,NAD precursor,noncancer
ampicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
LY223982,COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1,0,Phase 2,leukotriene receptor antagonist,noncancer
SAR407899,O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,0,Phase 2,rho associated kinase inhibitor,noncancer
BMS-587101,CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1,0,Phase 2,integrin antagonist,noncancer
tiopronin,CC(S)C(=O)NCC(O)=O,0,Launched,"chelating agent, reducing agent",noncancer
chlorphenesin,OCC(O)COc1ccc(Cl)cc1,0,Launched,muscle relaxant,noncancer
KT-433,CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1,0,Phase 2,uricosuric agent,noncancer
LOXO-101,O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F,0,Phase 2,tropomyosin receptor kinase inhibitor,targeted cancer
hydroxyprogesterone-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,0,Launched,progesterone receptor agonist,noncancer
SIB-1553A,CN1CCCC1CCSc1ccc(O)cc1,0,Phase 2,acetylcholine receptor agonist,noncancer
enoximone,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,1,Launched,phosphodiesterase inhibitor,noncancer
zolimidine,CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1,0,Launched,mucus protecting agent,noncancer
nolatrexed,Cc1ccc2nc(N)nc(O)c2c1Sc1ccncc1,0,Phase 3,thymidylate synthase inhibitor,targeted cancer
mofezolac,COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1,0,Launched,cyclooxygenase inhibitor,noncancer
bentazepam,O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,1,Launched,benzodiazepine receptor agonist,noncancer
ripazepam,CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1,0,Phase 2,benzodiazepine receptor agonist,noncancer
DIPT,CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,0,Launched,"dopamine reuptake inhibitor, serotonin reuptake inhibitor",noncancer
veliflapon,OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1,0,Phase 3,leukotriene synthesis inhibitor,noncancer
mabuprofen,CC(C)Cc1ccc(cc1)C(C)C(=O)NCCO,0,Launched,cyclooxygenase inhibitor,noncancer
difenpiramide,O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1,0,Launched,"cyclooxygenase inhibitor, prostaglandin inhibitor",noncancer
AZD1446,Clc1ccc(o1)C(=O)N1CC2CNCC2C1,0,Phase 2,acetylcholine receptor agonist,noncancer
dyclonine,CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1,0,Launched,sodium channel blocker,noncancer
fanetizole,C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1,0,Phase 3,neutrophil superoxide production,noncancer
poziotinib,COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C,1,Phase 2,EGFR inhibitor,targeted cancer
hydralazine,NNc1nncc2ccccc12,0,Launched,vasodilator,noncancer
natamycin,C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O,0,Launched,fungal ergosterol inhibitor,noncancer
peretinoin,CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O,0,Phase 3,retinoid receptor agonist,Unknown
lixivaptan,Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1,0,Phase 3,vasopressin receptor antagonist,noncancer
decoquinate,CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC,0,Launched,antiprotozoal agent,noncancer
CL316243,C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1,0,Phase 2,adrenergic receptor agonist,noncancer
tranexamic-acid,NC[C@H]1CC[C@@H](CC1)C(O)=O,0,Launched,"antifibrinolytic, plasminogen activator inhibitor",noncancer
PF-05190457,Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1,0,Phase 2,growth hormone secretagogue receptor inverse agonist,noncancer
EGF816,CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12,0,Phase 2,EGFR inhibitor,targeted cancer
cefcapene-pivoxil,CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
pardoprunox,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,1,Phase 3,"serotonin receptor agonist, dopamine receptor agonist",noncancer
buclizine,CC(C)(C)c1ccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)cc1,0,Launched,histamine receptor antagonist,noncancer
ABT-639,Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F,0,Phase 2,calcium channel blocker,noncancer
clorotepine,CN1CCN(CC1)C1Cc2ccccc2Sc2ccc(Cl)cc12,0,Launched,"dopamine receptor antagonist, adrenergic receptor antagonist",noncancer
delavirdine,CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1,0,Launched,non-nucleoside reverse transcriptase inhibitor,noncancer
PF-03049423,CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1,0,Phase 2,phosphodiesterase inhibitor,noncancer
capreomycin,NCCCC(N)CC(=O)NCC1NC(=O)C(CO)NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC1=O)=C/NC(N)=O)C1CCNC(=N)N1,0,Launched,protein synthesis inhibitor,noncancer
testolactone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2,0,Launched,aromatase inhibitor,targeted cancer
polidocanol,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,0,Launched,local anesthetic,noncancer
ETC-1002,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,0,Phase 3,AMPK inhibitor,noncancer
chloroprocaine,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,0,Launched,sodium channel blocker,noncancer
GSK2190915,CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1,0,Phase 2,lipoxygenase inhibitor,noncancer
vasopressin,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O,0,Launched,vasopressin receptor agonist,noncancer
fagomine,OC[C@H]1NCC[C@@H](O)[C@@H]1O,0,Phase 2,glucosidase inhibitor,noncancer
etoposide-phosphate,COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,1,Launched,topoisomerase inhibitor,chemo
brivaracetam,CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1,1,Launched,voltage-gated sodium channel blocker,noncancer
L-glutamic-acid,N[C@@H](CCC(O)=O)C(O)=O,0,Launched,glutamate receptor agonist,noncancer
INT-747,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12,0,Phase 3,FXR agonist,Unknown
sutezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1,0,Phase 2,protein synthesis inhibitor,noncancer
dromostanolone-propionate,CCC(=O)OC1CCC2C3CCC4CC(=O)C(C)CC4(C)C3CCC12C,0,Launched,androgen receptor modulator,targeted cancer
danirixin,Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1,0,Phase 2,CC chemokine receptor antagonist,noncancer
haloperidol-decanoate,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,0,Launched,psychoactive drug,noncancer
velneperit,CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F,0,Phase 2,neuropeptide receptor antagonist,noncancer
ospemifene,OCCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1,0,Launched,selective estrogen receptor modulator (SERM),noncancer
verinurad,CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O,0,Phase 2,urate transporter inhibitor,noncancer
dapiprazole,Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1,0,Launched,adrenergic receptor antagonist,noncancer
resibufogenin,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1,0,Phase 2,Na/K-ATPase inhibitor,noncancer
LY2452473,CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N,0,Phase 2,androgen receptor modulator,targeted cancer
albuterol,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,0,Launched,adrenergic receptor agonist,noncancer
colforsin,CC(=O)O[C@H]1[C@@H](O)C2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C,0,Phase 2,adenylyl cyclase activator,targeted cancer
tavaborole,OB1OCc2cc(F)ccc12,0,Launched,leucyl-tRNA synthetase inhibitor,Unknown
daucosterol,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C,0,Phase 2,apoptosis stimulant,targeted cancer
GSK2330672,CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1,0,Phase 2,bile acid transporter inhibitor,noncancer
acalabrutinib,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12,0,Phase 3,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
tofogliflozin,CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1,1,Launched,sodium/glucose cotransporter inhibitor,noncancer
olmutinib,CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1,0,Launched,"EGFR inhibitor, Bruton's tyrosine kinase (BTK) inhibitor",targeted cancer
bendazac,OC(=O)COc1nn(Cc2ccccc2)c2ccccc12,0,Launched,cyclooxygenase inhibitor,noncancer
taprenepag,OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1,0,Phase 2,prostaglandin receptor agonist,noncancer
cefetamet,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
grapiprant,CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,0,Launched,prostaglandin inhibitor,noncancer
diftalone,O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12,0,Launched,cyclooxygenase inhibitor,noncancer
octreotide,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,0,Launched,somatostatin receptor agonist,targeted cancer
terguride,CCN(CC)C(=O)N[C@H]1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1,0,Launched,"dopamine receptor agonist, serotonin receptor antagonist",noncancer
bremelanotide,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O,0,Phase 3,melanocortin receptor agonist,noncancer
zilpaterol,CC(C)N[C@H]1CCn2c(O)nc3cccc([C@@H]1O)c23,0,Launched,adrenergic receptor agonist,noncancer
fimasartan,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Launched,angiotensin receptor antagonist,Unknown
Org-12962,FC(F)(F)c1ccc(nc1Cl)N1CCNCC1,0,Phase 2,serotonin receptor agonist,noncancer
phenylpiracetam,NC(=O)CN1CC(CC1=O)c1ccccc1,0,Launched,noradrenaline uptake inhibitor,noncancer
bicyclol,COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO,0,Launched,NFkB pathway inhibitor,noncancer
litronesib,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,1,Phase 2,kinesin-like spindle protein inhibitor,targeted cancer
AD-5467,CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C,0,Phase 2,aldose reductase inhibitor,noncancer
setipiprant,OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12,0,Phase 3,prostaglandin inhibitor,noncancer
bromantan,Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1,0,Launched,"dopamine reuptake inhibitor, serotonin reuptake inhibitor",noncancer
sivelestat,CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O,0,Launched,elastase inhibitor,noncancer
enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F,0,Launched,isocitrate dehydrogenase inhibitor,targeted cancer
rifamycin-sv,CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C,0,Phase 3,RNA synthesis inhibitor,noncancer
fluocinonide,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C,0,Launched,glucocorticoid receptor agonist,noncancer
E-64,CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N,0,Preclinical,"cysteine protease inhibitor, calpain inhibitor",noncancer
cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,1,Launched,calcineurin inhibitor,noncancer
UNC0737,COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C,0,Preclinical,histone lysine methyltransferase inhibitor,noncancer
molidustat,O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1,0,Phase 2,hypoxia inducible factor inhibitor,noncancer
tiaramide,OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O,0,Launched,anti-inflammatory agent,noncancer
ginsenoside-rg3,CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C,0,Launched,"angiogenesis inhibitor, apoptosis stimulant",noncancer
daltroban,OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1,0,Phase 3,thromboxane receptor antagonist,noncancer
hemoglobin-modulators-1,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,0,Phase 3,hemoglobin modulator,noncancer
altinicline,CN1CCC[C@H]1c1cncc(c1)C#C,0,Phase 2,nicotinic receptor agonist,noncancer
AMG-337,COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1,0,Phase 2,MET inhibitor,targeted cancer
leteprinim,OC(=O)c1ccc(NC(=O)CCn2cnc3c(O)ncnc23)cc1,0,Phase 2,nerve growth factor agonist,targeted cancer
JNJ-40411813,CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O,0,Phase 2,glutamate receptor positive allosteric modulator,noncancer
benproperine,CC(COc1ccccc1Cc1ccccc1)N1CCCCC1,0,Launched,antitussive,noncancer
tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,1,Phase 2,EGFR inhibitor,targeted cancer
glycerol-monolaurate,CCCCCCCCCCCC(=O)OCC(O)CO,0,Launched,beta lactamase inhibitor,noncancer
alacepril,C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,Unknown
phenserine,CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21,0,Phase 3,"acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor",noncancer
sipatrigine,CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl,0,Phase 2,voltage-gated sodium channel blocker,noncancer
trepibutone,CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O,0,Launched,cholinergic receptor antagonist,noncancer
atiprimod,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,1,Phase 2,"JAK inhibitor, STAT inhibitor",targeted cancer
amflutizole,Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O,0,Phase 2,xanthine oxidase inhibitor,noncancer
denotivir,Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1,0,Launched,antiviral,noncancer
perzinfotel,OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O,0,Phase 2,glutamate receptor antagonist,noncancer
caramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1,0,Launched,cholinergic receptor antagonist,noncancer
triclocarban,Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1,0,Launched,other antibiotic,noncancer
gabexate,CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1,0,Launched,serine protease inhibitor,noncancer
chlortetracycline,CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,0,Launched,protein synthesis inhibitor,Unknown
vorapaxar,CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1,0,Launched,thrombin receptor antagonist,noncancer
piperacillin,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
UNC0638,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
hexoprenaline,OC(CNCCCCCCNCC(O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1,0,Launched,adrenergic receptor agonist,noncancer
cloranolol,CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl,0,Launched,adrenergic receptor antagonist,noncancer
amibegron,CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1,0,Phase 3,adrenergic receptor agonist,noncancer
cipemastat,CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C,0,Phase 3,metalloproteinase inhibitor,noncancer
guacetisal,COc1ccccc1OC(=O)c1ccccc1OC(C)=O,0,Launched,immunosuppressant,noncancer
drotaverine,CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC,0,Launched,phosphodiesterase inhibitor,noncancer
piboserod,CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1,0,Phase 2,serotonin receptor antagonist,noncancer
NE-100,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,0,Phase 2,sigma receptor antagonist,noncancer
butylphthalide,CCCCC1OC(=O)c2ccccc12,0,Launched,potassium channel antagonist,noncancer
dehydroepiandrosterone-sulfate,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O,0,Launched,"androgen receptor agonist, estrogen receptor agonist",noncancer
azeliragon,CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1,0,Phase 3,RAGE receptor antagonist,noncancer
YM-511,Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1,0,Phase 2,aromatase inhibitor,targeted cancer
testosterone-undecanoate,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,androgen receptor agonist,noncancer
carboxyamidotriazole,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,1,Phase 3,calcium channel blocker,targeted cancer
VX-745,Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1,0,Phase 2,p38 MAPK inhibitor,targeted cancer
misoprostol,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,0,Launched,prostanoid receptor agonist,noncancer
oritavancin,CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
dimemorfan,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31,0,Launched,sigma receptor agonist,noncancer
solamargine,CC1C2C(CC3C4CC=C5CC(CCC5(C)C4CCC23C)OC2OC(CO)C(OC3OC(C)C(O)C(O)C3O)C(O)C2OC2OC(C)C(O)C(O)C2O)OC11CCC(C)CN1,0,Phase 3,apoptosis inhibitor,noncancer
olmesartan,CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O,0,Launched,angiotensin receptor antagonist,noncancer
UNC0224,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
UNC0642,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
UNC0321,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
BRD4770,COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
GS-9973,C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1,1,Phase 2,syk inhibitor,noncancer
tetracycline,CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
brigatinib,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1,1,Launched,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor",targeted cancer
AKBA,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C,0,Phase 3,lipoxygenase inhibitor,targeted cancer
metyrapone,CC(C)(C(=O)c1cccnc1)c1cccnc1,1,Launched,cytochrome P450 inhibitor,noncancer
ethacizin,CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1,0,Launched,anticonvulsant,noncancer
remimazolam,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12,0,Phase 3,benzodiazepine receptor agonist,noncancer
YM022,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1,0,Phase 2,CCK receptor antagonist,noncancer
carbetocin,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,0,Launched,oxytocin receptor agonist,noncancer
medica-16,CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O,0,Phase 2,ATP citrase lyase inhibitor,noncancer
ozanimod,CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO,0,Phase 3,sphingosine 1 phosphate receptor agonist,noncancer
tecalcet,COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl,0,Phase 2,calcium-sensing receptor agonist,noncancer
solithromycin,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC,0,Phase 3,protein synthesis inhibitor,noncancer
exisulind,CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)(=O)=O,0,Phase 3,phosphodiesterase inhibitor,targeted cancer
lemborexant,Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1,0,Phase 3,orexin receptor antagonist,noncancer
JNJ-37822681,Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F,0,Phase 2,dopamine receptor antagonist,noncancer
dehydrocorydaline,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC,0,Phase 3,acetylcholinesterase inhibitor,noncancer
"1,12-Besm",CCNCCCNCCCCNCCCNCC,0,Phase 2,polyamine biosynthesis inhibitor,targeted cancer
toceranib,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1,0,Launched,protein tyrosine kinase inhibitor,targeted cancer
aprindine,CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1,0,Launched,voltage-gated sodium channel blocker,noncancer
TGR-1202,CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12,0,Phase 3,PI3K inhibitor,targeted cancer
etafenone,CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1,0,Launched,calcium channel blocker,noncancer
selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1,0,Phase 3,"platelet aggregation inhibitor, IP1 prostacyclin receptor agonist",noncancer
gentiopicrin,OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 3,glutamate receptor downregulator,noncancer
isavuconazole,C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)C(O)(Cn1cncn1)c1cc(F)ccc1F,0,Phase 3,cytochrome P450 inhibitor,noncancer
irosustat,NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1,0,Phase 2,steroid sulfatase inhibitor,targeted cancer
A-366,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
UNC0646,COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
prolylleucylglycinamide,CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O,0,Phase 2,melanocyte-stimulating hormone release inhibitor,noncancer
dabigatran,Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1,0,Launched,thrombin inhibitor,noncancer
epacadostat,NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O,0,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",targeted cancer
AMG319,CC(Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1,0,Phase 2,PI3K inhibitor,targeted cancer
SRT2104,Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1,0,Phase 2,SIRT activator,noncancer
BQ-123,CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C,0,Phase 2,endothelin receptor antagonist,noncancer
norethisterone-enanthate,CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C,0,Launched,contraceptive agent,noncancer
RSV604,Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O,0,Phase 2,RSV replication inhibitor,noncancer
tolamolol,Cc1ccccc1OCC(O)CNCCOc1ccc(cc1)C(N)=O,0,Phase 3,adrenergic receptor antagonist,noncancer
presatovir,Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O,0,Phase 2,RSV fusion inhibitor,noncancer
moxaverine,CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1,0,Launched,phosphodiesterase inhibitor,noncancer
XL-647,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,1,Phase 3,"EGFR inhibitor, VEGFR inhibitor",targeted cancer
pumosetrag,Oc1c(cnc2ccsc12)C(=O)N[C@H]1CN2CCC1CC2,0,Phase 2,serotonin receptor agonist,noncancer
avatrombopag,OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1,0,Launched,thrombopoietin receptor agonist,noncancer
riodipine,COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC,0,Phase 2,calcium channel blocker,noncancer
prinaberel,Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1,0,Phase 2,estrogen receptor agonist,noncancer
rubitecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,1,Phase 3,topoisomerase inhibitor,chemo
elbasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,0,Launched,HCV inhibitor,noncancer
degarelix,CC(C)CC(NC(=O)C(Cc1ccc(NC(N)=O)cc1)NC(=O)C(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,0,Launched,gonadotropin releasing factor hormone receptor antagonist,targeted cancer
rilmenidine,C1CC1C(NC1=NCCO1)C1CC1,0,Launched,"adrenergic receptor agonist, imidazoline receptor agonist",noncancer
omarigliptin,CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F,0,Launched,dipeptidyl peptidase inhibitor,noncancer
menadione-bisulfite,CC1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O,0,Phase 2,vitamin K,noncancer
GS-9620,CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1,0,Phase 2,toll-like receptor agonist,noncancer
flindokalner,COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F,0,Phase 3,potassium channel agonist,noncancer
pralidoxime,C[n+]1ccccc1\C=N\O,0,Launched,acetylcholinesterase inhibitor,noncancer
entrectinib,CN1CCN(CC1)c1ccc(C(=O)Nc2n[nH]c3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1,0,Phase 2,"ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor",targeted cancer
PF-06463922,CC1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,0,Phase 2,ALK tyrosine kinase receptor inhibitor,targeted cancer
bafetinib,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,1,Phase 2,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor",targeted cancer
GKT137831,CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12,0,Phase 2,NADPH oxidase inhibitor,noncancer
oleuropein,COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)C1CC(=O)OCCc1ccc(O)c(O)c1,0,Phase 2,estrogen receptor agonist,targeted cancer
ODM-201,C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc([nH]n1)C(C)O,0,Phase 3,androgen receptor antagonist,Unknown
RTA-408,CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,0,Phase 2,nitric oxide production inhibitor,Unknown
peficitinib,NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2,0,Phase 3,JAK inhibitor,noncancer
efinaconazole,C[C@@H](N1CCC(=C)CC1)C(O)(Cn1cncn1)c1ccc(F)cc1F,0,Launched,lanosterol demethylase inhibitor,noncancer
priralfinamide,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,0,Phase 3,sodium channel blocker,noncancer
arbidol,CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,0,Launched,cytochrome P450 inhibitor,noncancer
tofisopam,CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12,0,Launched,"phosphodiesterase inhibitor, cytochrome P450 inhibitor",noncancer
daprodustat,OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,0,Phase 3,hypoxia inducible factor inhibitor,noncancer
trimethoquinol,COc1cc(CC2NCCc3cc(O)c(O)cc23)cc(OC)c1OC,0,Launched,adrenergic receptor antagonist,noncancer
perifosine,CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1,0,Phase 3,AKT inhibitor,targeted cancer
clonixin-lysinate,NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O,0,Launched,cyclooxygenase inhibitor,Unknown
ginsenoside-rd,CC(C)=CCCC(C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C,0,Phase 3,calcium channel blocker,noncancer
frovatriptan,CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O,0,Launched,serotonin receptor agonist,noncancer
AFN-1252,CN(Cc1oc2ccccc2c1C)C(=O)\C=C\C1=CNC2=NC(=O)CCC2=C1,0,Phase 2,FABI inhibitor,noncancer
chlorproguanil,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1,0,Launched,dihydrofolate reductase inhibitor,noncancer
zaltidine,Cc1ncc([nH]1)-c1csc(NC(N)=N)n1,0,Phase 3,histamine receptor antagonist,noncancer
ibuprofen-piconol,CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1,0,Launched,cyclooxygenase inhibitor,noncancer
naphthoquine-phosphate,CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O,0,Launched,antimalarial agent,noncancer
vercirnon,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1,0,Phase 3,CC chemokine receptor antagonist,noncancer
caroverine,CCN(CC)CCN1C(=O)C(Nc2ccccc12)=Cc1ccc(OC)cc1,0,Launched,"glutamate receptor antagonist, calcium channel blocker",noncancer
erdafitinib,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,1,Phase 2,FGFR inhibitor,targeted cancer
rosoxacin,CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1,0,Launched,topoisomerase inhibitor,noncancer
maropitant,COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C,0,Launched,neurokinin receptor antagonist,noncancer
pyrantel,OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O,0,Launched,nicotinic receptor agonist,noncancer
icaritin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O,0,Phase 2,PPAR receptor antagonist,targeted cancer
cyamemazine,CC(CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N,0,Launched,serotonin receptor antagonist,noncancer
INCB-3284,COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,0,Phase 2,CC chemokine receptor antagonist,noncancer
droloxifene,CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,0,Phase 3,selective estrogen receptor modulator (SERM),targeted cancer
eliglustat,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1,0,Launched,Glycosyl transferase inhibitor,noncancer
gidazepam,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,1,Launched,GABA benzodiazepine site receptor agonist,noncancer
radafaxine,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1,0,Phase 2,dopamine-norepinephrine reuptake inhibitor,noncancer
imidafenacin,Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
MK-0354,C1Cc2[nH]nc(-c3nnn[nH]3)c2C1,0,Phase 2,niacin receptor agonist,noncancer
apratastat,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1,0,Phase 2,"matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor",noncancer
siponimod,CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F,0,Phase 3,sphingosine phosphate receptor modulator,noncancer
oxyfedrine,COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
tianeptine,CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O,0,Launched,selective serotonin reuptake enhancer (SSRE),noncancer
atizoram,COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1,0,Phase 2,phosphodiesterase inhibitor,noncancer
elagolix,COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O,0,Phase 3,gonadotropin releasing factor hormone receptor antagonist,Unknown
mabuterol,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(c1)C(F)(F)F,0,Launched,adrenergic receptor agonist,noncancer
nastorazepide,CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1,0,Phase 2,CCK receptor antagonist,targeted cancer
